NZ622045B2 - Peptide nanoparticles and uses thereof - Google Patents
Peptide nanoparticles and uses thereof Download PDFInfo
- Publication number
- NZ622045B2 NZ622045B2 NZ622045A NZ62204512A NZ622045B2 NZ 622045 B2 NZ622045 B2 NZ 622045B2 NZ 622045 A NZ622045 A NZ 622045A NZ 62204512 A NZ62204512 A NZ 62204512A NZ 622045 B2 NZ622045 B2 NZ 622045B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- peptide
- leu
- trp
- lys
- particle
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 932
- 239000002105 nanoparticle Substances 0.000 title description 49
- 239000002245 particle Substances 0.000 claims abstract description 493
- 125000001151 peptidyl group Chemical group 0.000 claims abstract description 217
- 239000003446 ligand Substances 0.000 claims abstract description 159
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 131
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 117
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 87
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 87
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 83
- 230000027455 binding Effects 0.000 claims abstract description 45
- 125000003301 D-leucyl group Chemical group N[C@@H](C(=O)*)CC(C)C 0.000 claims abstract description 42
- 125000003941 D-tryptophan group Chemical group [H]C1=C([H])C([H])=C2C(C([C@@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims abstract description 31
- BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 claims abstract description 14
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 230000000149 penetrating effect Effects 0.000 claims abstract description 5
- LYMVXFSTACVOLP-ZFWWWQNUSA-N Trp-Leu Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C([O-])=O)=CNC2=C1 LYMVXFSTACVOLP-ZFWWWQNUSA-N 0.000 claims abstract 4
- 108010080629 tryptophan-leucine Proteins 0.000 claims abstract 4
- 150000001413 amino acids Chemical group 0.000 claims description 176
- 210000004027 cell Anatomy 0.000 claims description 164
- 239000013543 active substance Substances 0.000 claims description 121
- 125000003277 amino group Chemical group 0.000 claims description 119
- 239000000203 mixture Substances 0.000 claims description 108
- 238000000034 method Methods 0.000 claims description 83
- 108020004414 DNA Proteins 0.000 claims description 58
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 108020004459 Small interfering RNA Proteins 0.000 claims description 23
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 21
- 238000000338 in vitro Methods 0.000 claims description 15
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 13
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 11
- 239000002679 microRNA Substances 0.000 claims description 11
- 108091070501 miRNA Proteins 0.000 claims description 8
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 67
- 238000001890 transfection Methods 0.000 abstract description 16
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract description 9
- 229940024606 amino acid Drugs 0.000 description 191
- 102000004196 processed proteins & peptides Human genes 0.000 description 191
- 235000001014 amino acid Nutrition 0.000 description 183
- -1 polycapr‘olactone Polymers 0.000 description 122
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 59
- 229930187593 rose bengal Natural products 0.000 description 58
- 229940081623 rose bengal Drugs 0.000 description 58
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 58
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 55
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 55
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 47
- 239000011324 bead Substances 0.000 description 45
- 102000004169 proteins and genes Human genes 0.000 description 44
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 43
- 125000005647 linker group Chemical group 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- 150000001875 compounds Chemical class 0.000 description 35
- 239000003814 drug Substances 0.000 description 35
- 102000053602 DNA Human genes 0.000 description 34
- 108020004682 Single-Stranded DNA Proteins 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 239000002253 acid Substances 0.000 description 32
- 150000001408 amides Chemical class 0.000 description 32
- 239000000463 material Substances 0.000 description 32
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 28
- 125000000539 amino acid group Chemical group 0.000 description 26
- UTOYCOKRJWZPNT-SQNCZLKBSA-N flutax 2 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC(=O)[C@@H](NC(=O)C=1C=C(C(=CC=1)C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21)C(O)=O)C)C(=O)C1=CC=CC=C1 UTOYCOKRJWZPNT-SQNCZLKBSA-N 0.000 description 26
- 241001354243 Corona Species 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- 239000012581 transferrin Substances 0.000 description 23
- 102000004338 Transferrin Human genes 0.000 description 21
- 108090000901 Transferrin Proteins 0.000 description 21
- 229920000642 polymer Polymers 0.000 description 21
- 102000000844 Cell Surface Receptors Human genes 0.000 description 20
- 238000011534 incubation Methods 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 20
- 108091034117 Oligonucleotide Proteins 0.000 description 19
- 238000009472 formulation Methods 0.000 description 19
- 229940124597 therapeutic agent Drugs 0.000 description 19
- 238000009826 distribution Methods 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 17
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 16
- 150000001576 beta-amino acids Chemical class 0.000 description 16
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
- 125000002091 cationic group Chemical group 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- 102000007238 Transferrin Receptors Human genes 0.000 description 14
- 108010033576 Transferrin Receptors Proteins 0.000 description 14
- 239000000975 dye Substances 0.000 description 14
- 150000002500 ions Chemical class 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 230000021736 acetylation Effects 0.000 description 13
- 238000006640 acetylation reaction Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000005538 encapsulation Methods 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 230000004962 physiological condition Effects 0.000 description 13
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 239000007790 solid phase Substances 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 229920001577 copolymer Polymers 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000000178 monomer Substances 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 9
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000002073 fluorescence micrograph Methods 0.000 description 9
- 238000011068 loading method Methods 0.000 description 9
- 230000003278 mimic effect Effects 0.000 description 9
- 229950006344 nocodazole Drugs 0.000 description 9
- 239000000816 peptidomimetic Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 108010020147 Protein Corona Proteins 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 125000000129 anionic group Chemical group 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000004945 emulsification Methods 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000010647 peptide synthesis reaction Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 108091023037 Aptamer Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 150000008575 L-amino acids Chemical class 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 229920000249 biocompatible polymer Polymers 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000002983 circular dichroism Methods 0.000 description 7
- 210000000172 cytosol Anatomy 0.000 description 7
- 238000002296 dynamic light scattering Methods 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000012800 visualization Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010026389 Gramicidin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 239000011543 agarose gel Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 230000000021 endosomolytic effect Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229920001477 hydrophilic polymer Polymers 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 238000005192 partition Methods 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- 101150003852 pnp2 gene Proteins 0.000 description 6
- 229920000768 polyamine Polymers 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000004626 scanning electron microscopy Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 235000019766 L-Lysine Nutrition 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- DTERQYGMUDWYAZ-UHFFFAOYSA-N N-acetyl-N-thioacetyl-Lysine Natural products CC(=O)NCCCCC(N)C(O)=O DTERQYGMUDWYAZ-UHFFFAOYSA-N 0.000 description 5
- 229920000954 Polyglycolide Polymers 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 239000004621 biodegradable polymer Substances 0.000 description 5
- 229910052796 boron Inorganic materials 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 229920002301 cellulose acetate Polymers 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 5
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000012216 imaging agent Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000003712 lysosome Anatomy 0.000 description 5
- 230000001868 lysosomic effect Effects 0.000 description 5
- 230000000873 masking effect Effects 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000002077 nanosphere Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 229920000747 poly(lactic acid) Polymers 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 5
- 229960004799 tryptophan Drugs 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 4
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000000429 assembly Methods 0.000 description 4
- 230000000712 assembly Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 238000001553 co-assembly Methods 0.000 description 4
- 230000008045 co-localization Effects 0.000 description 4
- 238000000942 confocal micrograph Methods 0.000 description 4
- 230000001268 conjugating effect Effects 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 108010021843 fluorescent protein 583 Proteins 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- 229960004905 gramicidin Drugs 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 239000004626 polylactic acid Substances 0.000 description 4
- 229920001451 polypropylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- GXMBHQRROXQUJS-UHFFFAOYSA-N (2-hept-2-ynylsulfanylphenyl) acetate Chemical compound CCCCC#CCSC1=CC=CC=C1OC(C)=O GXMBHQRROXQUJS-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 150000008545 L-lysines Chemical class 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101100240983 Mus musculus Nrbp1 gene Proteins 0.000 description 3
- 229920002732 Polyanhydride Polymers 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 229920001710 Polyorthoester Polymers 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 238000003917 TEM image Methods 0.000 description 3
- 102100026143 Transferrin receptor protein 2 Human genes 0.000 description 3
- 101710145355 Transferrin receptor protein 2 Proteins 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000001142 circular dichroism spectrum Methods 0.000 description 3
- 238000000975 co-precipitation Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- 229960000633 dextran sulfate Drugs 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229940014144 folate Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 238000010915 one-step procedure Methods 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 239000004633 polyglycolic acid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 239000012857 radioactive material Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical class C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000012134 supernatant fraction Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- QCPFFGGFHNZBEP-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 QCPFFGGFHNZBEP-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 108050004290 Cecropin Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 150000001251 acridines Chemical class 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 229940124277 aminobutyric acid Drugs 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GSOLWAFGMNOBSY-UHFFFAOYSA-N cobalt Chemical compound [Co][Co][Co][Co][Co][Co][Co][Co] GSOLWAFGMNOBSY-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 2
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000003413 degradative effect Effects 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 150000002669 lysines Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 235000020075 ouzo Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000083 poly(allylamine) Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000002745 poly(ortho ester) Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001281 polyalkylene Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 229920001855 polyketal Polymers 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- ZWCXYZRRTRDGQE-LUPIJMBPSA-N valyl gramicidin a Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-LUPIJMBPSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical group C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- WOGUASPHMADVMU-CQSZACIVSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@](C)(C(O)=O)C1=CC=CC=C1 WOGUASPHMADVMU-CQSZACIVSA-N 0.000 description 1
- ZYCITKXROAFBAR-GFCCVEGCSA-N (2r)-2-benzyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC[C@H](C(O)=O)CC1=CC=CC=C1 ZYCITKXROAFBAR-GFCCVEGCSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 description 1
- RBGNOZINYUCSMY-INIZCTEOSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-naphthalen-2-ylbutanoic acid Chemical compound C1=CC=CC2=CC(CC[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CC=C21 RBGNOZINYUCSMY-INIZCTEOSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- IAYJZWFYUSNIPN-KFRZSCGFSA-N (2s,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](OC=2C=CC(=CC=2)[N+]([O-])=O)[C@H](O)[C@H]1O IAYJZWFYUSNIPN-KFRZSCGFSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- KJTPWUVVLPCPJD-AUWJEWJLSA-N (2z)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one Chemical compound O=C1C=2C(N)=C(OC)C(OC)=CC=2C\C1=C\C1=CC(C)=C(O)C(C)=C1 KJTPWUVVLPCPJD-AUWJEWJLSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- JAEIBKXSIXOLOL-SCSAIBSYSA-N (3r)-pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)[C@@H]1CCNC1 JAEIBKXSIXOLOL-SCSAIBSYSA-N 0.000 description 1
- PAFSELQEYJTCCG-FQEVSTJZSA-N (3s)-3-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[4-[(2-methylpropan-2-yl)oxy]phenyl]butanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](CC(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 PAFSELQEYJTCCG-FQEVSTJZSA-N 0.000 description 1
- YWEDBQXENWAMAS-HKBQPEDESA-N (3s)-3-(9h-fluoren-9-ylmethoxycarbonylamino)-6-oxo-6-(tritylamino)hexanoic acid Chemical compound C([C@@H](CC(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 YWEDBQXENWAMAS-HKBQPEDESA-N 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 1
- TYAFIFFKPSWZRM-HYXAFXHYSA-N (z)-2-amino-4-methylpent-2-enoic acid Chemical compound CC(C)\C=C(/N)C(O)=O TYAFIFFKPSWZRM-HYXAFXHYSA-N 0.000 description 1
- OXFGRWIKQDSSLY-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-2-ium-1-carboxylate Chemical compound C1=CC=C2C(C(=O)O)NCCC2=C1 OXFGRWIKQDSSLY-UHFFFAOYSA-N 0.000 description 1
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical class C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 1,2-dihydrophenazine Chemical compound C1=CC=C2N=C(C=CCC3)C3=NC2=C1 ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Chemical group OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- BGGCPIFVRJFAKF-UHFFFAOYSA-N 1-[4-(1,3-benzoxazol-2-yl)phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 BGGCPIFVRJFAKF-UHFFFAOYSA-N 0.000 description 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
- VMMUACFKZYTOEE-UHFFFAOYSA-N 1-aminocyclopent-3-ene-1-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)C1(N)CC=CC1 VMMUACFKZYTOEE-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- HIYWOHBEPVGIQN-UHFFFAOYSA-N 1h-benzo[g]indole Chemical compound C1=CC=CC2=C(NC=C3)C3=CC=C21 HIYWOHBEPVGIQN-UHFFFAOYSA-N 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- VAPDZNUFNKUROY-UHFFFAOYSA-N 2,4,6-triiodophenol Chemical compound OC1=C(I)C=C(I)C=C1I VAPDZNUFNKUROY-UHFFFAOYSA-N 0.000 description 1
- AHDSRXYHVZECER-UHFFFAOYSA-N 2,4,6-tris[(dimethylamino)methyl]phenol Chemical compound CN(C)CC1=CC(CN(C)C)=C(O)C(CN(C)C)=C1 AHDSRXYHVZECER-UHFFFAOYSA-N 0.000 description 1
- VHGPACPVCRTFES-UHFFFAOYSA-N 2-(4-methylanilino)naphthalene-1-sulfonic acid Chemical compound C1=CC(C)=CC=C1NC1=CC=C(C=CC=C2)C2=C1S(O)(=O)=O VHGPACPVCRTFES-UHFFFAOYSA-N 0.000 description 1
- BGAVVPDORCZLJU-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-2-phenylpropanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NC(C)(C(O)=O)C1=CC=CC=C1 BGAVVPDORCZLJU-UHFFFAOYSA-N 0.000 description 1
- CGPQRFCFBISLKF-UHFFFAOYSA-N 2-[2-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]acetic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC=C1CC(O)=O CGPQRFCFBISLKF-UHFFFAOYSA-N 0.000 description 1
- YGDVXSDNEFDTGV-UHFFFAOYSA-N 2-[6-[bis(carboxymethyl)amino]hexyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCCCCCN(CC(O)=O)CC(O)=O YGDVXSDNEFDTGV-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- CXOWHCCVISNMIX-UHFFFAOYSA-N 2-aminonaphthalene-1-carboxylic acid Chemical compound C1=CC=CC2=C(C(O)=O)C(N)=CC=C21 CXOWHCCVISNMIX-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- YTWPGUQMZQRYGM-UHFFFAOYSA-N 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid Chemical compound C1=C(O)C=C2C(C(=O)O)NCCC2=C1 YTWPGUQMZQRYGM-UHFFFAOYSA-N 0.000 description 1
- UKLNSYRWDXRTER-UHFFFAOYSA-N 7-isocyanato-3-phenylchromen-2-one Chemical compound O=C1OC2=CC(N=C=O)=CC=C2C=C1C1=CC=CC=C1 UKLNSYRWDXRTER-UHFFFAOYSA-N 0.000 description 1
- NLSUMBWPPJUVST-UHFFFAOYSA-N 9-isothiocyanatoacridine Chemical compound C1=CC=C2C(N=C=S)=C(C=CC=C3)C3=NC2=C1 NLSUMBWPPJUVST-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101150034533 ATIC gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 1
- 108010073361 BioXtra Proteins 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091005944 Cerulean Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241000669072 Chrysomphalus dictyospermi Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229930182819 D-leucine Natural products 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710183768 Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 229920000028 Gradient copolymer Polymers 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001000116 Homo sapiens Unconventional myosin-Ig Proteins 0.000 description 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 108010000775 Hydroxymethylglutaryl-CoA synthase Proteins 0.000 description 1
- 102100028888 Hydroxymethylglutaryl-CoA synthase, cytoplasmic Human genes 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- DGYHPLMPMRKMPD-UHFFFAOYSA-N L-propargyl glycine Natural products OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 241000251752 Myxine glutinosa Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- NPKISZUVEBESJI-AWEZNQCLSA-N N-benzoyl-L-phenylalanine Chemical compound C([C@@H](C(=O)O)NC(=O)C=1C=CC=CC=1)C1=CC=CC=C1 NPKISZUVEBESJI-AWEZNQCLSA-N 0.000 description 1
- YPIGGYHFMKJNKV-UHFFFAOYSA-N N-ethylglycine Chemical compound CC[NH2+]CC([O-])=O YPIGGYHFMKJNKV-UHFFFAOYSA-N 0.000 description 1
- NPKISZUVEBESJI-UHFFFAOYSA-N Nalpha-benzoyl-L-phenylalanine Natural products C=1C=CC=CC=1C(=O)NC(C(=O)O)CC1=CC=CC=C1 NPKISZUVEBESJI-UHFFFAOYSA-N 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 101150023830 PYR1 gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000094111 Parthenolecanium persicae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 229910018503 SF6 Inorganic materials 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 102000005782 Squalene Monooxygenase Human genes 0.000 description 1
- 108020003891 Squalene monooxygenase Proteins 0.000 description 1
- 102100037997 Squalene synthase Human genes 0.000 description 1
- 229930182558 Sterol Chemical class 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229910052775 Thulium Inorganic materials 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- UATJOMSPNYCXIX-UHFFFAOYSA-N Trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UATJOMSPNYCXIX-UHFFFAOYSA-N 0.000 description 1
- 102100035824 Unconventional myosin-Ig Human genes 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 238000005144 WAX chromatography Methods 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940060532 allent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N alpha-isobutyric acid Natural products CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000002769 anti-restenotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 108010044715 asialofetuin Proteins 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 150000007657 benzothiazepines Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- JCZLABDVDPYLRZ-AWEZNQCLSA-N biphenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C1=CC=CC=C1 JCZLABDVDPYLRZ-AWEZNQCLSA-N 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 108010082025 cyan fluorescent protein Proteins 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005520 electrodynamics Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- PJWPNDMDCLXCOM-UHFFFAOYSA-N encainide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 PJWPNDMDCLXCOM-UHFFFAOYSA-N 0.000 description 1
- 229960001142 encainide Drugs 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 1
- HCTJHQFFNDLDPF-UHFFFAOYSA-N ethyl 3-(benzylamino)propanoate Chemical compound CCOC(=O)CCNCC1=CC=CC=C1 HCTJHQFFNDLDPF-UHFFFAOYSA-N 0.000 description 1
- RJCGNNHKSNIUAT-UHFFFAOYSA-N ethyl 3-aminopropanoate;hydron;chloride Chemical compound Cl.CCOC(=O)CCN RJCGNNHKSNIUAT-UHFFFAOYSA-N 0.000 description 1
- BUDBHJPMAKXMLD-UHFFFAOYSA-N ethyl 6-methyl-2-phenylquinoline-4-carboxylate Chemical compound N=1C2=CC=C(C)C=C2C(C(=O)OCC)=CC=1C1=CC=CC=C1 BUDBHJPMAKXMLD-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940085942 formulation r Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N furocoumarin Natural products C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003707 glutamic acid hydrochloride Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000003949 imides Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- DDVBPZROPPMBLW-ZJBINBEQSA-N latrunculin a Chemical compound C([C@H]1[C@@]2(O)C[C@H]3C[C@H](O2)CC[C@@H](/C=C\C=C/CC\C(C)=C/C(=O)O3)C)SC(=O)N1 DDVBPZROPPMBLW-ZJBINBEQSA-N 0.000 description 1
- DDVBPZROPPMBLW-UHFFFAOYSA-N latrunculin-A Natural products O1C(=O)C=C(C)CCC=CC=CC(C)CCC(O2)CC1CC2(O)C1CSC(=O)N1 DDVBPZROPPMBLW-UHFFFAOYSA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 239000002073 nanorod Substances 0.000 description 1
- 125000005184 naphthylamino group Chemical group C1(=CC=CC2=CC=CC=C12)N* 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- GHLZUHZBBNDWHW-UHFFFAOYSA-N nonanamide Chemical compound CCCCCCCCC(N)=O GHLZUHZBBNDWHW-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019407 octafluorocyclobutane Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- IWHCAJPPWOMXNW-LYKMMFCUSA-N peptide t Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 IWHCAJPPWOMXNW-LYKMMFCUSA-N 0.000 description 1
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 1
- 229950003332 perflubutane Drugs 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Polymers 0.000 description 1
- 150000004291 polyenes Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Chemical group 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- BPGBAEXPBQHBSV-UHFFFAOYSA-N pyr1 Chemical compound C1=C2C3=C(C)C(C(NC=C4)=O)=C4C(C)=C3NC2=CC=C1OC(=O)C1=CC=CC=C1 BPGBAEXPBQHBSV-UHFFFAOYSA-N 0.000 description 1
- 150000003220 pyrenes Chemical class 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 239000002265 redox agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 108700022109 ropocamptide Proteins 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- COFLCBMDHTVQRA-UHFFFAOYSA-N sapphyrin Chemical compound N1C(C=2NC(C=C3N=C(C=C4NC(=C5)C=C4)C=C3)=CC=2)=CC=C1C=C1C=CC5=N1 COFLCBMDHTVQRA-UHFFFAOYSA-N 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- RJVBVECTCMRNFG-ANKJNSLFSA-N swinholide a Chemical compound C1[C@H](OC)C[C@H](C)O[C@H]1CC[C@H](C)[C@H](O)[C@H](C)[C@@H]1[C@@H](C)[C@H](O)C[C@H](O)[C@H](C)[C@@H](OC)C[C@H](CC=C2)O[C@@H]2C[C@@H](O)C/C=C(\C)/C=C/C(=O)O[C@H]([C@@H](C)[C@@H](O)[C@@H](C)CC[C@@H]2O[C@@H](C)C[C@H](C2)OC)[C@@H](C)[C@H](O)C[C@H](O)[C@H](C)[C@@H](OC)C[C@H](CC=C2)O[C@@H]2C[C@@H](O)C/C=C(\C)/C=C/C(=O)O1 RJVBVECTCMRNFG-ANKJNSLFSA-N 0.000 description 1
- GDACDJNQZCXLNU-UHFFFAOYSA-N swinholide-A Natural products C1C(OC)CC(C)OC1CCC(C)C(O)C(C)C1C(C)C(O)CC(O)C(C)C(OC)CC(CC=C2)OC2CC(O)CC=C(C)C=CC(=O)O1 GDACDJNQZCXLNU-UHFFFAOYSA-N 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 150000003528 tetrahydropyranones Chemical class 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 108010065972 tick anticoagulant peptide Proteins 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 235000017103 tryptophane Nutrition 0.000 description 1
- 150000003654 tryptophanes Chemical class 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 125000005289 uranyl group Chemical group 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000001018 xanthene dye Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Abstract
Discloses peptide particles comprising an amphiphilic peptide, the amphiphilic peptide comprising a hydrophobic peptidyl segment and a hydrophilic peptidyl segment, wherein the hydrophobic peptidyl segment consists essentially of an amino acid sequence of (Trp-Leu)m-(Trp)n or (Leu-Trp)p-(Leu)q, wherein each Trp is D-Trp or L-Trp and each Leu is D-Leu or L-Leu, m and p are independently an integer from 1 to 5, and n and q are independently 0 or 1, provided that when Trp is D-Trp then Leu is L-Leu, and when Trp is L-Trp then Leu is D-Leu, or vice versa; and wherein the hydrophilic peptidyl segment consists essentially of an amino acid sequence of (Lys)r, wherein r is an integer from 1 to 15. Further discloses wherein the peptide particle further comprises a ligand for binding to a target cell adsorbed on its outer surface or a nucleic acid molecule, and uses of such peptide particles in the manufacture of cell penetrating or transfection. ein each Trp is D-Trp or L-Trp and each Leu is D-Leu or L-Leu, m and p are independently an integer from 1 to 5, and n and q are independently 0 or 1, provided that when Trp is D-Trp then Leu is L-Leu, and when Trp is L-Trp then Leu is D-Leu, or vice versa; and wherein the hydrophilic peptidyl segment consists essentially of an amino acid sequence of (Lys)r, wherein r is an integer from 1 to 15. Further discloses wherein the peptide particle further comprises a ligand for binding to a target cell adsorbed on its outer surface or a nucleic acid molecule, and uses of such peptide particles in the manufacture of cell penetrating or transfection.
Description
W0 2013/028843
PEPTIDE NANOPARTICLES AND USES THEREOF
CROSS REFERENCE TO RELATED APPLICATIONS
This Application claims the benefit under 35 U.S.C §119(e) of US. Provisional
Application Nos. 61/526,526 filed August 23, 2011, the t of which is herein
incorporated by reference in its entirety.
GOVERNMENT T
This invention was made with government support under grant no. R01
GM090317 awarded by National utes of Health. The government has certain rights in
this invention.
TECHNICAL FIELD
The present invention relates to amphiphilic peptides and particles comprising the
amphiphilic es.
BACKGROUND
Nanoparticles are useful in the stabilization and delivery of drugs: they improve
solubility, extend shelf lives, reduce side effects and sustain drug exposure for a prolonged
therapeutic . The matrix used for targeted drug delivery is usually composed of ,
polymers or metals and assembled into vesicles, micelles or paiticles. See Torchilin V. (2006)
Adv Drug Deliv. 58: 1532; Stark W (2011) Angew Chem Int Ed. 50: 1242; Soussan E et a1.
(2009) ACIE. 48: 274. The main ndent particle variables that determine the in vivo
applicability include size, surface charge, and dispersibility, mainly governed by the
hydrophobic . Nel A et a1. (2009) Nat Matter. 8: 543. In contrast to these classical
carrier materials, it is exceedingly difficult to design a colloidal delivery system exclusively
from amino acids, mainly due to solubility issues of short hydrophobic peptides.
The ution of hobic peptides is tedious and thus often requires
elaborate protocols of solvent addition [14]. Despite all efforts, many hydrophobic peptides
are not soluble at all and consequently difficult to synthesize by Fmoc- or otection
group chemistry: peptide precipitation on the solid phase during synthesis leads to small
yields and dominant quantities of by-products.
Yet a particle matrix composed of peptides is desirable as it can degrade into
single amino acids. In addition, unlike other matrix materials, e.g., polymer, products of
peptide synthesis can be purified to up to 98 %, avoiding molecular polydispersity and thus
issues with the reproducibility of physicochemical properties. Further, properties of peptide
structure can be readily modulated, e.g., by introduction of amino acid point mutations.
Accordingly, there is still a strong need for engineering a degradable drug carrier, which can
be synthesized and purified in a simple process.
SUMMARY
Various aspects and embodiments provided herein relate to amphiphilic peptides,
peptide les comprising one or more embodiments of the amphiphilic es described
herein, and uses of the amphiphilic peptides or peptide particles described herein. The net
charges of the amphiphilic peptides described herein can be adjusted by controlling the
number of charged groups present on amino acid residues of the amphiphilic es, e.g.,
by masking one or more charged amino groups, e.g., with acetylation. Therefore, the
amphiphilic peptides and e particles bed herein can be used as delivery carriers or
vehicles for different types of active agents, e.g., charged or uncharged molecules, or polar or
non-polar molecules. In addition, the peptide particles described herein can be adjusted for
their solubilities, e.g., at a physiological condition, by controlling the ratios oftwo or more
embodiments of the hilic es present in the peptide particles. For e, fully-
masked (e.g., fully-acetylated) amphiphilic es can generally form insoluble peptide
particles, while particles formed from partially-masked (e. g., partially-acetylated) or non-
masked (e.g., non-acetylated) peptides generally have a higher lity than the fully-
masked (e. g., fully-acetylated) amphiphilic peptides, e.g., at a physiological condition. Thus,
in some embodiments, the solubility of the peptide particles described herein, e.g., at a
physiological condition, can be controlled by forming the peptide particles with a mixture of
these amphiphilic peptides with distinct solubilities and varying their amounts in the peptide
particles accordingly.
[0007a} In a first aspect, the invention provides a peptide particle sing an
amphiphilic peptide, the amphiphilic peptide comprising a hydrophobic peptidyl segment and
a hydrophilic peptidyl segment,
wherein the hobic yl segment ts essentially of an amino acid
ce of (Trp-Leu)m-(Trp)n or (Leu-Trp)p-(Leu)q, wherein each Trp is D-Trp or L-
Trp and each Leu is D-Leu or L-Leu, m and p are independently an integer from 1 t0
7325831_1 (GI-{Manors} 9962“ NZ 21-Jan-18
, and n and q are independently 0 or 1, provided that when Trp is D-Trp then Leu is
L-Leu, and when Trp is L-Trp then Leu is D-Leu, or vice versa; and
wherein the hydrophilic peptidyl segment consists essentially of an amino acid
sequence of (Lys),, wherein r is an r from 1 to 15, and
wherein the peptide particle further comprises a ligand for binding to a target cell
adsorbed on its outer surface.
[0007b] In a second aspect, the invention provides use of the peptide particle of the first
aspect in the manufacture of a composition for ed delivery of an active agent.
[0007c] In a third aspect, the invention provides an in vitro method for targeted delivery
of an active agent, the method comprising contacting a cell with the peptide particle of the
first aspect.
[0007d] In a fourth aspect, the invention provides use of:
(a) a vely-charged amphiphilic peptide comprising a hobic peptidyl
t and a hydrophilic peptidyl segment,
n the hydrophobic peptidyl segment consists essentially of an amino
acid sequence of (Trp-Leu)m-("l‘rp)n or (Len-Trp)p-(Leu)q, wherein each Trp is
D-Trp or L-Trp and each Leu is D-Leu or L-Leu, m and p are independently
an integer from I to 5, and n and q are independently 0 or 1, provided that
when Trp is D-Trp then Leu is L-Leu, and when Trp is L—Trp then Leu is D—
Leu, or vice versa,
wherein the hydrophilic peptidyl segment consists essentially of an amino acid
sequence of (Lys),, wherein r is an integer from 1 to 15, and
wherein at least one of the Lys residues or the N-terminus amino group of the
amphiphilic peptide is not acetylated; and
(b) a nucleic acid le,
in the manufacture of a cell-penetrating agent or transfecting agent.
In a fifth aspect, the invention provides an in vitro method for penetrating or
transfecting a cell, the method comprising contacting a cell with a ition comprising:
(a) a vely-charged amphiphilic peptide sing a hydrophobic peptidyl segment and
a hilic peptidyl segment,
wherein the hydrophobic peptidyl segment ts essentially of an amino
acid sequence of ('I‘rp-Leu)m-(Trp)I1 or (Leu-Trp)p-(Leu)q, wherein each Trp is
D—Trp or L—Trp and each Leu is D-Leu or L-Leu, m and p are independently
732583l_1 (GHMBIIOB) PWZMNZ 21-Jan~18
an integer from 1 to 5, and n and q are independently 0 or 1, provided that
when Trp is D-Trp then Leu is L-Leu, and when Trp is L-Trp then Leu is D-
Leu, or vice versa,
wherein the hydrophilic yl segment consists essentially of an amino acid
sequence of (Lys)r, wherein r is an integer from 1 to 15, and
wherein at least one of the Lys residues or the N-terminus amino group of the
amphiphilic peptide is not acetylated; and
(b) a nucleic acid molecule.
In a sixth aspect, the invention provides a peptide particle sing a first
amphiphilic peptide and a second amphiphilic peptide, the first and the second hilic
peptide each independently comprising a hydrophobic peptidyl segment and a hydrophilic
peptidyl segment,
wherein the hydrophobic peptidyl segment consists essentially of an amino acid sequence of
("l“rp-Leu),,,-(Trp)n or (Leu—Trp)p-(Leu)q, wherein each Trp is D-Trp or L-Trp and each Leu is
D-Leu or L-Leu, m and p are independently an integer from 1 to 5, and n and q are
independently 0 or 1, provided that when Trp is D-Trp then Leu is L-Leu, and when Trp is L-
Trp then Leu is D-Leu, or vice versa; and
n the hydrophilic peptidyl segment consists essentially of an amino acid sequence of
(Lys),, wherein r is an integer from 1 to 15, and
wherein the N—terminus amino group and all of the Lys residues of the first amphiphilic
peptide are ated; and
wherein at least the N-terminus amino group or one of the Lys residues of the second
hilic peptide is not ated.
[0007g] In a seventh aspect, the invention provides use of the peptide particle of the sixth
aspect in the cture of a composition for delivery of a nucleic acid molecule to a cell.
[0007b] In an eighth aspect, the invention provides an in vitro method for delivery of a
nucleic acid le to a cell, the method comprising contacting a cell with the peptide
particle of the sixth aspect.
One aspect provided herein relates to an hilic peptide comprising a
hydrophobic peptidyl segment and a hydrophilic peptide t. The inventor has
ered that by modulating the hydrophilicity of the hydrophilic segment, they can control
the type of particle formed by the self-aggregation of the amphiphilic peptides.
732583l_1 (GHMnllers) P982“ NZ 21-Jan-16
Accordingly, one aspect of the inventions es an amphiphilic peptide
comprising a hobic peptidyl segment and a hydrophilic peptidyl segment, wherein the
hydrophobic peptidyl segment comprises a sequence of 2 to 10 alternating D- and L-amino
acids selected from alanine, valine, isoleucine, leucine (Leu), phenylalanine, ne or
7325831_1 (GHMBIICI‘S) 996244 NZ 21-Jan-18
PCT/U52012/052027
tryptophan (Trp), and wherein the hydrOphilic peptidyl segment comprises charged, or
uncharged but polar amino acids, or derivatives thereof.
In certain embodiments of this aspect and all other aspects described herein, the
hydrophobic peptidyl segment can comprise an amino acid ce of (Trp-Leu)m-(T113)n 0r
(Leu-Trp)p-(Leu)q, wherein each Trp is D—Trp or L-Trp and each Leu is D-Leu or L-Leu, m
and p are independently an integer from I to 20, and n and q are independently O or 1,
ed that when Tip is D-Trp then Leu is L-Leu, and when Trp is L—Trp then Leu is D-
Leu, or vice versa.
In some embodiments, the hydrophilic peptidyl segment can comprise at least one
charge present either on the N-terminus or an amino acid e. In such embodiments, the
at least one charge can be either a cationic or an anionic charge. In some embodiments, the at
least one ic charge can be in an amino acid residue selected from the group consisting
of Lys, Arg, His, and any combinations thereof. In some embodiments, the at least one
c charge can be in an amino acid residue selected from the group consisting of Asp or
Glu, and any combinations thereof.
In alternative embodiments, the hydrophilic peptidyl segment can comprise
uncharged but polar amino acids. In other embodiments, the hydrophilic peptidyl segment
can comprise at least one charge and at least one ged but polar amino acid. In various
embodiments, the at least one uncharged but polar amino acid residue can be ed from
the group consisting of Ser, Thr, Asn or Gln, and any combinations thereof.
In particular embodiments of this aspect and all other aspects described herein, the
hydrophilic peptidyl segment can comprise an amino acid sequence of (Lys),, n r is an
integer from 1 to 15. In some embodiments, r can be an integer from 2 to 5. In some
embodiments, r can be equal to 3.
In some embodiments of this aspect and all other aspects described , the
hydrophobic peptidyl segment can comprise a polymer. In some embodiments, the linked to
the hydrophobic peptidyl segment can be adapted to link covalently to the polymer. In certain
embodiments, the r can be biocompatible and/or biodegradable polymer. Examples of
the polymer include, but me not limited to, PEG, PGG, PEO, polycapr‘olactone, polylactic
acid, ycolic acid, polyhydroxyalkaboates, dextrans, polyanhydrides, PLA-PGA,
polyorthoester, polyfumarate, hydrogels, any art-recognized biocompatible and/or
biodegradable rs, and any ations thereof.
In certain embodiments of this aspect and all other aspects described herein, at
least one amino group in the amphiphilic peptide can be masked, e.g., by acetylation. In such
2012/052027
embodiments, the at least one amino group can be a N-terminus amino group of the
amphiphilic peptide. In other embodiments, the at least one amino group can be on a Lys
residue of the hydrophilic yl segment.
In some embodiments of this aspect and all other aspects described herein, all of
the amino groups in the hydrophilic peptidyl segment can be masked, e.g., acetylated. In
other embodiments, the N-terminus amino group of the amphiphilic peptide and at least one
of the amino groups in the hydrophilic peptidyl segment can be masked, e.g., acetylated. In
yet another embodiment, the N—terminus amino group of the amphiphilic peptide and all of
the amino groups in the hydrophilic peptidyl segment can be masked, e.g., acetylated. In
some embodiments where the hydrophilic yl t comprises an amino acid
sequence of (Lys),, the N-terminus amino group of the amphiphilic peptide and at least one
(including at least 2, at least 3, or more) of the Lys es of hydrophilic peptidyl segment
are masked, e.g., acetylated. In one embodiment where the hydrophilic peptidyl segment
comprises an amino acid sequence of (Lys),, the N-te1'minus amino group of the amphiphilic
peptide and all of the Lys residues of hydrophilic peptidyl segment are masked, e.g.,
acetylated.
In various embodiments, the hydrophobic yl segment can be linked to the
inus of the hydrophilic yl segment.
In ceitain embodiments, Leu is D-Leu. in some embodiments, Tip is L—Trp. In
some embodiments, Lys is L-Lys. In some embodiments, m or p can be independently
between 1 and 3. In one embodiment, m or p is 3. In one embodiment, it or q is 1.
ingly, one embodiment of the amphiphilic peptide ses the amino acid sequence
of (L—Lys)—(L-Lys)—(L-Lys)-(L-Tip)-(D-Leu)-(L-Trp)-(D~Leu)—(LvTrp)-(D-Leu)-(L-Tip),
wherein at least one of the L-Lys residues is acetylated,
ln some embodiments, the amphiphilic peptide can comprise the amino acid
sequence of Ac-(L~Lys)-(L—Lys)-(L-Lys)-(L-Trp)-(D-Leu)-(L-Trp)-(D-Leu)-(L-T1p)—(D—
Leu)-(L-Trp). In such ments, at least one of the L—Lys residues can be acetylated.
In other embodiments, the amphiphilic peptide can compiise the amino acid
sequence of Lys(Ac))-(L-Lys(Ac))-(L—Lys(Ac))-(L-Trp)-(D—Leu)- (L-Tip)-(D-Leu)-
(L-Trp)-(D-Leu)- (L-Tip)-X, wherein X is absent or NH:.
The amphiphilic peptide can have an amino acid sequence of any length. In some
embodiments, the amphiphilic peptide can have a length of about 5 to about 25 amino acid
residues.
The hydrophobic peptidyl segment or hydrophilic yl segment of the
PCT/U82012/052027
amphiphilic peptide can be modified. For example, at least one of the hydrophobic peptidyl
segment or the hydrophilic yl segment can compiise at least one point mutation. In
various embodiments, at least one backbone amide linkage can include an amide replacement
e. In other ments, the amphiphilic peptide can comprise at least one B-amino
acid, y—amino acid, or any combinations thereof.
In some embodiments, the hilic peptide comprises a hydrophobic peptidyl
segment and a hydrophilic peptidyl segment, wherein the hydr0phobic yl segment
comprises the amino acid sequence (AAl l-AA12)l,-(AAI3)d, wherein AAl ', AA12 and AA13 are
independently selected hydrophobic amino acids residues for each occurrence, b is an r
from 1 to 20, and dis 0 or 1, provided that AAll and AA13 have the opposite (i.e., D— and L—)
configuration and Al2 and A:3 have the opposite (i.e., D- and L-) uration; the
hydrophilic peptidyl segment comprises one or more hydrophilic amino acids 01' tives
thereof; and the amphiphilic peptide is lly or fully masked.
In some ments, an amphiphilic peptide comprises the amino acid sequence
(L-Lys),‘-((L-T1p)-(D-Leu))m‘—(L-Trp), wherein r’ is an integer from 3-21 and m‘ is an integer
from 3-20, and wherein at least one of N-terminus amino group or a side chain amino group
of at least one Lys residue is conjugated with a nitrogen— or amino—protecting group.
The inventor has discovered that some embodiments of the amphiphilic peptides
described herein can have cell penetration y. Thus, in some embodiments, amphiphilic
peptides described herein can be used as cell ation and/or transfection agents. In these
embodiments, the amphiphilic es can be designed to be positively-charged.
Accordingly, use of a composition comprising a positively-charged amphiphilic peptide as a
cell—penetrating agent or ection agent is provided herein, wherein the positive-charged
amphiphilic peptide comprises a hydrophobic peptidyl segment and a hydrophilic peptidyl
segment. The hydrophobic peptidyl segment of the positive-charged amphiphilic peptide
comprises an amino acid sequence of (Trp-Leu)m-(Trp)n or (LBu-Trp)p-(Leu)q, wherein each
Trp is D-Trp or L-Trp and each Leu is D-Leu or L—Leu, m and p are independently an integer
from 1 to 5, and n and q are independently 0 or 1, provided that when Trp is D-Trp then Leu
is L—Leu, and when Trp is L-Trp then Leu is D-Leu, or vice versa; while the hydrophilic
peptidyl segment comprises an amino acid sequence of (Lys),, wherein r is an integer from 1
to 15. Additionally, in the positively-charged amphiphilic peptide, at least one of the Lys
residues or the N-terminus amino group of the amphiphilic peptide is not ated. In some
embodiments, all of the Lys residues and the N-terminus amino group of the positively-
charged amphiphilic peptide are not acetylated.
In some embodiments, the positively-charged amphiphilic peptide can comprise
an amino acid sequence of )-(L-Lys)-(L-Lys)-(L-Tip)-(D-Leu)-(L-Trp)-(D-Leu)—(L—
Tip)-(D-Leu)-(L-Trp)-X, wherein X is absent or NHg.
In some ments, the composition can further comprise a nucleic acid
molecule (e.g., DNA or RNA) to be delivered into a cell.
Additionally, amphiphilic peptides described herein can also be used, either alone
or as part of a delivery system for delivering a compound of interest, e.g., an active agent, to
a cell. The delivery system can be a targeted delivery system. Compounds to be delivered
can include therapeutic agents, diagnostic agents and any combinations thereof. Accordingly,
one aspect of the inventions provides a method of using an amphiphilic peptide as a delivery
system, the method comprising xing an active agent with an hilic peptide and
contacting a cell with the complex. In some embodiments, the method can be used for
therapeutic or stic purposes.
In another aspect the invention provides particles comprising an hilic
peptide described herein. The inventor has discovered inter alia that the particles formed by
the amphiphilic peptides described herein differ from the particles bed in C. Dittrich,
PhD. Thesis, sittit Basel, 2007. To clarify, the particles fabricated from the
amphiphilic peptides described herein are different from those described in ch .
The peptides described in Dittrich (2007) do not comprise masked amino groups. As such,
the particles formed from such peptides are micelles, e.g., hollow particles, and not solid
les as described herein. Accordingly, in certain ments, the peptide particles
described herein are not micelles, e.g., hollow particles. Stated another way, in certain
embodiments, the peptide particles described herein are solid particles.
In some embodiments, the particle comprising an amphiphilic peptide described
herein can further se a ligand. Accordingly, in one embodiment, a peptide particle
described herein comprises an amphiphilic peptide, the amphiphilic peptide sing a
hydrophobic peptidyl segment and a hydrophilic peptidyl segment, wherein the hydrophobic
peptidyl segment comprises an amino acid sequence of (Trp-Leu)m-(Tip)n or (Len-Trp)p-
(Leu)q, wherein each Trp is D—Trp or L-Trp and each Leu is D-Leu or L-Leu, m and p are
independently an integer from 1 to 5, and n and q are independently 0 or 1, provided that
when Tip is D-Trp then Leu is L-Leu, and when Trp is L-Tip then Len is D-Leu, or vice
versa; and wherein the hydrophilic peptidyl segment comprises an amino acid sequence of
(Lys),, wherein r is an integer from 1 to 15, and wherein the peptide particle further
comprises on its outer surface a ligand.
In one embodiment, the ligand can be a cell surface receptor ligand 01' an
antibody. Exemplary cell surface receptor s include, but not limited to, transferrin,
EGF, folate and any combinations thereof. In certain embodiments, the ligand can be present
on an outer surface of the le. For example, the ligand can be adsorbed on the outer
surface of the particle described herein. In alternative embodiments, the ligand can be
covalently linked to the amphiphilic peptide. In one embodiment, the ligand is covalently
linked to the hydrophilic peptidyl segment of the amphiphilic peptide.
The thickness of the ligand present on the outer surface of the particle described
herein depends, in part, on the size of ligand molecule. In some embodiments, the thickness
of the ligand present on the outer surface of the particle can range from about 1 nm to about
100 nm. In one ment, the thickness of the ligand present on the outer surface of the
particle is about 10 nm. In some ments, a ratio of the ligand to the amphiphilic
peptides can range from about 1:10 to about l:l,000,000.
The ligand present on the peptide particle can be selected based on types of targets
(e.g., but not limited to, cells, bacteria, proteins, and/or nucleic acids) to which the peptide
particles will be delivered. For example, to facilitate delivery of a e particle described
herein to a cell, a ligand ic for the cell surface or can be selected. Hence, some
embodiments of the peptide particles bed herein can be used for targeted delivery of an
active agent using the e particles as delivery carriers or vehicles. In such embodiments,
the peptide particles can be used to deliver to a cell an active agent that is cell-impermeable
when delivered by itself.
Accordingly, in various embodiments of this aspect and all other aspects
described herein, the peptide particle can comprise one or more active agents. In such
embodiments, the active agent can be dispersed within the particle. The active agent can have
no net charge or a net charge. In some embodiments, the active agent can comprise at least
one ic group. Examples of the active agent include, without limitations, proteins,
peptides, antigens, antibodies or ns thereof, antibody-like molecules, enzymes, nucleic
acids, aptamers, small molecules, antibiotics, pharmaceutically active agents, therapeutic
agents, contrast agents, and any combinations f. In one embodiment, the active agent is
a pharmaceutically active agent or a therapeutic agent. In one ment, the active agent is
a nucleic acid molecule, including, but not d to, siRNA miRNA, shRNA, DNA and any
combinations f. In particular embodiments, the ratio of the active agent to the
amphiphilic peptides can range from about 1:1 to about 1:100,000, from about 1: l: to about
PCT/U82012/052027
1:10,000, from about 1:1 to about 1:1,000, from about 1:1 to about 1:100, or from about 1:1
to about 1:10.
The peptide particle of this aspect and all other aspects described herein can be of
any size. In some ments, the peptide particle can have a size of about 5 nm to about
,000 nm. In some embodiments, the particle can have a size of about 30 nm to about 150
In some embodiments, the e particle can comprise a mixture of fully-
masked (e.g., fully-acetylated) and partially-masked (e.g., partially—acetylated) hilic
peptides described herein. In those embodiments, the ratio of the fully-acetylated to the
partially-masked amphiphilic peptides can range from about 95:5 to about 1:1. In certain
embodiments, the particle can further comprise non-masked (e.g., non-acetylated)
amphiphilic peptides.
Accordingly, a mixed peptide particle comprising a fully-acetylated amphiphilic
peptide and a partially-acetylated or non-acetylated amphiphilic e is also provided
herein. In specific embodiments, the mixed peptide particle comprises a first amphiphilic
peptide and a second hilic peptide, wherein the first and the second amphiphilic
e each independently comprises a hydrophobic peptidyl segment and a hydrophilic
peptidyl segment, wherein the hydrophobic peptidyl segment comprises an amino acid
sequence of (Trp-Leu)m-(Trp)n or (_Leu-Trp)p-(Leu)q, wherein each Tip is D-Trp or L-Trp and
each Leu is D-Leu or L-Leu, m and p are independently an integer from 1 to 5. and n and q
are independently 0 or 1, provided that when Trp is D—Trp then Leu is L-Leu, and when Tip
is L-Tip then Leu is D—Leu, or vice versa; while the hilic peptidyl segment comprises
an amino acid sequence of (Lys),, wherein r is an integer from 1 to 15. Additionally, the N—
terminus amino group and all of the Lys residues of the first amphiphilic e are
acetylated; while at least the N-terminus amino group or one of the Lys es of the
second amphiphilic peptide is not acetylated. In some embodiments, none of the N-terminus
amino group and the Lys residues of the second hilic e is acetylated.
In particular ments, the first and second amphiphilic peptide can each
independently comprise an amino acid ce of (L-Lys)-(L-Lys)-(L-Lys)-(L-Trp)-(D-
Leu)-(L-Tip)-(D-Leu)-(L—Trp)-(D-Ieu)-(L-Trp)-X, wherein X is absent or NH;.
The ratio of the first amphiphilic peptide to the second amphiphilic peptide can be
varied based on a number of factors, e.g., but not limited to, desirable solubility andfor
stability of the peptide particle, and/or properties of the active agent to be loaded therein. In
some embodiments, the ratio of the first amphiphilic peptide to the second amphiphilic
peptide can be in a range of about 1:1 to about 1000: 1. In other ments, the ratio of the
first amphiphilic peptide to the second amphiphilic peptide can be in a range of about 5:1 to
about 100:1.
In some embodiments, the mixed e particle can further comprise an active
agent described . The active agent can be t in the mixed peptide particle in any
amounts, e.g., depending on the loading capacity of the peptide particle and/or binding
capacity of the first or second amphiphilic peptide. In some embodiments, the ratio of the
active agent to the second amphiphilic peptides can be in a range of about 1:1000 to 1:1, or
about 1:100 to about 1:10. In some embodiments, the ratio of the active agent to the second
amphiphilic peptide can be in a range of about 1:10 to about 1:2.
Without wishing to be bound by theory, the presence of the second amphiphilic
peptide in the mixed peptide particle can provide a cationic charge for binding with anionic
nucleic acid molecules. Thus, in some embodiments, the active agent can include a nucleic
acid molecule.
In some ments, the mixed peptide particle can further comprise on its outer
surface a ligand. As described earlier, selection of a ligand can be determined based on a
target molecule (e.g., but not limited to, cells, bacteria, proteins, nucleic acids) to which the
mixed peptide particle binds. Non-limiting examples of a ligand can include a cell e
receptor ligand or a protein such as an antibody. In some embodiments, the ligand can be
covalently linked to at least one of the first and the second amphiphilic peptide, e.g.. the
hydrophilic peptidyl segment of at least one of the first and the second amphiphilic peptide.
The mixed peptide particle described herein can be used to encapsulate any active
agent described herein. In a specific embodiment, the mixed peptide particle can be used to
encapsulate a nucleic acid molecule. Thus, a further aspect of the inventions es use of
one or more embodiments of the mixed peptide particle comprising a first amphiphilic
peptide and a second amphiphilic peptide for delivery of a nucleic acid le to a cell. In
some embodiments, the nucleic acid molecule can e RNA (e.g., but not limited to
siRNA, miRNA, shRNA), DNA, or any combinations thereof.
Compositions or kits for making one or more ments of a e particle or
a mixed peptide particle are also provided herein. In some embodiments, the composition or
kit can comprise an amphiphilic peptide described herein. The amphiphilic peptide provided
in the composition or kit can be stored in a container. Depending on a user’s choice of a
peptide particle or mixed le described herein to be produced, in some embodiments, the
ition or kit can comprise a first amphiphilic peptide and a second amphiphilic peptide
PCT/U52012/052027
described herein. The amphiphilic peptide can be provided in powder or lyophilized powder.
In some embodiments, the composition or kit can further comprise at least one t, e.g.,
for titution of the ed amphiphilic peptide, for emulsification of a particle
assembly mixture, or both. In some embodiments, the ition or kit can further comprise
a ligand described herein, e.g., provided in a separate container. In some embodiments, the
composition or kit can further comprise an active agent to be encapsulated into the peptide
particle. The active agent can be ed in a separate container.
BRIEF DESCRIPTION OF THE DRAWINGS
Figs. lA—lB show characterization results of ed CD3ac in accordance with
one or more embodiments of the invention. Fig. 1A shows a mass spectrum measured on an
orbitrap mass spectrometer. Fig. 1B shows an overlaid RP-HPLC elution profiles of CD3ac
and synthesis intermediate CD3 measured by absorption at 280 nm. Product purity exceeds
95% in both cases.
Figs. 2A-2C show SEM images of CD3ac peptide nanoparticles in ance
with one or more embodiments of the invention. Figs. 2A-ZB show SEM images of
lyophilized CD3ac beads. Fig. 2C shows an SEM Image of a CD3ac-bead, broken in the
process of freeze-drying. The image reveals the solid property of the peptide itates.
Figs. 3A-3B show linear fits of dynamic light scattering (DLS) results. It is
determined that both particle concentration (Fig. 3A) and detection angle (Fig. 3B) unlikely
influence the diffusion properties of CD3ac beads in aqueous solution.
Fig. 4 shows a set of circular dichroism spectra of CD3ac derivatives CD1, CD2,
CD3 and CD4. Displayed numbers equal the number of N-terminally attached lysine
residues.
Figs. 5A-SB show the s of solely L-amino acids on properties of peptide
nanoparticles. Fig. 5A shows an SEM image of precipitated . cal assembly as
observed in CD3ac particles could not be observed with precipitated LCD3ac. Fig. 5B show
circular dichroism spectra of CD3 (straight line) and LCD3 (dashed line), indicating the
differences in secondary structure due to the chirality of leucine amino acids. LCD3 ts
alpha-helical characteristics.
Figs. 6A-6C show confocal microscopy images of CD3ac beads co-assembled
with rose bengal (RB), 5-carboxy-fluorescein (CF), or a mixture of both. Fig. 6A Show
confocal microscopy images of CD3ac beads co-assembled with RB. Fig. 6B show confocal
microscopy images of CD3ac beads co-assembled with CF. Fig. 6C show CD3ac beads
PCT/U52012/052027
loaded with RB and CF, indicating the ability of the peptide beads to simultaneously
encapsulate compounds of high and low solubility in s solution. As shown in Figs.
6A-6C, RB-containing CD3ac beads are observed as individual spheres, whereas beads
containing exclusively CF tend to aggregate. In Figs. 6A-6C, upper left panels: fluorescence
emission of RB; bottom right panels: fluorescence emission of CF; top right panels: phase
contrast image; and bottom left panels: co—localization of both fluorescent channels. The
width of one panel corresponds to 55 pm.
Figs. 7A-7B show encapsulation efficiency of rose bengal (RB) in CD3ac
nanoparticles. Fig. 7A show results of co-precipitation efficiency of RB with CD3ac. The x-
axis describes the initially dissolved concentration ratio of CD3ac to RB, prior to solvent
exchange and assembly. Left y-axis: molar composition of precipitate (0). Right :
molar ratio of encapsulated to overall RB (A). As an example, at an initial ratio of
RB: CD3ac = 1:4, about 15 mol-% of the beads consist of RB and about 33% of initially
dissolved RB was encapsulated in the assemblies. Fig. 7B shows tryptophan absorption of
pellet (A) and atant fractions (0) containing different amounts of RB, indicating that
CD3ac assembly is not compromised by equimolar concentrations of RB cargo.
Figs. 8A-8I show results of characterization of CD3ac peptide particles assembled
in the presence of transferrin d with AF568 (Tfn-AFS68) and Flutax-2 and transferrin
(Tfn). Figs. 8A-8C show fluorescence microscopy images of peptide particles’ red (Fig. 8A)
and green (Fig. 8B) fluorescence before nation. The merged image (Fig. 8C) shows
ential fluorescence distribution for Tfn-AF-568 (ring) and Flutax~2 (equally
distributed). Figs. 8D-8F show fluorescent images of the same sample after nation for 6
hours. The characteristic ring of Tfn-AF—568 fluorescence disappeared (Fig. 8D) and the
emission intensity of Flutax-2 increased by a factor of 13.5 (Fig. 8E). Figs. 8G—8H Show
averaged gray level profile of n=10 particles in the red (Fig. 80) and green (Fig. 8H) channel
before and after trypsination. Fig. 81 shows a tic diagram of CD3ac peptide particles
with a protein corona (e.g., Tfn-AF568) before and after tiypsination.
Figs. 9A-9D show s of compositions of Flutax—2 and 568 within the
CD3ac peptide nanopaiticles. Figs. 9A and 9B show quantified ition of peptide
les self-assembled with Tfn-AF568 (Fig. 9A) and Flutax-2 (Fig. 9B), respectively. The
x-axis describes the concentration ratio of initially dissolved Tfn-AF568 or Flutax-2 to
CD3ac (123 uM), prior to solvent exchange and assembly. Left y-axis (open s): molar
composition of peptide nanoparticles (PNPs). Right y~axis (closed symbols): molar ratio of
PCT/U82012/052027
encapsulated to overall Tfn-AF568 or Flutax-Z. As an example in Fig. 98, at an initial ratio
of Flutax-ZzCD3ac = 0.], about 7.5 mol—% ofa PNP consists of Flutax-2 and about 80 % of
initially dissolved Flutax-2 was encapsulated. The consistent encapsulation efficiency of
Flutax-2 around 80 % corresponds to a logarithmic partition coefficient of 5.25. Fig. 9C
shows Tfn—AF568 fluorescence intensity distribution of PNPs before and after competition
with Tfn. Particles were led in the presence of 10 pg/mL Tfn-568 and imaged
immediately after formation. The black bars pond to ity distribution of the
ing fluorescence puncta. The distribution represented by gray bars describes the
fluorescence intensities of the same PNPs after an incubation period of 24 hours at 37 °C in
the presence of 1360 pg/mL Tfn. Fig. 9D shows a cumulative data plot Tfn-AF568
fluorescence intensity distribution of PNPs before and after ition with Tfn as shown in
Fig. 9C.
Figs. lOA—IOK show control of particle diameter and characterization of
nanoparticle morphology by TEM. Figs. lOA-lOC show Tfn~AF568 fluorescence on peptide
particles assembled from 492 itM, 246 rrM and 123 rrM CDBac. Scale bars correspond to
1 pm. Fig. 10D show three overlaid fluorescence intensity profiles, each of which shows the
average results of 10 particles. Results are represented by mean +/- standard deviation.
Fig. 10E shows a tic interpretation of intensity es illustrating the relation of
particle size, corona fluorescence and the limited resolution of light microscopy. Figs. 10F-
101 show negative staining TEM images of CD3ac particles assembled in the e
(Figs. G) and presence (Figs. 10H-IOI) of 10 itg/mL Tfn. Protein—containing (e.g., Tfn-
containing) samples can be distinguished by a layer of intermediate contrast around the
peptide particles. Occasional holes (indicated by black arrow) were resulted from vacuum
applied in the TEM and similar observation has been described in Hyuk I. et al., (2005) Nat
Matter 4: 67]. Figs. 10.] -10K show that final particle size depends on the presence of Tfn
during assembly. Particle formation in the absence of Tfn-AF568 results in an average
particle diameter of 100 nm (Fig. 10]) where the presence of protein during particle assembly
reduces the diameter to 51 nm (Fig. 10K). The ess of the protein corona corresponds to
9.0 +/- 2.1 nm (inset of Fig. 10K).
Figs. 1 lA-I 1H show effects of Tfn competition on PNPTIW‘F508 binding to CHOFMax—2
cells. mam?“ is used herein as an acronym for CD3ac e iticles self-
assembled in the presence of cargo (e.g., -Z used herein) and corona (e.g., Tfn-AF568
used herein). Figs. llA—l 1C show cence microscopy images of CHO cells incubated
PCT/U82012/052027
with PNPFCfiu'JQ’“ for one hour. alization of scent puncta in the green (Flutax—Z)
and red channel (Tfn-AF568) indicates the identity of particles, which accumulate on cells.
Figs llD-l lF show CHO cells ted with PNPUW‘”68 for one hour in the presence of
Flumx—Z
]7 uM Tfn. PNP association is significantly d. Scale bars correspond to 10 um. Fig.
116 show averaged peptide nanoparticle (PNP) counts per cell (e.g., CHO or TRVb). The
value for the negative control (NC) corresponds to false ve fluorescence puncta on CHO
cells incubated in the absence of PNPTfu—AF56B but otherwise identical trations of Tfn-
F{mm—2
AF568 and Flutax—Z. s are mean +/- , double asterisk indicates P < 109,
Kolmogorov-Smimov. Fig. 11H show a set of images showing CHO cells after 1 hour
incubation with PNPU"“"‘FSO8
Hula-2 . The upper row and the lower row show cells incubated in the
absence and presence of 17 trM Tfn, tively. The area outlined in a white square is
magnified in Figs. llA—l 1F. Scale bars correspond to 20 pm.
Figs. 12A-12M show experimental results of internalization of nanoparticles. Figs.
12A-12D show fluorescence microscopy images of CHO cells incubated with PNP”"A’"5"8
Flumx—Z
for 1 hour. Fig. 12E shows distributions of Flutax-2/Tfn~AF568 fluorescence of PNI’UEFAF568
Flulru' —2
(G/R) after 1 hour incubation of CHO cells with PNPU'H’MFlumx-Z . Grey bars represent G/R on
the glass slide, black bars correspond to G/R found within the cell perimeter. Fig. 12F shows
schematic of particle association and internalization after 1 hour. Figs. 120-121 show
fluorescence microscopy images of CHO cells incubated with PNPTIW‘F568 for 6 hours,
Flutax-Z
wherein the shift of les towards higher G/R values serves as a surrogate of particle
internalization. Fig. 12K shows that the distribution of G/R values is significantly increased
after a longer incubation period (black bars). In contrast, the distribution of G/R values on the
glass slide (grey bars) is statistically indistinguishable from the G/R values of the same
subpopulation after 1 hour. Fig. 12L shows schematic of particle association and
internalization after 6 hours. For particles in lysosomal compartments, corona is
proteolytically digested yielding decreased Tfn—AF568 fluorescence and increased Flutax-2
fluorescence. Fig. 12M shows images indicating color shift of PNPU’H‘”68
-2 . The upper row
shows CHO cells incubated with PNPU’M‘F568 for 1 hour and contrasts the lower row, where
Flurax—l
the same cell line was incubated with PNP”"‘"F568 for 6 hours. The area outlined in a white
Flumx-Z
square is magnified in Figs. 12A- 12D and 120—12]. Scale bars correspond to 20 um.
PCT/U82012/052027
Figs. 13A- 131 show release of cargo after incubation with PNPm'AF568 for 24
Fltunx—Z
hours. Figs. l3A-13C show fluorescence microscopy images of CHO cells incubated for 24
hours with 67 nM Flutax-2 and 0.09 itg/mL Tfn-AF568. Figs. 13D-13G show fluorescence
images of CHO cells incubated for 24 hours with the same amount of Flutax~2 and Tfn—
AF568 ssembled with CD3ac to form PNPTfH‘F56B
Flumx—Z . Fig. 13H shows averaged Flutax-Z
fluorescence intensity dependent of cell line (CHO, TRVb) and competition with dissolved
unlabeled Tfn. The negative control (NC) corresponds to cellular autofluorescence in the
green channel. Results are mean +/— s.e.m., single asterisk indicate P < 0.01, double asterisk
indicates P < 10"), Kolmogorov—Smimov. Scale bars correspond to 10 um. I shows
images of CHO cells after 24 hours incubation with Flutax-Z. Both samples (upper and lower
row) contain 66.7 nM -2. The upper row shows a cell culture incubated with —Z
dissolved in the cell culture media, the lower row the same cell line incubated with Flutax-2
previously self-assembled into PNPm'A”68Flaunt—2 . The area outlined in a white square is magnified
in Figs. G. Scale bars correspond to 20 um.
Fig. 14 shows a set of fluorescence microscopy images of peptide paiticles (e.g.,
CD3ac) assembled with Flutax—2 and Tfn-AF568. The upper row shows the sample prior to
nation. Red and green channel are not congment as the dispersed particles move and
there is a time delay between the images caused by the change of excitation and emission
filters. Identical particles are set in brackets and are superimposed in Figs. 8A-8F. The lower
row shows the same sample after 6 hours tion with trypsin. The red corona disappears
and the remaining particles adhere to the surface of the glass cover slide.
Figs. ISA-158 show fluorescence calibration cuwes of 568 (Fig. 15A) and
Flutax-2 (Fig. 15B). Both measured in a on of 60 % H30, 30 % DMSO, 10 % FBS. The
organic solvent is required to dissolve the nanoparticles in the pellet fraction and the ce
of PBS minimizes adsorption of labeled analytes to plastic surfaces, providing linearity
between fluorophore concentration and measured fluorescence.
Figs. l6A-16B show a peptide nanoparticle according to one or more
embodiments of the ion. Fig. 16A shows a schematic diagram of a CD3ac particle
functionalized with EGF molecules, which can be ally labeled with Texas Red (for
visualization purposes). Fig. 16B is a set of fluouescent images showing the EGF-
functionalized CD3ac patticles uptaken by the cells.
Figs. l7A-17K show experimental results of cells (e.g., HeLa cells) d with
one embodiments of the peptide nanopaiticles encapsulated with nocodazole (which is an
PCT/U82012/052027
chemical agent that can merize microtubules and be used as an anti-neoplastic .
Fig. 17A shows a schematic representation of four different mental conditions, wherein
PB 1e represents BOP-functionalized CD3ac rticles encapsulated with 20 “M
nocodazole, and the experimental results are shown in Figs. 17Bn17F. Fig. 17B shows a set of
fluorescent images showing microtubule structures of the cells after 1 hour of incubation
under the conditions indicated in Fig. 17A. The red fluorescent signals inside the cells
indicate the PBle nanoparticles uptaken by the cells. Fig. 17C shows a set of fluorescent
images showing PB 1e nanoparticles uptaken by the cells after various periods of times as
indicated. Figs. 17D~17F shows fluorescent images of microtubular structures of HeLa cells
d under different conditions as indicated. Fig. 170 shows a schematic representation of
four ent experimental conditions, wherein PBle represents BOP-functionalized CD3ac
nanopatticles encapsulated with 40 uM nocodazole, and the experimental results are shown
in Figs. 17H-17K. Figs. 17H-17I shows images of cells after 4 hours of tion under
different conditions as indicated. Fig. 171 shows fluorescent images of microtubular
structures (indicated by green) of cells under different conditions. The red signals inside cells
indicate the PBle nanoparticles uptaken by the cells. Figs. l7J-17K shows images of cells
after 24 hours of incubation under ent conditions as indicated. Fig. 17K shows
fluorescent images of microtubular structures (indicated by green) of cells under ent
conditions. The red signals inside cells indicate the PB 1e nanopaiticles uptaken by the cells.
Figs. 18A-18C show another embodiment of the peptide nanoparticles in
accordance with the ion, wherein the CD3ac nanoparticles are onalized with an
antibody. Fig. 18A shows schematic representations of CD3ac nanoparticles functionalized
with primary or secondary antibodies. Fig. 188 shows that the CD3ac nanoparticles
functionalized with rabbit anti transferrin IgG can bind to transferrin (labeled with A568),
and thus shown as bright spots on the right of the figure. Fig. 18C shows that the CD3ac
nanopaiticles functionalized with rabbit anti transferrin IgG can bind to abbit IgG
(labeled with 55), and thus shown as bright spots on the right of the figure.
Figs. 19A-19B show fluorescent images of non-acetylated peptide rticles
(CD3) for use as a transfection agent in vitro. Fig. 19A shows that CD3 particles can be used
to deliver oligonucleotides inside cells. Fig. 193 shows no cell transfection with
oligonucleotides in the absence of CD3 particles.
Figs. 2OA-20B show encapsulation efficiency of oligonucleotides in non-
acetylated peptide particles. Fig. 20A is a set of time-course images showing migration of
PCT/U52012/052027
oligonucleotides and proteins across an agarose gel during electrophoresis. In Fig. 20A, the
upper lane was loaded with a mixture containing ~21 pM CD3 peptides (H—LK—LK-LK-LW-
DL-LW-DL-LW-NHJ”, ~5.4 pM ssDNA
(5‘-TTGTGCCGCCTTTGCAGGTGTATC-3‘)24', ~0.24 pM ssDNA (AF488-5‘-
TTGTGCCGCCTTTGCAGGTGTATC—3924', and ~4. l4 ug/mL Tfn-AFS 68, while the lower
(control) lane was loaded with a similar mixture but without CD3 peptides. After about
40-min electrophoresis, excess ssDNA and Tfn migrated across the agarose gel toward the
anode, while the peptide particles formed at the loading zone of the e gel (as evidenced
by co-localization of the AF488 signal and AF568 fluorescence signal) were not able to
migrate in the agarose gel due to their larger size. Fig. ZOB is a set of HP—WAX (weak anion
exchange) chromatography data showing that a majority of CD3 peptides and ssDNA were
encapsulated in peptide particles (pellet), and little remained in supernatant. Peak at ~15 min:
CD3 peptides; Peaks at ~14.5 min and ~15 min: ssDNA ted and partially-hybridized,
respectively.
Fig. 21 is a microscopic fluorescent image g uptake of nucleic acid—
containing peptide particles by HeLa cells. In this embodiment, the peptide particles were
formed from a mixture comprising CD3 peptides, CD3ac peptides, oligonucleotides (e.g.,
ssDNA) and trasferrin. The co-localization of the ssDNA—AF488 cence signal with the
peptide particles (as indicated by transferrin»AF568 fluorescence, where transferrin forms on
the external surface of the particle) indicates the stability of the peptide particles at a
physiological ion and the capability of such peptide particles to r nucleic acid
molecules or oligonucleotides to cells.
Figs. 22A-22D show data for stability of ssDNA-containing peptide particles in
serum (e.g., ~10% serum) and efficiency of cell transfection using the peptide particles.
Fig. 22A shows that the stability of PNPl particles (ssDNA-containing CD3 peptide
particles) in water is temperature-dependent and more PNPl particles tend to dissociate at a
higher temperature. Fig. 223 shows stability data for a time-course study of the PNPI
particles in water, ting that the ity of PNPl particles in water is temperaturedependent
and the PNPl particles tend to dissociate faster at a higher temperature, e.g., at a
temperature higher than 4 °C. Fig. 22C is a set of fluorescent images showing HeLa cells
incubated in the presence of PNPl particles or PNP2 particles (ssDNA-containing
CD3/CD3ac peptide particles) at temperatures of about 4°C and about 37°C. The upper
panels of Fig. 22C show that diffuse and er 568 fluorescence signal was
PCT/U82012/052027
detected in the cytosol when the cells were incubated with the PNPl particles at about 37 °C,
as compared to more punctated Tfn—AF568 fluorescence detected in the cells incubated at
about 4 °C. However, this contrast was not observed in the cells incubated with the PNP2
particles, as shown in the lower panels of Fig. 22C. Instead, the lower panels of Fig. 22C
show that punctated and comparable Tfn-AF568 fluorescence signals were observed in both
the cells incubated at about 4 °C and about 37 °C, in the presence of the PNP2 les.
These findings indicate that the PNP'l particles tend to dissociate in serum (e. g., ~10% serum)
at about 37 °C; while the PNP2 particles appear to be more stable in serum (e.g., ~10%
serum) at about 37 °C for at least about 30 mins. Fig. 22D is a fluorescent image of negative
control cells (i.e., HeLa cells incubated in the presence of ssDNA without PNPl or PNP2
particles or corresponding peptides), indicating that much lower fluorescence ity of
AF488-ssDNA is observed in the negative control than that in the cells incubated with the
PNPl or PNP2 particles.
DETAILED DESCRIPTION OF THE INVENTION
Various aspects and embodiments provided herein relate to amphiphilic peptides,
e particles comprising one or more embodiments of the hilic peptides bed
herein, and uses of the amphiphilic es or peptide particles described . The net
charges of the amphiphilic peptides bed herein can be adjusted by controlling the
number of d groups present on amino acid residues of the amphiphilic peptides, e.g.,
by masking one or more charged amino groups, e.g., with acetylation. Therefore, the
amphiphilic peptides and peptide particles described herein can be used as delivery carriers or
vehicles for different types of active agents, e.g., charged or uncharged les, or polar or
non-polar molecules. In addition, the peptide particles described herein can be adjusted for
their solubilities, e.g., at a physiological condition, by controlling the ratios of two or more
embodiments of the amphiphilic peptides present in the peptide particles. For example, fully-
masked (e.g., fully-acetylated) amphiphilic peptides can generally form insoluble peptide
particles, while les formed from partially-masked (e.g., lly-acetylated) or non—
masked (e.g., non-acetylated) es lly have a higher solubility (or lower stability)
than the fully-masked (e.g., fully-acetylated) amphiphilic peptides, e.g., at a logical
condition. Thus, in some embodiments, the solubility or stability of the peptide particles
described herein, e.g., at a physiological condition, can be controlled, e.g., by forming peptide
les with a mixture of amphiphilic peptides with distinct solubilities and varying their
W0 2013/028843
amounts in the peptide particles accordingly. Accordingly, verstability and stability of
amphiphilic peptides and peptide particles described herein can be tailored for a variety of
applications, e.g., drug delivery and/or sustained release of an active agent.
By the term “stability” or “stable” used herein is meant an ability of a peptide
le to retain its original volume (e.g., at least about 50%, at least about 60%, at least
about 70%, at least about 80%, at least about 90%, at least about 95%, or more of its original
) for a period of time, e.g., at least about 30 mins or longer (including at least about 1
hour, at least about 3 hours, at least about 6 hours, at least about 12 hours, at least about 24
hours, or longer), under a ed condition, e.g., a physiological condition. Stability of a
peptide particle can be, in part, governed by its solubility under a specified condition. The
more soluble is a peptide particle under a specified condition, the less stable is the e
le under the specified ion. In one embodiment, the term “stability” or “stable” as
used herein refers to a peptide particle being insoluble under a specified ion, e. g., in an
aqueous medium at a specified temperature. In some embodiments, the aqueous medium is
water. In some embodiments, the aqueous medium is a physiological medium, e.g., with a
certain salt concentration, pH and/0r protein/serum concentration.
In one aspect, an amphiphilic peptide comprising a hydrophobic peptidyl segment
and a hydrophilic peptide segment is provided herein. The inventor has discovered inter alia
that by modulating the hydrophilicity of a hydrophilic amino acid residue of an amphiphilic
peptide, the amphiphilicity of the amphiphilic peptide can be modulated such that it
unexpectedly leads to self-assembly of the es into solid particles. The amphiphilicity
can be modulated by conjugating a hydrOphilic group to an amino acid in the hydrOphilic
peptidyl segment, or by masking a hydrophilic group in the hydrophilic yl t, or
masking the N-terminus amino group of the amphiphilic peptide. For example, when the
hydrophilic amino acid is a charged amino acid, the hydrophilicity can be modulated by
conjugating the charged part of the molecule with a protecting group. Accordingly, in some
embodiments, at least one amino group in the amphiphilic peptide is conjugated with a
nitrogen- or amino-protecting group.
In some embodiments, the amphiphilic peptide is fully masked. As used herein, a
fully masked peptides refers to an amphiphilic e in which the N-terminus amino group
and all of the side chain amino groups in the hilic peptidyl segment are conjugated
with a en- or amino-protecting group.
In some embodiments, the amphiphilic peptide is partially masked. As used
, a partially masked peptide refers to an amphiphilic peptide in which one or more of
PCT/U52012/052027
the N-terminus amino group or side chain amino groups in the hydrophilic peptidyl segment
is not conjugated with a nitrogen- or amino-protecting group; however, the amphiphilic
peptide still comprises at least one amino group ated with a nitrogen- or amino-
protecting group.
As used herein, a “nitrogen protecting group” or an “amino ting group”
refers to es that block or mask the NH; group. Exemplary amino-protecting groups
include, but are not limited to, carbamate protecting groups, such as 2-
hylsilylethoxycarbonyl (Teoc), l-methyl-l —(4—biphenylyl)ethoxycaibonyl (Bpoc), t—
butoxycarbonyl (BOC), allyloxycarbonyl (Alloc), 9-fluorenylmethyloxycarbonyl (Fmoc), and
benzyloxycarbonyl (Cbz); amide protecting groups, such as formyl, acetyl, trihaloacetyl,
l, and nitrophenylacctyl; sulfonamide protecting groups, such as 2-
nitrobenzenesulfonyl: and imine and cyclic imide protecting groups, such as phthalimido and
dithiasuccinoyl. Further amino protecting groups, as well as other representative ting
groups, are disclosed in Greene and Wuts, Protective Groups in Organic Synthesis, Chapter
2, 2d ed., John Wiley & Sons, New York, 1991, and Oligonucleotides And Analogues A
Practical Approach, Ekstein, F. Ed., IRL Press, NY, 1991, content of which is herein
incorporated by reference in its entirety.
In some embodiments, the nitrogem or amino-protecting group is acyl or alkyl,
e.g., acetyl, ethanoyl, propionyl, t-butanoyl, , ethyl, , butyl, pentyl, or hexanyl.
In some embodiments, the N—terminus amino group of an amphiphilic peptide is
conjugated with a nitrogen- or amino-protecting group.
In some embodiments, at least one (e.g., l, 2, 3, 4, 5,6,7, 8, 9, 10 or more)
sidechain amino group of an amino acid of the amphiphilic peptide is conjugated with a
nitrogen- or amino-protecting group. The amino acid whose side chain amino group is to be
conjugated can be t at any position in the amphiphilic peptide. The sidechain
conjugated amino acids can be present next to each other or not next to each other. When
three or more sidechain conjugated amino acids are present some of the sidechain amino
acids can be present next to another sidechain ated amino acid while some of the
sidechain conjugated amino acids are not next to r sidechain conjugated amino acid.
Additionally, when two or more nitrogen- or amino—protecting groups are t, they can
all be the same all different or any combination of same and different.
In some embodiments, at least one (e.g., l, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more)
sidechain amino group of an amino acid in the hydrophilic peptidyl segment is conjugated
with a nitrogen— or amino-protecting group. Without limitations, the sidechain conjugated
amino acid can be t at any position of the hydrophilic peptidyl t. For example,
reading from the N-terminal, at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and so on of the
hydrophilic peptidyl segment.
In some embodiments, the N-terminus amino group of the amphiphilic peptide
and at least one sidechain amino group (including, e.g., at least one, at least two, at least three
or more sidechain amino groups) in the hydrophilic peptidyl segment of the amphiphilic
peptide is conjugated with a nitrogen- or amino-protecting group. In some embodiments, the
N-terminus amino group of the amphiphilic peptide and at least one sidechain amino group
(including, e.g., at least one, at least two, at least three or more sidechain amino groups) in
the hydrophilic peptidyl segment of the amphiphilic peptide is acetylated.
In some embodiments, the N-terminus amino group of the amphiphilic peptide
and all of the sidechain amino groups in the hydrophilic peptidyl segment of the amphiphilic
peptide are conjugated with a nitrogen- or amino-protecting group. In some embodiments, the
N-terminus amino group of the amphiphilic peptide and all of the sidechain amino groups in
the hydrophilic peptidyl t of the amphiphilic peptide are ated.
Without wishing to be bound by a theory ce of a nitrogen- or amino-
protecting group in the amphiphilic peptide modulate the hilicity of the amphiphilic
peptide. Thus, hilic nature of the amphiphilic peptide can be tuned by varying the
number of nitrogen- or amino-protecting groups in the amphiphilic peptide.
The amphiphilic peptide can have an amino acid sequence of any length. In some
ments, the amphiphilic peptide can have a length of about 5 to about 25 amino acid
residues. In one embodiment, the amphiphilic peptide has a length of about 10 amino acid
residues.
Hvdroghobic ggegtidv/ segment
As used herein, the term "hydrophobic peptidyl segment" refers to a peptidyl
segment having a relatively high t of hydrophobic amino acid. For example, a
hydrophobic peptidyl segment refers to a yl segment, in which at least about 50% or
more (including at least about 50%, at least about 60%, at least about 70%, at least about
80%, at least about 90%, at least about 95% or more) of the amino acid residues are
hydrOphobic amino acid es. In one embodiment, a hydrophobic peptidyl segment is a
peptidyl t, in which all of the amino acids are hydrophobic amino acids.
Accordingly, in some embodiments, the hobic peptidyl segment is
comprises the amino acid sequence (AA'l-AA12)b—(AA13)d, wherein AA”, AAl2 and AA13 are
PCT/U52012/052027
independently selected hydrophobic amino acids residues for each occurrence, b is an r
from 1 to 20, and d is 0 or 1, provided that AAll and AA12 have the opposite (i.e., D- and L-)
configuration and A12 and A13 have the opposite configuration. For example, if amino acids
represented by AAll have the D- configuration then amino acids represented by AA12 have
the L» configuration and AA”, if t, has the D- configuration. atively, if the
amino acids represented by AAll have the L- configuration then amino acids represented by
AA12 have the D- configuration and AA”, if present, has the L- configuration.
In some embodiments, the hydrophobic yl segment comprises a sequence of
2 to 10 alternating D- and L- amino acids selected from the group consisting of alanine,
valine, isoleucine, 1eucine(Leu), phenylalanine, tyrosine, phan (Trp) and any
combinations thereof.
As used herein, the term "hydrophobic amino acid" refers to an amino acid
ting a hydrophobicity of greater than zero according to the normalized consensus
hydrophobicity scale of Eisenberg, 1984, J. Mol. Biol. 179: 2 (1984). Exemplary
hydrophobic amino acids include, but are not limited to, Ala, Val, Ile, Leu, Phe, Tyr, Tip,
Pro, Met, Gly and derivatives thereof.
In some embodiments, a hydrophobic amino acid is an aromatic amino acid. As
used herein, the term tic amino acid" refers to a hydrophobic amino acid with a side
chain having at least one aromatic or heteroaromatic ring. The aromatic or heteroaromatic
ring may contain one or more substituents such as —OH, —SH, —CN, —F, —Cl, —Br, —I,
~NO2, —NO, —NH3, NHR, —NRR, ~C(O)R, ~C(O)OH, —C(O)OR, —C(O)NH3, —
C(O)NHR, —C(O)NRR and the like where each R is independently (C1 —C6) alkyl,
substituted (C2—C6) alkyl, (C2—C6) alkenyl, substituted (C2-C6) alkenyl, (C2—C6) alkynyl,
tuted (C2-C6) alkynyl, (CS-€20) aryl, substituted (CS-€20) aryl, (C6-C26) alkaryl,
substituted (CG-C26) alkaryl, 5-20 membered heteroaryl, substituted 5-20 membered
heteroaiyl, 6-26 membered alkheteroaryl or substituted 6-26 membered alkheteroary].
Exemplary aromatic amino acids include, but are not limited to, Phe, Tyr and Trp.
In some embodiments, a hydrophobic amino acid is an aliphatic amino acid. As
used herein, the term atic amino acid" refers to a hydrophobic amino acid having an
aliphatic hydrocarbon side chain. ary aliphatic amino acids include, but are not
limited to, Ala, Val, beu and Ile.
In some ments, a hydrophobic amino acid is a nonpolar amino acid. As
used herein, the temi "nonpolar amino acid" refers to a hydrophobic amino acid having a side
chain that is ged at physiological pH and which has bonds in which the pair of
W0 28843 PCT/U82012/052027
electrons shared in common by two atoms is generally held equally by each of the two atoms
(i.e., the side chain is not polar). Exemplary nonpolar amino acids include, but are not
limited to, Leu, Val, Ile, Met, Gly and Ala.
As will be appreciated by those of skill in the an, the categories of amino acids
described herein are not mutually exclusive. Thus, amino acids having side chains ting
two or more physical»chemical properties can be included in multiple categories. For
example, amino acid side chains having aromatic moieties that are r substituted with
polar substituents, such as Tyr, can exhibit both ic hydrophobic properties and polar or
hydrophilic properties, and can therefore be included in both the ic and polar
categories. The appropriate categorization of any amino acid will be apparent to those of skill
in the an, especially in light of the detailed disclosure provided herein.
In some embodiments, for each occurrence AAl '. AA12 and AA[3 are selected
independently from the group consisting of Pro, lle, Phe, Val, Leu, Trp, Met, Ala, Gly, Tyr,
and any combinations thereof.
Without limitation, all of the AA” and AA12 can be the same, all different, or any
ations of same and different. Accordingly, in some embodiments, all of AA11 are
same. In some ments, all of AA12 are same. In some embodiments, all of AAll are
same, all of AAI2 are same, and AA” is different from AA”.
] In some embodiments, at least one of AAI 1, AA12 and AA'3 is not Tyr or Leu.
In some ments, at least one AAIl is not Tyr.
In some embodiments, at least one of AA'2 is not Leu.
In some ments, AA13 is not Tyr or Lea.
In some embodiments, AA11 is Tyr.
In some embodiments, AA'2 is Leu.
In some embodiments, the hydrophobic peptidyl segment comprises an amino
acid sequence (Trp-Leu),,.-(Trp)In or (Len-Trp)p-(Leu)q, wherein m and p are independently an
integer from 3 to 20, and n and q are independently 0 or 1. Each Trp can be D-Trp or L-Trp,
and each Leu can be D-Leu or L-Leu. When Trp is D-Trp, then Leu is L-Leu, and when Tip
is L-Trp, then Leu is D-Leu. Similarly, when Leu is L-Leu, then Tip is D-Trp, and when Leu
is D-Leu, then Trp is L-Trp,
In some embodiment, m and p are independently an integer of l, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, l2, l3, 14, or 15. In some embodiments, m and p are independently an integer from
1 to 5 (e.g., an integer of 1, 2, 3, 4, or 5). In some embodiments, m or p is an integer of 1, 2,
or 3. In one embodiment, m or p is an integer of 3.
PCT/U82012/052027
In one embodiment, the hydrophobic peptidyl segment comprises an amino acid
sequence ((L-Trp)-(D-Leu))3-(L»Trp).
Hydroghilic Qegtidyl segment
] As used herein, the term "hydrophilic peptidyl t“ refers to a yl
segment having hydrophilicity properties relative to a hydrocarbon moiety. in some
embodiments, the hydrophilic peptidyl segment refers to a peptidy] segment having
hydrophilicity properties relative to the hydrophobic peptidyl segment of an amphiphilic
peptide described . Generally, the hydrophilic peptidyl segment comprises at least one
hydrophilic amino acid. As used herein, the term philic amino acid” refers to an
amino acid residue ting a hydrophobicity of less than zero according to the normalized
consensus hydrophobicity scale of Eisenberg et al.. J. Mol. Biol. 179: 125-142 (1984), content
of which is incorporated herein by reference. Exemplary hydrophilic amino acids include, but
are not limited to Lys, Arg, His, Asp, Glu, Ser, Thr, Asn, Gln, and derivatives thereof.
] In some ments, the hydrophilic amino acid is a charged or uncharged
amino acid. As used herein, the term “charged amino acid” refers to an amino acid residue
that has a net charge. Accordingly, a charged amino acid can be a cationic amino acid or an
anionic amino acid. As used herein, the term “uncharged amino acid” refers to an amino acid
residue that has no net charge. A charged amino acid residue can be modified into an
uncharged amino acid by masking the charge of the amino acid, for example, by conjugating
a protecting group to a charge-carrying atom. In one embodiment, a charged amino acid
residue can be modified into an uncharged amino acid by acetylation.
{00102} In some ments, the hydrophilic amino acid is a polar amino acid. As used
herein, the term "polar amino acid" refers to a hydrophilic amino acid having a side chain that
is charged or unchanged at physiological pH, but which has at least one bond in which the
pair of electrons shared in common by two atoms is held more closely by one of the atoms.
Exemplary polar amino acids e, but are not limited to, Asn, Gln, Ser, Thr, and any
combinations thereof.
In some embodiments, the hydrophilic amino acid is a charged or uncharged polar
amino acid.
In some embodiments, the hilic amino acid is a cationic amino acid. As
used herein, the term “cationic amino acid” refers to an amino acid residue that comprises a
vely charged side chain under normal physiological ions. Thus, the term
“cationic amino acid” includes any naturally occurring amino acid or mimetic therefore
PCT/U32012/05202‘7
having a positively d side chain under normal physiological conditions. lly,
amino acid residues comprising an amino group in their variable side chain are considered as
cationic amino acids. ary cationic amino acids include, but are not limited to, lysine,
ine, arginine, hydroxylysine, ornithine, and their respective derivatives, analogues, and
stereoisomeric configurations thereof.
In some the hydrophilic amino acid is an anionic amino acid. As used herein, the
term "anionic amino acid" refers to a hydrophilic amino acid having a negative charge.
Exemplary anionic amino acids include, but are not limited to, Glu, Asp, and derivatives
thereof.
In some embodiments, the hydrophilic amino acid is an acidic amino acid. As
used herein, the term "acidic amino acid" refers to a hydrophilic amino acid having a side
chain pK value of less than 7. Acidic amino acids typically have negatively d side
chains at physiological pH due to loss of a hydrogen ion. Exemplary acidic amino acids
include, but are not limited to, Glu, Asp, and derivatives thereof.
In some the hydrophilic amino acid is a basic amino acid. As used herein, the
term "basic amino acid" refers to a hydrOphilic amino acid having a side chain pK value of
greater than 7. Basic amino acids typically have positively charged side chains at
physiological pH due to association with hydronium ion. Exemplary basic amino acids
include, but are not d to, His, Arg, Lys, and tives thereof.
In some embodiments, the hydrophilic peptidyl segment comprises at least one
charged amino acid, or at least one uncharged polar amino acid, or a combination thereof. In
some embodiments, the hydrophilic peptidyl segment comprises at least one amino acid
selected from the group consisting of Lys, Arg, His, Asp and Glu, or at least one amino acid
selected from the group consisting of Ser, Thr, Asn, and Gln, or a combination thereof. In
some embodiments, the hydrOphilic peptidyl t can comprise one amino acid selected
from the group consisting of Lys, Arg, and His.
In some embodiments, at least one amino group in the hydrophilic peptidyl
segment is masked or conjugated with a nitrogen- or amino-protecting group.
In some embodiments, the hydrOphilic peptidyl segment comprises the amino acid
sequence r, wherein AAZI is a hydrophilic amino acid selected independently for each
occurrence and f is an integer from 1 to 21.
] t limitations, all of the AA“ can be the same, all ent, or any
combination of same and different.
] In some embodiments, f is 2, 3, 4,5, 6, 7, 8, 9, 10, 11, 12, l3, 14, or 15.
PCT/U82012/052027
In some embodiments, the hydrophilic peptidyl segment ses an amino acid
sequence (Lys),, wherein r is an integer from 1 to 15. In some embodiments, r is an r of
1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. In some embodiments, r is an integer from 2
to 5 (e.g., r is an integer of 2, 3, 4, or 5). In one embodiment, r is an integer of 3.
In some ments, the hydrophilic peptidyi segment ses an amino acid
sequence selected from the group consisting of )- (L-Lys)— (L-Lys), (L-Lys)- (L-Lys)-
(L-LyS(AC)). )- (L-Lys(AC))-(L—Ly8), (L-Lys(Ac))- )- (L-LyS), (L-LyS)- (L-
LyS(AC))‘ (L-LyS(AC)), (L-LyS(AC))-(L-LyS)-(L-LYS(AC)), (L-LYS(AC))- (L-LyS(AC))- (L-
Lys), L—Lys(Ac))- (L—Lys(Ac))- (L-Lys(Ac)), and any combinations thereof, wherein “Ac”
refers to acetylation of the Lys amino acid residue.
In some embodiments, the hydrophilic peptide segment includes or is a
hydrophilic polymer. As used herein, the term “hydrophilic polymer” refers to a polymer
having hydrophilicity properties relative to a hydrocarbon moiety. In some embodiments, the
term “hydrophilic polymer” refers to a polymer having hilicity properties relative to
the hydrophobic peptidyl segment of an amphiphilic peptide described herein. hilicity
of a polymer can be determined by, for example, ASTM D570 testing. Generally, hydrophilic
polymers are water-soluble. Exemplary hilic polymers include, but are not limited to,
poly(ethy1ene glycol), poly (ethylene oxide), poly(propylene glycol), poly (ethylene oxide—
co-propylene oxide), hyaluronic acid, poly(2-hyd1‘oxyethy1 methacrylate), heparin,
polyvinyl(pyr1‘olidone), chondroitan sulfate, chitosan, glucosaminoglucans, dextran, dextrin,
dextran sulfate, cellulose acetate, carboxymethyl cellulose, hydroxyethyl cellulose,
cellulosics, poly(trimethylene glycol), etramethylene glycol), polypeptides,
polyacr'ylamide, polyacrylimide, thy1ene amine), poly(allyl amine), and blends thereof.
Exemplary e modifications
In some embodiments, an amphiphilic peptide described herein can comprise at
least one (e.g., 1, 2, 3,4,5, 6, 7, 8, 9, 10, ll, 12, 13, 14, 15, or more) amino acid selected
from the group consisting of alanine; argnine; asparagine; aspartic acid; cysteine; glutamic
acid; glutamine; glycine; histidine; isoleucine; leucine; lysine; methionine; phenylalanine;
proline; serine; threonine; phan; tyrosine; ; homocysteine; phosphoserine;
othreonine; phosphotyrosine; hydroxyproline; y-car‘boxyglutamate; hippuric acid;
0ctahydroindole-Z-carboxylic acid; statine; 1,2,3,4,-tetrahydroisoquinolinecarboxylic acid;
penicillamine (3—mercapto—D-valine); ornithine (Orn); citruline; alpha-methyl-alanine; para~
benzoylphenylalanine; par'a-aminophenylalanine; pwfluorOphenylalanine; phenylglycine;
PCT/U82012/052027
prOpargylglycine; N-methylglycins (sarcosine, Sar); and utylglycine; diaminobutyric
acid; 7—hydroxy—tetrahydroisoquinoline carboxylic acid; naphthylalanine; biphenylalanine;
cyclohexylalanine; amino-isobutyric acid (Aib); nowaline; norleucine (Nle); terHeucine;
tetrahydroisoquinoline carboxylic acid; pipecolic acid; phenylglycine; homophenylalanine;
cyclohexylglycine; dehydroleucine; ethylglycine; l-amino—l—cyclopentanecarboxylic
acid; 1-amino-l-cyclohexanecarboxylic acid; amino-benzoic acid; amino-naphthoic acid;
gamma-aminobutyric acid; difluor‘Ophenylalanine; nipecotic acid; N-a-imidazole acetic acid
(IMA); thienyl-alanine; lglycine; desamino—Tyr; aminovalen'c acid (Ava);
utaminic acid ; a—aminoisobutyric acid (aAib); y-aminobutyric acid ; 0t-
aminobutyric acid (rtAbu); ay-aminobutyric acid (ayAbu); 3-pyridylalanine (Pal); pyl-
a—Nglysine (ILys); Napthyalanine (Nal); a—napthyalaninc ((X—Nal); B—napthyalanine (B—Nal);
Acetyl-B—napthyalanine (Ac-B—napthyalanine); 0t,[3—napthyalanine; oloyl-lysine
(PicLys); 4-halo-Phenyl; 4-pyrolidylalanine; isonipecotic ylic acid ; beta-amino
acids; and isomers, analogs and derivatives thereof. One of skill in the art would know that
this definition includes, D- and L-amino acids; alpha-, beta- and amino acids;
chemically modified amino acids; naturally occurring non-proteogenic amino acids; rare
amino acids; and chemically synthesized compounds that have properties known in the art to
be characteristic of an amino acid. Additionally, each embodiment can include any
combinations of the .
Furthermore, as used herein, the term “amino acid” includes a compound or
molecule which departs from the structure of the naturally occurring amino acids, but which
have substantially the structure of an amino acid, such that they can be used for tution
of the naturally-occurring amino acids within a peptide, after which the peptide’s ty,
e.g., aggregate forming activity, is still retained. Thus, for example, in some embodiments
amino acids can also include amino acids having side chain modifications or substitutions,
and also include related organic acids, amides or the like. Without limitation, an amino acid
can be a proteogenic or non-proteogenic amino acid. As used herein, the term “proteogenic”
indicates that the amino acid can be incorporated into a protein in a cell through well-known
metabolic pathways.
In some embodiments, an amphiphilic peptide comprises at least one (tag, 1, 2, 3,
4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more) chemically modified amino acid. As used
herein, the term “chemically modified amino acid” refers to an amino acid that has been
treated with one or more reagents. A chemically modified amino acid can be present at any
PCT/U32012/052027
position in the amphiphilic e. When more than one chemically modified amino acids
are present, they can be positioned next to or not next to each other. When three or more
chemically d amino acids are present some of the chemically modified amino acids
can be present next to each other while some of the chemically modified amino are not next
to another chemically modified amino acid.
] In some embodiments, the hydrOphilic peptidyl segment comprises a chemically
modified amino acid. Without limitations, the chemically modified amino acid can be
present at any position of the hydrophilic peptidyl segment, for example, reading from the N-
terminal, at position I, 2, 3, 4, 5, 6, 7, 8, 9, 10, and so on of the hydrophilic peptidyl t.
In some ments, the hydrophobic peptidyl segment comprises a chemically
modified amino acid. Without limitations, the chemically modified amino acid can be
present at any position of the hydrophobic peptidyl t, for e, reading from the
inal, at position I, 2, 3, 4, 5, 6, 7, 8, 9, 10, and so on of the hydrophobic peptidyl
segment.
In some embodiments, both the hydrophilic and hydrophobic peptidyl segments
can each comprise at least one chemically modified amino acid. When both the hydrophilic
and hydrophobic peptidyl segments comprise a chemically modified amino acid, the number
of such chemically ed amino acids present in each segment can be the same or
different.
In some embodiments, the amphiphilic peptide comprises at least one (e.g., 1, 2, 3,
4, 5, 6, 7, 8, 9, 10 or more) beta-amino acid. When more than one beta-amino acids are
present, they can be positioned next to or not next to each other. When three or more beta-
amino acids are present some of the beta—amino acids can be present next to another beta-
amino acid while some of the beta-amino acids are not next to another beta-amino acid.
In some ments, the hydrophilic peptidyl t comprises a beta-amino
acid. Without limitations, the beta-amino acid can be present at any position of the
hydrophilic peptidyl segment, for example, reading from the N-terminal, at position 1, 2, 3, 4,
, 6, 7, 8, 9, 10, and so on of the hydrophilic peptidyl segment.
In some embodiments, the hydrOphobic peptidyl segment comprises a beta-amino
acid. Without limitations, the beta-amino acid can be present at any position of the
hobic peptidyl segment, for example, reading from the N-terminal, at position 1, 2, 3,
4, 5, 6, 7, 8, 9, IO, and so on of the hydrOphobic peptidyl segment.
] In some embodiments, both the hydrophilic and hydrophobic peptidyl segments
can each se at least one mino acid. When both the hydrophilic and hydrophobic
2012/052027
peptidyl segments comprise a beta-amino acid, the number of such beta-amino acids in each
segment can be the same or different.
Exemplary beta-amino acids include, but are not limited to, lomoproline
hloride; (i)(Boc-amino)—4-(4-biphenylyl)butyric acid; (Fmoc-amino)—2-
phenylpropionic acid; (1S,3R)-(+)(Boc-amino)cyclopentanecarboxylic acid; (2R,3R)
(Boc-amino)hydroxyphenylbutyric acid; (25,310(Boc-amino)hydroxy
phenylbutyric acid; (R)[(Boc-amino)methyl]-3—phenylpropionic acid; (R)(Boc-amino)—
2-methylpropionic acid; (R)(Boc-amino)—2-phenylpropionic acid; (R)—3—(Boc—amino)(2-
naphthyl)bUtyl‘iC acid; (R)(Boc-amino)phenylpentanoic acid; (R)(Fmoc-amino)(2-
naphthy1)butyiic acid; (R)-(—)-Pyrrolidine—3—carboxylic acid; (R)-Boc-3,4-dimethoxy—B—Phe-
OH; (R)-Boc(3-pyridyl)-B-Ala-OH; (R)-Boc~3-(trifluoromethyl)-B-Phe-OH; (R)-Boc
cyano-B-Phe-OH; cmethoxy—B—Phe-OH; (R)-Bocmethy1-[3-Phe-OH; (R)-Boc
(4-pyridy1)-B-Homoala-OH; (R)-Boc(trifluoromethyl)—B—Homophe-OH; (R)-Boc
(trifluoromethyl)—B—Phe-OH; (R)-Bocbromo-B-Phe~OH; (R)-Bocchloro-B-Homophe-
OH; (R)-Bocchloro—B-Phe-OH; (R)-Boccyano-B—Homophe-OH; (R)-Boccyano-[3—
Phe-OH; (R)-Bocfluoro-B-Phe-OH; (R)—Bocmethoxy-B-Phe-OH; (R)-Bocmethyl-B-
Phe-OH; (R)-Boc-[3-Tyr-OH; (R)-Fmoc(3-pyridyl)-B-Homoala-OH; (R)—Fmocfluoro-[3-
Homophe-OH; (S)-(+)—Pyrrolidinecarboxylic acid; (S)—3-(Boc—amino)methylpr0pionic
acid; (S)(Boc-amino)—4—(2—naphthyl)butyric acid; (S)(Boc—amino)phenylpentanoic
acid; (S)(Fmoc-amino)—2—methylpropionic acid; (S)—3—(Fmoc-amino)(2-
naphthyl)butyn’c acid; (Fmoc-amino)hexenoic acid; (S)(Fmoc-amino)—5—pheny1—
pentanoic acid; (S)(Fmoc-amino)—6—phenylhexenoic acid; (S)-Boc—2—(trifluoromethyl)-
B-Homophe—OH; (S)-Boc(trifluoromethyl)—[3-Homophe-OH; c(tiifluoromethyl)-
B—Phe—OH; ccyano-[3-Homophe-OH; (S)-Bocmethyl-B—Phe—OH; c-3,4-
dimethoxy-B-Phe-OH; (S)-Boc(trifluoromethyl)-B-Homophe-OH; (S)-Boc
(trifluoromethyl)-B-Phe—OH; (S)-Bocmethoxy-B~Phe—OH; (S)-B0cmethyl-fi-Phe-OH;
(S)-Boc(4-pyridyl)-B-Homoala-OH; (S)-Boc-4—(trifluoromethyl)-B-Phe-OH; (S)-Boc
B-Phe-OH; cchloro-B-Homophe—OH; (S)-Bocchloro-[3-Phe-OH; (S)—B0c—
4-cyano-B-Homophe-OH; (S)—Boccyano—B—Phe-OH; (S)-Bocfluoro-B-Phe-OH; (bj—Boc—
4—iodo—[3—Homophe-OH; (S)-Bocmethyl-B-Homophe-OH; (S)-Boc—4—methyl—B—Phe-OH;
(S)-Boc-B—Tyr~OH; (S)-Boc-y,y-diphenyl-B-Homoala-OH; (S)-Fmocmethyl-B—Homophe-
OH; (S)-Fmoc-3,4-difluoro-B-Homophe—OH; (S)-Fmoc(tn'fluoromethyl)-B-Homophe-OH;
(S)—Fmocw3-cyano-B-Homophe-OH; (S)-Fmocmethyl-B-Homophe—OH; (S)«Fmoc-y,y-
diphenyl-B-Homoala-OH; 2—(Boc-aminomethyl)phenylacetic acid; 3-Amino(3-
PCT/U82012/052027
bromophenyl)propionic acid; o-4,4,4—trifluorobutyric acid; 3-Aminobutanoic
acid;DLAminoisobutyn'c acid; DL—B—Aminoisobutyric acid puriss; DL—B-Homoleucine;
DL-B-Homomethionine; DL-B-Homophenylalanine; DL-B-Leucine; DL-B-Phenylalanine; L-
B-Homoalanine hydrochloride; L-B-Homoglutamic acid hloride; L—B-Homoglutamine
hydrochloride; L—B—Homohydroxyproline hydrochloride; L—B-Homoisoleucine hydrochloride;
L-B-Homoleucine hydrochloride; L-B-Homolysine dihydrochloride; momethionine
hydrochloride; L-fi-Homophenylalanine ally] ester hydrochloride; L-B-Homophenylalanine
hydrochloride; L-B-Homoserine; L—B—Homothreonine; L-B—Homotryptophan hydrochloride;
L-B-Homotyrosine hydrochloride; L-B-Leucine hydrochloride; Boc-D-B-Leu-OH; Boc—D-B-
Phe—OH; Boc~Ba-Homopr0-OH; Boc-B-Glu(Ole)-OH; Boc-B-Homoarg(Tos)—OH; Boc-B-
u(Ole)-OH; Boc-B-Homohyp(le)—OH (dicyclohexylammonium) salt technical,;
Boc-B-Homolys(Z)-OH; Boc-B-Homoser(le)-OH; Boc-B-Homothr(le)-OH; Boo-BHomotyr
(le)-OH; Boc-B-Ala-OH; Boc-B-Gln—OH; Homoala-OAII; Boc-B-Homoala-
OH; Boc-B—Homogln-Ol—I; Boc-B-Homoile-OH; Homoleu-OH; Boc—B—Homomet-OH;
Boc—B—Homophe—OH; Boc-B-Homotrp-OH; Boc-B-Homotrp-OMe; Boc—B—Leu—OH; Boo-B-
Lys(Z)-OH (dicyclohexylammonium) salt; Boc-B-Phe-OH; Ethyl 3-(benzylamino)propionate;
Fmoc-D-B-Homophe-OH; Fmoc-L—[33—homoproline; Fmoc—[S—D—Phe-OH; Fmoc-B-Gln(Tit)-
OH; Fmoc-B-Glu(OtBu)—OH; Fmoc-B-Homoarg(Pmc)—OH; Fmoc-B-Homogln(Trt)—OH;
Fmoc-B-Homoglu(0tBu)—OH; -Homohyp(tBu)—OH; Fmoc-B-Homolys(Boc)-OH;
Fmoc-B-I—lomoser(tBu)—OH; Fmoc-B-Homothr(tBu)*OH; Fmoc-B-Homotyr(tBu)-OH; Fmoc-
B-Ala~OH; Fmoc—B~Gln-OH; Fmoc-B-Homoala—OH; Fmoc-B-Homogln—OH; Fmoc-B-
Homoile-OH; Fmoc-B-HomolewOI-I; Fmoc-B-I—lomomet-OH; Fmoc-B-Homophe-OH; Fmoc-
trp-OH; Fmoc-B-Leu-OH; Fmoc—B~Phe-OH; N-Acetyl-DL-B-phenylalanine; Z-D-B-
Dab(Boc)-OH; Z-D-B-Dab(Fmoc)—OH pumm,; —Homoalanine; Z~B~D~Homoala-OH;
Z-B-Glu(0rBu)-OH technical,; Z-B-Homotrp(Boc)—Ol-l; a-OH pumm; Z-B-Ala-ONp
pumm,; Z-B-Dab(Boc)—OH; Z-B-Dab(Fmoc)-OH; Z-B—Homoala-OH; B-Alanine; B-Alanine
BioXtra,; B-Alanine ethyl ester hydrochloride; ine methyl ester hydrochloride; [3—
Glutamic acid hydrochloride; cis Amino—3—cyclopentene-1 -carboxylic acid hydrochloride;
cis(Boc-amino)cyclohexanecarboxylic acid; and cis(Fmoc-
amino)cyclohexanecarboxylic acid.
In some embodiments, an amphiphilic peptide described herein can comprise at
least one (e.g., l, 2, 3, 4, 5, 6, 7, 8, 9, 10, ll, l2, l3, 14, 15 or more) modified amide linkage,
e.g., an amide bond in the backbone replaced by a linkage selected from the group consisting
of reduced psi peptide bond, urea, thiourea, carbamate, yl urea, trifluoroethylamine,
PCT/U82012/052027
ortho-(aminoalkyl)-phenylacetic acid, aminoalkyl)~phenylacetic acid, meta-
(aminoalkyl)—phenylacetic acid, thioamide, tetrazole, boronic ester, and olefinic group. The
amide replacement linkage can be t at any position in the amphiphilic peptide. When
two or more amide replacement linkages are present, they can be positioned next to (e.g., on
both sides of a given amino acid) or not next to each other (e.g., only one side of a given
amino acid is linked via a peptide replacement linkage to the next amino acid).
In some embodiments, the amide replacement e is t in the hydrophilic
yl segment. Without limitations, the amide replacement linkage can be present at any
on of the hydrophilic peptidyl segment, for example, reading from the N-terminal, at
position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and so on of the hydrophilic peptidyl segment.
In some ments, the amide replacement linkage is present in the
hydrophobic peptidyl segment. Without limitations, the amide replacement linkage can be
present at any position of the hydrophobic peptidyl segment, for example, reading from the
N—terminal, at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and so on of the hydrophobic peptidyl
segment.
In some embodiments, both the hydrophilic and hydrophobic peptidyl segments
can each se at least one amide replacement linkage. When both the hydrophilic and
hydrophobic peptidyl segments comprise an amide replacement linkage, the number of such
amide replacement linkages in each segment can be the same or different.
The C-terminus of an amphiphilic peptide described herein can be unmodified or
modified by conjugating a carboxyl protecting group or an amide group. ary carboxyl
protecting groups include, but are not limited to, esters such as methyl, ethyl, t-butyl,
methoxymethyl, 2,2,2-ttichloroethyl and 2-haloethyl; benzyl esters such as nylmethyl,
diphenylmethyl, p-bromobenzyl, o-nitrobenzyl and the like; silyl esters such as tn’methylsilyl,
triethylsily], ldimethylsilyl and the like; amides; and hydrazides. Other carboxylic acid
protecting groups can include optionally protected alpha—amino acids which are linked with
the amino moiety of the alpha-amino acids. In some embodiments, the C-terminus of an
hilic peptide is conjugated with NHg, NH-alkyl, or N(alkyl)2.
Linkage between hydrolzhilir‘ and hobir‘ segments
t limitations, the hydrophilic peptidyl segment can be linked to either the
N—terminus or the C-terminus of the hydrophobic peptidyl t. Accordingly, an
amphiphilic peptide can be (hydrophilic peptidyl segment)-linker—(hydrophobic peptidyl
segment) or (hydrophobic peptidyl segment)-linker-(hydrophilic peptidyl segment). In one
PCT/U52012/052027
embodiment, the hiIic peptidyl segment is linked to N-terminus of the hydrophobic
peptidyl segment. Stated another way, in one embodiment, the hydrophobic yl segment
is linked to the C-terminus of the hydrophilic peptidyl segment. The linkage between the
hydrophilic and hydrophobic peptidyl segments can be an amide linkage, an amide
replacement linkage, or a linker as defined herein.
In some embodiments, the linkage between the hydrophilic and hydrophobic
peptidyl segments is an amide linkage (e.g., (O)-) or an amide replacement linkage.
In some embodiments, the linkage between the hydrophilic and hydrophobic
peptidyl segments includes an amino acid, two amino acids, or a peptide comprising from 3
to [5 amino acids. It is to be understood that when the hilic and hobic yl
segments are linked by a chain of amino acids, the linker can comprise one or more of the
peptide modifications descfibed , e.g., amide replacement linkage, beta-amino acids, D-
amino acids, ally modified amino acids etc.
Exemplary amphighiflf peptides and uses lhgrggl
In some embodiments, an amphiphilic peptide comprises an amino acid sequence
(L—AA21)i~-((L-AA' AA”))b--(L-AA'3)‘ wherein AA21 is a Lys residue or a substitution
thereof; AAll and AA'3 is each independently a Tip residue or a substitution thereof, AA11 is
a Leu residue or a substitution thereof, and wherein f’ is an integer from 3-21 and b’ is an
integer from 3-20, and wherein at least one of N—teiminus amino group or a side chain amino
group of at least one AA“ residue is conjugated with a nitrogen— or amino-protecting group.
] The term "substitution" when refern'ng to a peptide, refers to a change in an amino
acid for a different entity, for example r amino acid or amino-acid .
Substitutions can be conservative or non-conservative substitutions. In some embodiments,
the substitution is a conservative substitution. As used herein, the term "conservative
substitution" refers to an amino acid substitution in which the substituted amino acid residue
is of similar charge, and/or similar hydrophobicity as the replaced residue. The substituted
residue can be of similar size as, or r size or larger size than, the replaced residue,
provided that the substituted residue has similar biochemical properties as the replaced
residue. Conservative substitutions of amino acids include, but are not limited to,
substitutions made amongst amino acids within the following groups: (i) the small non—polar
amino acids: alanine (Ala), methionine (Met), isoleucine (Ile), leucine (Leu), and valine
(Val); (ii) the small polar amino acids: glycine (Gly), seiine (Ser), ine (Thr) and
cysteine (Cys); (iii) the amido amino acids: ine (Gin) and asparagine (Asn); (iv) the
PCT/U82012/052027
aromatic amino acids: phenylalanine (Phe), tyrosine (Tyr) and tryptophan (Trp); (v) the basic
amino acids: lysine (Lys), arginine (Arg) and histidine (His); and (vi) the acidic amino acids:
glutamine acid (Glu) and aspartic acid (Asp). Substitutions which are charge-neutral and
which replace a residue with a smaller residue can also be considered "conservative
substitutions" even if the es are in different groups (e.g., replacement of phenylalanine
with the smaller cine). The term "consewative substitution" also encompasses the use
of amino acid mimetics, analogs, variants, or non-proteinogenic or andard amino acid.
By way of example only, AdaA or AdaG can be tuted for valine (Val); L-I-
thioazolidine-4—carboxy]ic acid or D-or—L-l-oxazolidine-4~carboxylic acid (See Kauer, US.
Pat. No. (4,511,390)) can be substituted for proline; and Aib, B—Ala, or Acp can be
substituted for glycine (Gly).
] Accordingly, in some embodiments, AA21 can be a Lys residue, or a conservative
substitution thereof, e.g., Arg or His. In one embodiment, AA21 is a Lys residue or a
derivative thereof.
In some embodiments, AAll and AA13 can each be independently a Trp residue,
or a conservative tution thereof, e.g., Phe, or Tyr. In one embodiment, AA11 and AA11
is each independently a Trp residue or a derivative thereof.
In some embodiments, AA12 can be a Leu residue, or a conservative substitution
thereof, e.g., Ala, Met, Ile, or Val. In one embodiment, AA12 is a Leu residue or a derivative
thereof.
In some embodiments, an amphiphilic peptide comprises an amino acid sequence
(L-Lys),‘-((L-Trp)—(D-Leu))m‘-(L-Trp), wherein i" is an integer from 3-21 and m‘ is an integer
from 3-20, and n at least one of N-terminus amino group or a side chain amino group
of at least one Lys residue is conjugated with a en- or amino-protecting group.
] In some embodiment, r’ and m’ are independently 3, 4, 5, 6, 7, 8, 9, 10, ll, 12, 13,
14, or 15. In some embodiments, both of r’ and m’ are the same. In one embodiment, both
1" and m’ are 3.
In some embodiments, the amphiphilic peptide comprises the amino acid
sequence selected from the group consisting of: Ac—(L-Lys(Ac))-(L-Lys(Ac))~(L—Lys(Ac))-
((L-Trp)-(D-Leu))3-(L-Trp)-NH2 (also ed to as CD3ac herein, wherein the abbreviation
“ac” or “Ac” refers to acetylation of either N-terminus amino group of an amphiphilic peptide
or an amino group of a Lys e in the hydrophilic peptidyl segment);
AC-(L-Ly5)-(L-LYS)-(L-LYS)-((L-TIP)-(D-LCU))3-(L-Trp)-NH2;
W0 2013/028843 PCT/U82012/052027
(L-Lys)-(L—Lys>-tL—Lys(Ac))-((L-Trp)-(D-Leu>>3-(L-Tm>—NH2;
)-(L-Lys(AC))—(L—LyS)—((L~Trp)-(D-Leu))3-(L-T1p)-NH2;
(L-Lys<Ac))-(L—Lys)-(L-Lys)-((L-Trp)-(D-Leu>)a-(L-Trp)-NH2;
(L-Lys)-(L-LyS(AC))-(L-LyS(AC))-((L-TIP)-(D-L€U))3-(L-TFP)-NH2;
(L-LYS(AC))-(L~LYS)-(L-LYS(AC))-((L-TFP)-(D-LCU))3-(L~TI‘P)-NH2;
(L-LyS(AC))-(L-L)'S(AC))-(L-Ly5)-((L-TI}J)-(D-LCU))3-(L-T1P)-NH-z;
(L-Lys(Ac))-(L-Lys(Ac))-(L-Lys(Ac))-((L-Trp)-(D-Leu))3-(L-Trp)-NH2;
LyS(AC))-(L-LyS(AC))-(L-LyS(AC))-((L-TI‘P)-(D-LCUDJ-(L-TIP)-NH2;
AC-(L-Ly5)-(L-Lys)-(L-LYS)-((L-TI‘P)-(D~LeU))3-(L-TrP);
(L—Lys)—(L-Lys)-(L—Lys<Ac)>-(<L—Trp)«Danna-(hm);
(L-LYS)-(L-Lys(ACD-(L-LYS)-((L-TI‘P)-(D-LCU))3-(L-TI‘P);
(L-Ly5(AC))-(L-L)’S)-(L“LYS)—((L-TI'P)-(D-Lelle-(L-TIP);
(L-LYSHL-LYS(AC))-(L-Ly5(AC))-((L-TIP)-(D-LCU))3-(L-TFP);
(L-Lys(AC))—(L-LyS)-(L-LyS(AC))-((L-Trp)-(D-Leu))3-(L-Tlp);
(L-Lys(AC))-(L-LyS(AC))-(L-L544)-((L-Tfp)-(D-L£U))3-(L-TIP);
(L-Ly5(AC))-(L-LYS(AC))-(L-LyS(AC))-((L-Tl'P)-(D-L6U))3-(L-Tlp);
Ac-(L-Lys)-(L-Lys)-(L—Lys(Ac))-((L-Tip)-(D—Leu))3-(L-Trp)-NH3;
Ac-(L-Lys)-(L-Lys(Ac))-(L-Lys)-((L-Tip)-(D-Leu))3-(L-T1‘p)—NH3;
Ac-(L-Lys(Ac))-(L—Lys)-(L-Lys)-((L-Tip)—(D-Leu))3-(L-T1p)-NH3;
AC-(L-Lys}(L-Lys(ACD-(L-LYS(AC))-((L~T1'P)-(D-LCU))3-(L-TI‘P)-NH2;
AC-(L-LYS(AC))-(L-LyS)-(L-LyS(AC))-((L-TI'P)-(D~LEU))3-(L~Tl‘p)-NH2;
AC-(L-LYS(AC))-(L-L)’S(AC))—(L-Ly5)-((L-TIP)-(D-LCU))3-(L-Tlp)-Nsz
Ac-(L-Lys)-(L-Lys)-(L-Lys(Ac))—((L-Trp)-(D-Leu))3-(L-Trp);
Ac—(L-LyS)-(L-LyS(AC))-(L-LyS)-((L-T1p)-(D—Leu))3-(L-Tlp);
Ac—(L-Lys(Ac))-(L-Lys)—(L-Lys)-«Hm-(D-LeuML—Tm);
Lys)-(L-Lys(Ac))—(L-Lys(Ac))-((L-Ti]3)-(D-Leu))3-(L-Trp);
AC-(L’LYS(AC))~(L‘LYS)-(L-Lys(AC))-((L-Tl‘p)’(D-LCU))3-(L-TI‘P);
AC-(L-LyS(AC»-(L-Ly5(AC))-(L-Lys)-((L-T1P)-(D-LeU))3~(L-TIP);
Ac-(L-Lys(Ac))-(L-Lys(Ac))-(L—Lys(Ac))-((L-Tl‘p)~(D~Leu))3-(L-Trp); and any
combinations thereof.
In some embodiments, the hydrophilic peptidyl segment of the amphiphilie
peptide can comprise a cysteine. In some embodiments, the cysteine can be present on the N-
us of the hydrophilic yl segment.
The inventor has discovered that some embodiments of the amphiphilic peptides
W0 20131028843 2012/052027
bed herein can have cell penetration ability. Thus, in some embodiments, amphiphilic
es described herein can be used as cell ation and/or transfection agents. In these
embodiments, the amphiphilic peptides can be designed to be positively-charged.
Accordingly, use of a composition comprising a vely-charged hilic peptide as a
cell—penetrating agent or transfection agent is provided herein, wherein the positive-charged
amphiphilic peptide comprises a hydrOphobic peptidyl segment and a hydrophilic peptidyl
segment. The hydrophobic peptidyl segment of the positive-charged amphiphilic e
comprises an amino acid sequence of (Trp-Leu)m-(Tl'p)n or ip)p-(Leu)q, wherein each
Tip is D-Trp or L-Trp and each Leu is D-Leu or L-Leu, m and p are independently an integer
from 1 to 5, and n and q are independently 0 or I, ed that when Tip is D-Tip then Leu
is L-Leu, and when Tip is L—Trp then Leu is D-Leu, or vice versa; while the hydrophilic
peptidyl segment comprises an amino acid sequence of (Lys)r. wherein r is an integer from 1
to 15. onally, in the positively-charged amphiphilic peptide, at least one of the Lys
residues or the N-terminus amino group of the amphiphilic e is not acetylated. In some
embodiments, all of the Lys residues and the N-terminus amino group of the positively-
charged amphiphilic peptide are not acetylated.
In some embodiments, the positively~charged amphiphilic peptide can comprise
an amino acid sequence of (L-Lys)-(L-Lys)—(L—Lys)-(L-Trp)-(D-Leu)—(L—Trp)—(D-Leu)-(L-
Trp)-(D-Leu)—(L~T1p)-X, wherein X is absent or NHg.
In some embodiments, the composition can further comprise a nucleic acid
molecule or oligonucleotide (e.g., DNA or RNA) to be delivered into a cell. In some
embodiments, the composition can further comprise a plurality (e.g., at least 2 or more) of
nucleic acid les or oligonucleotides (e.g., DNA or RNA including, but not limited to,
siRNA, shRNA, miRNA). In some embodiments, the nucleic acid molecules or
oligonucleotides can be designed for use in therapeutic intervention, e.g., gene therapy or
siRNA therapy.
e synthesis
The amphiphilic peptides described herein can be synthesized according to the
usual methods of solution and solid phase peptide chemistry, or by classical methods known
in the an. Purification of peptides is well known in the art and can be, for e, I-IPLC.
Methods describing useful peptide synthesis and purification methods can be found, for
example, in US. Pat. App. Pub. No. 20060084607, content of which is incorporated herein
by reference.
PCT/U52012/052027
Peptides bed herein can be synthetically constructed by suitable known
peptide polymen’zation techniques, such as exclusively solid phase techniques, l solid—
phase techniques, fragment condensation 01' classical solution couplings. For example, the
es of the invention can be synthesized by the solid phase method using standard
methods based on either t—butyloxycat‘bonyl (BOC) or 9-fluorenylmethoxy—carbonyl (FMOC)
protecting groups. This methodology is described by G. B. Fields et al. in Synthetic Peptides:
A User's Guide, W. M. Freeman & Company, New York, N.Y., pp. 77-183 (1992) and in the
textbook -Phase Synthesis”, Stewart & Young, Freemen & Company, San sco,
1969, and are exemplified by the sure of U.S. Pat. No. 4,105,603, issued Aug. 8, 1979.
Classical solution synthesis is described in detail in “Methoden der Organischen Chemic
(Houben—Weyl): Synthese von Peptiden”, E. Wunsch (editor) (1974) Georg Thieme Verlag,
Stuttgart West Geimany. The fragment condensation method of synthesis is exemplified in
U.S. Pat. No. 3,972,859. Other available syntheses are exemplified in U.S., Pat. No.
3,842,067, U.S. Pat. No. 3,872,925, issued Jan. 28, 1975, Meri‘ifield B, Protein Science
(1996), 5: 1947—1951; The chemical synthesis of ns; Mutter M, Int J Pept Protein Res
1979 Mar; 13 (3): 274-7 s on the coupling rates in liquid-phase peptide synthesis using
competition ments; and Solid Phase Peptide Synthesis in the series Methods in
logy (Fields, G. B. (1997) Solid-Phase Peptide Synthesis. Academic Press, San
Diego.#9830). Content of all of the foregoing sures is incorporated herein by reference,
Methods for preparing peptide mimetics include modifying the N-terminal amino
group, the C-terminal carboxyl group, and/or changing one or more of the amino linkages in
the peptide to a non-amino linkage. Two or more such modifications can be coupled in one
peptide mimetic inhibitor. Modifications of peptides to produce peptide mimetics are
described, for example, in US Pat. No. 5,643,873 and No. 5,654,276, t of both of
which is incorporated herein by reference.
Peptide mimetics
In some embodiment, the amphiphilic peptide is a peptide mimetic. For example,
the hydrophilic peptide segment can be peptide mimetic, the hydrophobic peptidyl segment
can be a e mimetic, or both can be peptide mimetics.
Methods of designing peptide mimetics and screening of functional peptide
mimetics are well known to those skilled in the an. One basic method of designing a
molecule which mimics a known n or peptide is first to identify the active region(s) of
the known protein (for example, in the case of an antibody-antigen interaction, one identifies
PCT/U52012/052027
which region(s) of the antibody that permit binding to the antigen), and then searches for a
mimetic which es the active . If the active region of a known protein is relatively
small, it is anticipated that a mimetic will be smaller (e.g. in molecular ) than the
protein, and correspondingly easier and cheaper to synthesize. Such a mimetic could be used
as a convenient substitute for the protein, as an agent for interacting with the target le.
s for preparing peptide mimetics include modifying the N—terminal amino
group, the C-terminal carboxyl group, and/or changing one or more of the amide linkages in
the peptide to a non-amide or a modified amide linkage. Two or more such modifications can
be d in one peptide mimetic. Modifications of peptides to e peptide mimetics
are described, for example, in US Pat. No. 5,643,873 and No. 5,654,276, content of both of
which is incorporated herein by reference.
] For example, Reineke et al. (1999, Nature Biotechnology, l7;271-275, content of
which is herein incorporated by reference) designed a mimic molecule which mimics a
binding site of the interleukin— 10 protein using a large library of short synthetic peptides,
each of which corresponded to a short section of interleukin 10. The binding of each of these
peptides to the target (in this case an antibody t interleukin- 10) was then tested
ind1vidually by an assay technique, to fy potentially relevant peptides. Phage display
libraries of peptides and alanine scanning method can be used.
Other methods for designing peptide mimetics to a particular peptide or protein
include those described in European Patent EP1206494, the SuperMimic program by
Andrean Goede et. a]. 2006 BMC Bioinformatics, 7:11; and MIMETIC program by W.
Campbell et. al.,2002, Microbiology and Immunology 46:211-215. The SuperMimic program
is designed to identify compounds that mimic parts of a protein, or positions in ns that
are suitable for inserting mimetics. The application provides libran’es that contain
peptidomimetic building blocks on the one hand and protein structures on the other. The
search for promising peptidomimetic linkers for a given e is based on the superposition
of the peptide with several conformers of the mimetic. New synthetic elements or proteins
can be ed and used for searching. The MIMETIC computer program, which generates
a series of peptides for interaction with a target peptide sequence is taught by W. Campbell
et. al., 2002. In depth discussion of the topic is reviewed in “Peptide Mimetic Design with
the Aid of Computational Chemistry” by James R. od Jr. in Reviews in
Computational Chemistry s in Computational Chemistry, Jan 2007, Volume 9 Book
Series: Reviews in Computational Chemistry, Editor(s): Kenny B. Lipkowitz, Donald B.
BoydPrint ISBN: 9780471186397 ISBN: 9780470125861 Published by John Wiley &Sons,
2012/052027
Inc.; and in T. Tselios. et. a1., Amino Acids, 14: 333-341, 1998. Content of all of the
references described in this paragraph is herein incorporated by reference.
Methods for ing libraries containing diverse populations of peptides,
peptoids and peptidomimetics are well known in the art and various libraries are
commercially available (see, for example, Ecker and Crooke, Biotechnology 13:351-360
(1995), and Blondelle et al., Trends Anal. Chem. 14:83-92 (1995), and the references cited
therein, each of which is incorporated herein by reference; see, also, Goodman and Ro,
Peptidomimetics for Drug Design, in “Burger's Medicinal Chemistry and Drug Discovery”
Vol. 1 (ed. M. E. Wolff; John Wiley & Sons 1995), pages 803-861, and Gordon et al., J. Med.
Chem. 37:1385-1401 (1994), each of which is incorporated herein by reference). One skilled
in the art understands that a peptide can be produced in vitro directly or can be expressed
from a nucleic acid. which can be produced in vitro. Methods of synthetic peptide and nucleic
acid chemistry are well known in the art. Content of all of the references described in this
paragraph is herein orated by reference.
A library of peptide molecules also can be ed, for example, by constructing
a cDNA sion library from mRNA collected from a tissue of interest. Methods for
producing such libraries are well known in the art (see, for example, Sambrook et. al.,
Molecular g: A laboratory manual (Cold Spring Harbor Laboratory Press 1989), which
is incorporated herein by reference). Preferably, a peptide encoded by the cDNA is expressed
on the surface of a cell or a virus ning the cDNA.
Ligands and active agents
] A wide variety of entities, e.g., s, can be coupled to an amphiphilic peptide
described herein or a peptide particle described later. Ligands can include naturally occurring
molecules, or recombinant or tic molecules. In some embodiments, a ligand can alter
the distribution, targeting or lifetime of an amphiphilic peptide described herein or a e
particle made therefrom. In some embodiments, a ligand can e an enhanced affinity
(e.g., increased binding strength) for a selected target, e.g., molecule, cell or cell type,
compartment, e. g., a ar or organ compartment, tissue, organ or region of the body, as,
e.g., compared to a species absent such a ligand. In some embodiments, a ligand can provide
an enhanced specificity of an amphiphilic peptide described herein or a peptide particle made
therefrom for a selected , as, e.g., ed to an amphiphilic peptide without such a
ligand. The term “specificity” as used herein refers to the ability of an amphiphilic peptide or
a peptide particle to preferentially bind to a selected target over any other entities. For
PCT/U52012/052027
example, the presence of a ligand on an amphiphilic e and/or a peptide particle
described herein can enable the amphiphilic peptide or peptide particle to preferentially bind
to a selected target over any other entities, as compared to an hilic peptide or peptide
particle t such a ligand.
{00158} Without limitation, a ligand can be selected from the group consisting of
polymers, es, polypeptides, proteins, peptidomimetics, glycoproteins, lectins,
nucleosides, nucleotides, nucleic acids, monosaccharides, disaccharides, trisaccharides,
oligosaccharides, polysacchan’des, lipopolysaccharides, vitamins, lipids, steroids, hormones,
cofactors, receptors, receptor ligands, and any combinations thereof.
] In some embodiments of this and other s described herein, the ligand is
selected from the group consisting of polyethylene glycol (PEG, e. g., PEG-2K, PEG-5K,
PEG-10K, PEG-12K, K, PEG-20K, PEG-40K), MPEG, [MPEG]; Poly (ethylene
oxide) (PEO), poly(propylene glycol) (PPG), poly (ethylene oxide-co-propylene oxide),
hyaluronic acid, poly(2-hydroxyethyl methacrylate), heparin, polyvinyl(pyn'olidone),
chondroitan sulfate, chitosan, glucosaminoglucans, dextran, dextrin, dextran sulfate, cellulose
acetate, carboxymethyl cellulose, yethyl cellulose, cellulosics, poly(trimethylene
glycol), poly(tetramethylene glycol), polypeptides, polyacrylamide, polyacrylimide,
poly(ethylene amine), poly(allyl amine), styrene-maleic acid anhydride copolymer, poly(L—
lactide-co-glycolied) copolymer, divinyl ether-maleic anhydn'de copolymer, N-(2—
hydroxypropyl)methacrylamide copolymer (HMPA), nyl alcohol (PVA), polyurethane,
poly(2—ethylacryllic acid), N-isopropylacrylamide polymers, osphazine,
polyethylenimine, spermine, spermidine, polyamine, pseudopeptide-polyamine,
peptidomimetic polyamine, dendrimer polyamine, ne, amidine, protamine, thyrotropin,
melanotropin, lectin, surfactant protein A, mucin, transferrin, sphonate, polyglutamate,
polyaspartate, an aptamer, asialofetuin, onan, procollagen, insulin, transferrin, albumin,
acridines, cross- psoralen, mitomycin C, TPPC4, texaphyn'n, Sapphyrin, polycyclic aromatic
hydrocarbons (e.g., phenazine, dihydrophenazine), bile acids, terol, cholic acid,
tane acetic acid, l-pyrene butyiic acid, dihydrotestosterone, 1,3-Bis-
O(hexadecy])glycerol, geranyloxyhexyl group, hexadecylglycero], bomeol, menthol, 1,3-
propanediol, heptadecyl group, palmitic acid, myristic acid, OB-(oleoyl)lithocholic acid, 03-
(oleoyl)cholenic acid, dimethoxytn'tyl, or azine), RGD peptide, radiolabeled markers,
haptens, naproxen, aspirin, dinitrophenyl, HRP, AP, lectins, n A, vitamin E, vitamin K,
n B, folic acid, BIZ, avin, biotin, pyridoxal, taxon, vincristine, vinblastine,
cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine,
PCT/U52012/052027
myosewin, tumor is factor alpha (TNFalpha), interleukin-1 beta, gamma interferon,
, ose, mannose, mannose-6P, clusters of sugars such as GalNAc cluster,
mannose cluster, galactose cluster, an aptamer, integrin receptor ligands, chemokine receptor
ligands, serotonin receptor ligands, PSMA, endothelin, GCPII, somatostatin, bacterial cell
wall permeating peptide, GALA e, EALA peptide, INF-7 peptide, Inf HA-2 peptide,
dilNF-7 peptide, dilNF-3peptide, GLF peptide, GALA—INF3 peptide, INF-5 peptide,
penetratin peptide, Tat fragment 48-60, PVEC peptide, transportan peptide, LL-37 peptide,
cecropin Pl peptide, a-defensin peptide, B-defensin peptide, PR-39 peptide, indolicidin
peptide, RFGF e, RFGF analogue, ecin, cecropins, lycotoxins, paradaxins,
buforin, CPF, in—like peptide (BLP), cathelicidins, ceratotoxins, S. (lava peptides,
hagfish intestinal antimicrobial peptides (HFIAPs), magainines, ins-Z, dermaseptins,
melittins, pleurocidin, HgA peptides, Xenopus peptides, esculentinis-l, caerins, and any
ations thereof.
In some embodiments, a ligand can include an active agent. As used herein, an
“active agent” refers to a molecule that is to be delivered to a cell. Accordingly, without
limitation, an active agent can be selected from the group consisting of small organic or
inorganic molecules, monosaccharides, disaccharides, trisaccharides, oligosaccharides,
polysaccharides, biological macromolecules, e.g., peptides, proteins, peptide analogs and
derivatives f, peptidomimetics, nucleic acids, nucleic acid analogs and derivatives,
cleotides, oligonucleotides, s, an extract made from biological materials such
as bacteria, plants, fungi, or animal cells or tissues, naturally occurring or synthetic
compositions, particulates, or any combinations thereof. An active agent can be charge
neutral or comprise a net charge, e.g., active agent is anionic or cationic. Furthermore, an
active agent can be hydrophobic, hydrophilic, or hilic. In some embodiments, the
active agent comprises at least one aryl or heteroaryl group.
As used herein, the term “particulate” refers to a particle, powder, flake, etc., that
inherently exists in a relatively small form and may be formed by, for example, grinding,
shredding, fragmenting, pulverizing, atomizing, or ise subdividing a larger form of the
material into a relatively small form.
] As used herein, the term “small le” can refer to compounds that are
“natural product-like,” however, the term “small molecule” is not limited to “natural product-
like” compounds. Rather, a small molecule is typically characterized in that it ns
l carbon—carbon bonds, and has a molecular weight of less than 5000 Daltons (5 kD),
preferably less than 3 kD, still more preferably less than 2 kD, and most preferably less than
PCT/U82012/052027
1 kD. In some cases it is highly preferred that a small molecule have a molecular mass equal
to or less than 700 s.
In some embodiments, the active agent can be a peptide or a n. As used
herein, the term de” is used in its broadest sense to refer to compounds containing two
or more amino acids, amino acid lents or other non-amino groupsjoined to each other
by peptide bonds or modified peptide bonds. Peptide equivalents can differ from
conventional peptides by the replacement of one or more amino acids with related organic
acids (such as PABA), amino acids or the like or the substitution or modification of side
chains or functional . A peptide can be of any size so long; however, in some
embodiments, peptides having twenty or fewer total amino acids are preferred. Additionally,
the peptide can be linear or cyclic. Peptide sequences cally recited herein are written
with the amino terminus on the left and the carboxy us on the right. In addition, the
term “peptide” broadly es proteins, which lly are polypeptides. As used herein,
the term “protein” is used to describe proteins as well as fragments thereof. Thus, any chain
of amino acids that exhibits a three dimensional structure is included in the term “protein”,
and protein nts are accordingly embraced.
] A peptidomimetic is a molecule capable of folding into a defined three-
dimensional stmcture similar to a natural peptide
As used herein, the term “nucleic acid” refers to a polymers (polynucleotides) or
oligomers (oligonucleotides) of nucleotide or nucleoside monomers consisting of naturally
occurring bases, sugars and intersugar linkages. The term “nucleic acid” also includes
polymers or ers comprising non-naturally occum'ng monomers, or portions thereof,
which function similarly. Such modified or substituted nucleic acids are often preferred over
native forms e of properties such as, for example, enhanced cellular uptake and
increased stability in the presence of nucleases.
A nucleic acid can be single-stranded or double—stranded. A single-stranded
nucleic acid can have double-stranded regions and a double—stranded nucleic acid can have
single-stranded regions. Exemplary nucleic acids include, but are not limited to structural
genes, genes including control and ation regions, self-replicating systems such as viral
or plasmid DNA, single-stranded and double-stranded siRNAs and other RNA interference
reagents (RNAi agents or iRNA agents), short-hairpin RNAs (shRNA), antisense
oligonucleotides, ribozymes, microRNAs, microRNA , aptamers, antimirs,
antagomirs, x-forming oligonucleotides, RNA activators, immune—stimulatory
oligonucleotides, and decoy oligonucleotides.
PCT/U82012/052027
In some embodiments, the active agent is biologically active or has biological
activity. As used herein, the term “biological activity” or “bioactivity” refers to the ability of
a compound to affect a biological sample. Biological activity can include, without limitation,
elicitation of a stimulatory, inhibitory, regulatory, toxic or lethal response in a biological
assay at the molecular, cellular, tissue or organ levels. For example, a ical activity can
refer to the ability of a compound to exhibit or modulate the effect/activity of an enzyme,
block a receptor, stimulate a or, modulate the expression level of one or more genes,
modulate cell proliferation, modulate cell division, modulate cell morphology, or any
ation thereof. In some instances, a biological activity can refer to the ability of a
compound to produce a toxic effect in a biological sample, or it can refer to an y to
al modify a target le or cell.
In some embodiments the active agent is a therapeutic agent. As used herein, the
term “therapeutic agent” refers to a biological or chemical agent used for treatment, curing,
ting, or preventing deleterious ions in a subject. The term “therapeutic agent”
also includes substances and agents for combating a e, condition, or disorder of a
subject, and includes drugs, diagnostics, and instrumentation. “Therapeutic agent” also
includes anything used in medical diagnosis, or in ing, correcting, or modifying
physiological functions. The terms “therapeutic agent" and “pharmaceutically active agent”
are used interchangeably .
A therapeutic agent can be selected according to the treatment objective and
ical action desired. Thus, a therapeutic agent can be selected from any class suitable
for the therapeutic objective. Further, the therapeutic agent may be selected or arranged to
provide therapeutic activity over a period of time.
Exemplary pharmaceutically active compound include, but are not limited to,
those found in on’s Principles of Internal Medicine, 13th Edition, Eds. T.R. Harrison
McGraw—Hill NY, NY; Physicians Desk Reference, 50‘h Edition, 1997, Oradell New Jersey,
Medical Economics Co.; Pharmacological Basis of Therapeutics, 8‘h Edition, Goodman and
Gilman, 1990; United States copeia, The National ary, USP XII NF XVII,
1990; current edition of Goodman and Oilman’s The Pharmacological Basis of Therapeutics;
and current edition of The Merck Index, the complete content of all of which are herein
incorporated in its entirety.
Exemplary pharmaceutically active agents include, but are not limited to, ds
and nonsteroidal anti—inflammatory agents, antirestenotic drugs, antimicrobial agents,
PCT/U82012/052027
angiogenic factors, calcium channel blockers, thrombolytic , antihypertensive agents,
anti-coagulants, antian‘hythmic agents, c glycosides, and the like.
In some embodiments, the therapeutic agent is selected from the group consisting
of salicylic acid and derivatives (aspirin), para-aminophenol and derivatives
(acetaminophen), arylpropionic acids (ibuprofen), corticosteroids, histamine receptor
antagonists and bradykinin or antagonists, leukotriene receptor antagonists,
glandin receptor antagonists, platelet activating factor receptor antagonists,
sulfonamides, trimethoprim-sulfamethoxazole, quinolones, penicillins, cephalosporin, basic
fibroblast growth factor (FGF), acidic fibroblast growth factor, vascular endothelial growth
factor, angiogenic orming growth factor alpha and beta, tumor necrosis factor,
angiopoietin, platelet-derived growth factor, dihydropyridines (e.g., nifedipine,
benzothiazepines such as dilitazem, and phenylalkylamines such as verapamil), urokinase
plasminogen activator, urokinase, streptokinase, angiotensin ting enzyme (ACE)
inhibitors, spironolactone, tissue plasminogen tor (tPA), diuretics, thiazides,
antiadrenergic agents, clonidine, propanolol, angiotensin-converting enzyme tors,
captopril, angiotensin receptor antagonists, losartan, calcium channel antagonists, nifedine,
heparin, warfarin, , tick anti-coagulant peptide, and low lar weight heparins
such as enoxaparin, lidocaine, namide, encainide, flecanide, beta adrenergic blockers,
propranolol, amiodarone, verpamil, diltiazem, nickel chloride, cardiac glycosides, angiotensin
converting enzyme inhibitors, ensin or antagonists, nitrovasodilators,
hypolipidemic agents (e.g., nicotinic acid, ol, etc.), bile acid-binding resins (e.g.,
tyramine, and fibric acid derivatives e.g., ate), HMG CoA reductase inhibitors,
HMG CoA synthase inhibitors, squalene synthase tors, squalene epoxidase inhibitors,
statins (e.g., lovastatin, cerivastatin, fluvastatin, pravastatin, simvaststin, etc), anti-
psychotics, SSRls, antiseizure medication, contraceptives, systemic and local analgesics
ic pain, bone growth/remodeling factors (osteoblast/osteoclast recruiting and
stimulating factors), neurotransmitters (L—DOPA, Dopamine, neur’opeptides), ema
drugs, TGF-beta), rapamycin, naloxone, paclitaxel, amphotericin, Dexamethasone, flutamide,
ycin, phenobarbital, cimetidine, atenolol, aminoglycosides, hormones (e.g.,
thyrotropin-releasing hormone, p-nitrophenyl beta—cellopentaosideand luteinizing hormone-
releasing hormone), vincristine, amiloride, digoxin, morphine, procainamide, quinidine,
quinine, ranitidine, triamterene, trimethoprim, vancomycin, aminoglycosides, and penicillin,
and pharmaceutically acceptable salts thereof.
PCT/U52012/052027
In some embodiments, the active agent is a siRNA, a shorthahpin RNA
(shRNA), an antisense ucleotide, a ribozyme, a microRNA, a microRNA mimic, an
aptamer, an antimir, an antagomir, a x-forming oligonucleotide, a RNA activator, an
immunostimulatory oligonucleotide, a decoy ucleotide, a plasmid, or a DNA vector.
In some embodiments, the therapeutic agent is a radioactive material. Suitable
radioactive materials include, for example, 0f 90yttrium, 192iridium, 198gold, ”Siodine,
l‘7ce51um, “cobalt, ”cobalt, 56cobalt,57cobalt,57magne51um,1 .
. 551ron, 3 phOSphorous,. 3
9ostrontium,. 31 mb1dium,06bismuth,(’7gallium,7bromine,-- 2 ~ . 7 . 129 - 73
selenium,- 72
cesrum, selemum,.
72 . - 1 23 l
lead, l'Ind1um,5 iron,- 2. 167 '2 , ~
arsenic, 103palladium, thulium, 57nickel, 6 zinc, 0 copper,- 2
201thallium and 123iodine. Without wishing to be bound by a theory, les compiising a
radioactive material can be used to treat diseased tissue such as tumors, arteriovenous
malformations, and the like.
In some embodiments, the active agent is an g agent. As used herein, the
term “imaging agent” refers to an element or functional group in a molecule that allows for
the detection, g, and/or monitoring of the presence and/or ssion of a
condition(s), pathological disorder(s), and/or disease(s). The imaging agent may be an
echogenic substance r liquid or gas), tallic isotope, an Optical reponer, a boron
n absorber, a paramagnetic metal ion, a ferromagnetic metal, a gamma—emitting
sotope, a positron-emitting radioisotope, or an x—ray absorber. Without wishing to be
bound by a , an imaging agent allows tracking of a ition comprising such an
imaging agent.
Suitable optical reporters include, but are not limited to, cent reporters and
chemiluminescent groups. A wide variety of fluorescent reporter dyes are known in the art.
Typically, the fluorophore is an aromatic or heteroaromatic compound and can be a pyrene,
anthracene, naphthalene, acn’dine, stilbene, indole, benzindole, oxazole, thiazole,
benzothiazole, cyanine, carbocyanine, salicylate, anthranilate, coumarin, fluorescein,
rhodamine or other like compound. Suitable fluorescent reporters include xanthene dyes,
such as cein or rhodamine dyes, including, but not limited to, Alexa Fluor® dyes
(InvitrogenCorp.; Carlsbad, Calif), fluorescein, fluorescein isothiocyanate (FITC), Oregon
GreenTM, rhodamine, Texas red, tetrarhodamine isothiocynate (TRITC), 5-
yfluorescein (FAM), 2'7'-dimethoxy—4'5'-dichlorocarboxyfluorescein (JOE),
tetrachlorofluorescein (TET), 6-carboxyrhodamine (R60), N,N,N,N'—tetramefhyl
carboxyrhodamine ), 6-ca1boxy—X-rhodamine (ROX). Suitable fluorescent
reporters also include the naphthylamine dyes that have an amino group in the alpha or beta
position. For example, naphthylamino compounds include l-dimethylamino—naphthyl-S-
sulfonate, l~anilino—8—naphthalene ate, 2-p-toluidinylnaphthalene sulfonate, and 5—
(2'-aminoethyl)aminonaphthalene—l-sulfonic acid ). Other fluorescent er dyes
include coumarins, such as 3-phenyl-7—isocyanatocoumarin; acridines, such as 9-
isothiocyanatoacridine and acridine orange; N-(p(2-benzoxazolyl)phenyl)maleimide;
cyanines, such as Cy2, indodicarbocyanine 3 (Cy3), indodicarbocyanine 5 (Cy5),
indodicar'bocyanine 5.5 (Cy5.5), 3-(-carboxy-pentyl)-3'ethyl-5,5'-dimethyloxacarbocyanine
(CyA); lI-l,51-I,l 1H, ntheno[2,3,4—ij:5,6,7-i'j']diquinolizin-18—ium, 9-[2(01' 4)—[[[6—
[2,5—dioxo-l-pyrrolidinyl)oxy]oxohexyl] amino]sulfonyl]-4(or 2)-sulfophenyl]-
2,3,6,7,12,13,16,17octahydro-inner salt (TR or Texas Red); BODIPYTM dyes;
benzoxadiazoles; stilbenes; pyrenes; and the like. Many suitable forms of these cent
compounds are available and can be used.
Examples of fluorescent proteins suitable for use as imaging agents include, but
are not limited to, green scent protein, red fluorescent protein (e.g., DsRed), yellow
fluorescent protein, cyan fluorescent protein, blue fluorescent protein, and variants thereof
(see, e.g., US. Pat. Nos. 6,403, 374, 6,800,733, and 7,157,566). c examples of GFP
variants include, but are not limited to, enhanced GFP (EGFP), destabilized EGFP, the GFP
variants described in Doan et al, M01. Microbiol, 55: 1767—1781 , the GFP variant
bed in Crameri et al, Nat. Biotechnol., 14:315319 (1996), the cerulean fluorescent
ns described in Rizzo et al, Nat. Biotechnol, 221445 (2004) and Tsien, Annu. Rev.
Biochem., 67:509 (1998), and the yellow fluorescent protein described in Nagal et al, Nat.
Biotechnol., 20:87-90 (2002). DsRed variants are described in, e.g., Shaner et al, Nat.
Biotechnol., 22: 1567-1572 (2004), and include mStrawberi'y, mCherTy, morange, mBanana,
mHoneydew, and rine. Additional DsRed variants are described in, e.g., Wang et al,
Proc. Natl. Acad. Sci. USA, 101:16745-16749 (2004) and include en‘y and mPlum.
r examples of DsRed variants include mRFPmars described in Fischer et al, FEBS
Lem, 577:227-232 (2004) and by described in Fischer et al, FEBS Letl, 580:2495-
2502 (2006).
] Suitable echogenic gases include, but are not limited to, a sulfur hexafluoride or
perfluorocarbon gas, such as perfluor‘omethane, perfluoroethane, perfluoropropane,
perfluorobutane, perfluorocyclobutane, perfluropentane, or perfluor‘ohexane.
Suitable tallic isotopes include, but are not limited to, “C, ”C, ”N, ”F,
123I, 124I, and 1251. Suitable radioisotopes include, but are not limited to, 99mTc, 95Tc, mm,
62Cu, 64Cu, Ga, 680a, and 153Gd. Suitable paramagnetic metal ions include, but are not
WO 28843 PCT/U52012/052027
limited to, Gd(III), Dy(III), ), and Mn(II). Suitable X-ray absorbers include, but are not
limited to, Re, Sm, Ho, Lu, Pm, Y, Bi, Pd, Gd, La, Au, Au, Yb, Dy, Cu, Rh, Ag, and Ir. In
some embodiments, the radionuclide is bound to a chelating agent or ing agent-linker
attached to the aggregate. Suitable mdionuclides for direct conjugation include, without
limitation, 18F, 124l, 125I, 1"I, and mixtures thereof. Suitable radionuclides for use with a
chelating agent include, without limitation, 478c, (”Cu, 67Cu, 89Sr, 86Y, 87Y, 90Y, 105Rh, lllAg,
”’ln, 117msn’ ”9Pm, 153Sm7 166H0,177Lu,186Re,188R6, leAt’ 212Bi, and mixtures thereof.
Suitable chelating agents include, but are not limited to, DOTA, BAD, TETA, DTPA, EDTA,
NTA, HDTA, their phosphonate analogs, and mixtures thereof. One of skill in the art will be
familiar with methods for ing radionuclides, chelating agents, and chelating agent—
linkers to the particles.
A detectable response generally refers to a change in, or occurrence of. a signal
that is detectable either by observation or instrumentally. In certain instances, the detectable
response is fluorescence or a change in fluorescence, e.g., a change in fluorescence intensity,
fluorescence excitation or emission wavelength distiibution, fluorescence lifetime, and/or
fluorescence polaiization. One of skill in the art will appreciate that the degree and/or
location of labeling in a subject or sample can be compared to a standard or control (e.g.,
healthy tissue or organ). In certain other instances, the detectable response the detectable
response is radioactivity (i.e., radiation), including alpha particles, beta les, nucleons,
ons, positrons, neutrinos, and gamma rays emitted by a radioactive substance such as a
radionuclide.
c devices or methods known in the art for the in vivo detection of
fluorescence, e.g., from fluorophores or fluorescent proteins, include, but are not limited to,
in vivo nfrared fluorescence (see, e.g., Frangioni, Curr. Opin. Chem. Biol, 7:626-634
(2003)), the MaestroTM in vivo fluorescence imaging system (Cambridge Research &
Instrumentation, Inc.; , Mass), in vivo fluorescence imaging using a flying-spot
r (see, e.g., Ramanujam et a], IEEE Transartions on Biomedical Engineering,
48: 1034- 1041 , and the like. Other s or devices for ing an optical
response include, without limitation, visual inspection, CCD cameras, video cameras,
photographic film, laser—scanning devices, fluorometers, photodiodes, quantum counters,
rescence microscopes, scanning microscopes, flow cytometers, fluorescence
microplate readers, or signal amplification using photomultiplier tubes.
] Any device or method known in the art for detecting the radioactive emissions of
radionuclides in a subject is suitable for use in the t invention. For e, methods
WO 28843 PCT/U52012/052027
Such as Single Photon Emission erized Tomography (SPECT), which detects the
radiation from a single photon gamma—emitting radionuclide using a rotating gamma camera,
and uclide scintigraphy, which obtains an image or series of sequential images of the
distribution of a radionuclide in tissues, organs, or body systems using a llation gamma
camera, may be used for detecting the radiation emitted from a radiolabeled aggregate.
Positron on tomography (PET) is another suitable technique for detecting radiation in a
subject.
In some embodiments, the ligand is a cell surface receptor ligand. As used herein,
a “cell surface receptor ” refers to a molecule that can bind to the outer surface of a
cell. Exemplary, cell surface receptor ligand includes, for example, a cell surface receptor
binding peptide, a cell surface or binding glycopeptide, a cell surface receptor g
protein, a cell surface receptor binding glycoprotein, a cell surface receptor binding organic
compound, and a cell e receptor g drug.
Cell surface receptor ligands include, but are not limited to, cytokines, growth
factors, hormones, dies, and angiogenic factors.
In some embodiments, the cell surface receptor ligand is transferrin or EGF.
Ligands providing enhanced affinity for a selected target are also termed targeting
ligands herein. As used herein, the term ting ligand” refers to a molecule that binds to
or interacts with a target molecule. Typically the nature of the interaction or binding is
noncovalent, e.g., by hydrogen, electrostatic, or van der Waals interactions, however, binding
may also be covalent.
As used herein, the term “endosomolytic ligand” refers to molecules having
endosomolytic properties. Endosomolytic ligands promote the lysis of and/or transport of the
composition of the invention, or its components, from the ar compartments such as the
me, lysosome, endoplasmic reticulum (ER), golgi apparatus, microtubule, peroxisome,
or other lar bodies within the cell, to the asm of the cell. Some exemplary
endosomolytic ligands include, but are not limited to, imidazoles, poly or oligoimidazoles,
linear or branched polyethyleneimines (PEIs), linear and brached polyamines, e.g. spermine,
ic linear and branched polyamines, polycarboxylates, polycations, masked oligo or
poly cations or anions, acetals, polyacetals, ketals/polyketals, orthoesters, linear or branched
polymers with masked or ed cationic or anionic charges, dendrimers with masked or
unmasked cationic or anionic charges, polyanionic peptides, polyanionic peptidomimetics,
pH-sensitive es, natural and synthetic fusogenic lipids, natural and synthetic cationic
lipids.
As used herein, the terms “PK modulating ligand” and “PK modulator” refers to
molecules which can modulate the pharmacokinetics of the composition of the invention.
Some exemplaiy PK modulator include, but are not d to, lipophilic molecules, bile
acids, sterols, phospholipid analogues, peptides, protein binding agents, vitamins, fatty acids,
phenoxazine, aspirin, naproxen, ibuprofen, suprofen, ketoprofen, )-pranoprofen,
caiprofen, PEGs, biotin, and transthyretia-binding ligands (e.g., tetraiidothyroacetic acid, 2,
4, 6-triiodophenol and flufenamic acid).
In some embodiments, an hilic peptide comprises at least one (e.g., l, 2, 3,
4, 5 or more) ligand conjugate. When two or more s are present, the ligands can all
have same properties, all have ent properties or some s have the same properties
while others have different properties. For example, a ligand can have targeting properties,
have endosomolytic activity or have PK modulating properties. Accordingly, the two or
more ligands can be same ligand, different ligands, same type of ligand (e.g., targeting ligand,
endosomolytic ligand, PK tor), different types of ligands, or any combinations
f. In some embodiments, all the ligands have different properties.
In some embodiments, the amphiphilic peptide comprises a hydrophilic polymer
selected from the group consisting of poly(ethylene glycol), poly (ethylene oxide),
poly(propylene glycol), poly ene oxide—co-propylene oxide), hyaluronic acid, poly(2-
hydroxyethyl methacrylate), heparin, nyl(pyrrolidone), oitan sulfate, chitosan,
glucosaminoglucans, dextran, n, dextran sulfate, cellulose acetate, carboxymethyl
cellulose, hydroxyethyl cellulose, cellulosics, poly(trimethylene glycol), poly(tetramethylene
glycol), polypeptides, polyacrylamide, polyacrylimide, poly(ethylene amine), llyl
amine), and blends thereof, and wherein the hydrophilic polymer is covalently linked with the
hydrophobic peptidyl segment.
Linking to gegtides
A molecule (e.g. a ) can be conjugated to a peptide using any of a variety of
methods known to those of skill in the art. The molecule can be d or conjugated to the
peptide covalently or non-covalently. The covalent linkage between the molecule and the
peptide can be ed by a linker. The non-covalent linkage between the molecule and the
peptide can be based on ionic interactions, van der Waals interactions, dipole-dipole
interactions, hydrogen bonds, electrostatic interactions, and/or shape ition interactions.
Without limitations, ligands can be coupled to a peptide at s places, for
example, N-terminus, C—terminus, and/or at an internal position (e.g., side chain of an amino
PCT/U82012/052027
acid). When two or more ligands are present, the ligand can be on opposite ends of a peptide
(e.g., N-teiminus and C-terminus).
Generally, the ligand is located at the terminal end (e.g., at position 1,2, 3, 4, 5. 6,
7, 8, 9, or 10 ng from the end) that is furthest away from the hydrOphobic peptidyl
segment. Without wishing to be bound by a theory, this allows the ligand to be position on or
near the surface of a particle formed by ggregation of amphiphilic es.
In some embodiments, a ligand is located at the terminus of hydrophilic peptidyl
segment that is not linked with the hobic peptidyl segment. For example, if the N-
terminus of the hydrophilic peptidyl segment is linked to the hydrophobic peptidyl segment,
then the ligand is d at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 counting from C-terminus of
the hydrophilic peptidyl t. Alternatively, if the C-terminus of the hydrophilic peptidyl
segment is linked to the hydrophobic peptidyl segment, then the ligand is located at position
1,2, 3, 4, 5, 6, 7, 8, 9, 10 counting from N-terminus of the hydrOphilic peptidyl segment.
In some embodiments, the ligand is ed the peptide via a linker. The ligand
can be present on a monomer when said monomer is orated into a peptide during
synthesis. In some embodiments, the ligand can be incorporated via coupling to a
“precursor” monomer after said “precursor” monomer has been incorporated into the peptide.
For e, a monomer having, e.g., an amino-terminated linker (i.e., having no associated
ligand), e.g., monomer-linker—NH: can be incorporated into peptide. In a subsequent
operation, i.e., after incorporation of the precursor monomer into the peptide a ligand having
an electrophilic group, e.g., a pentafluorophenyl ester or aldehyde group, can subsequently be
attached to the precursor monomer by coupling the electrophilic group of the ligand with the
terminal philic group of the precursor monomer’s tether. In another non-limiting
example, a ligand having an electrophilic group can be attached to a N—terminus, C-teiminus
or an internal side chain amino group. In another e, a thiol sing ligand can be
linked to a peptide by a disulfide linker when the peptide comprises a cysteine.
Linkers
As used herein, the term “linker” means an organic moiety that connects two parts
of a nd. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur,
a unit such as NH, C(O), , SO, 302, SOzNH, SS, or a chain of atoms, such as
substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl,
substituted or unsubstituted C2—C6 alkynyl, tuted or unsubstituted C6-Cl-2 alyl,
tuted or unsubstituted C5-C1; heteroaryl, substituted or unsubstituted C5-C12
PCT/U52012/052027
cyclyl, tuted or unsubstituted C3-C1; cycloalkyl, where one or more enes
can be intermpted or ated by O, S, 8(0), 802, NH, C(O).
In some ments, the linker is a branched linker. The branchpoint of the
branched linker may be at least trivalent, but can be a tetravalent, pentavalent or hexavalent
atom, or a group presenting such multiple valencies. In some embodiments, the branchpoint
is -N, -N(R)-C, —O—C, «S-C, -SS-C, -C(O)N(R)-C, -OC(O)N(R)—C, -N(R)C(O)-C, or -
N(R)C(O)O-C; wherein R is independently for each occurrence H or optionally substituted
alkyl. In some embodiments, the branchpoint is glycerol or derivative thereof.
In some embodiments, linker comprises a cleavable linking group. As used
herein, a “cleavable linking group” is a chemical moiety which is sufficiently stable outside
the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is
holding together. In a preferred embodiment, the ble linking group is cleaved at least
times or more, preferably at least 100 times faster in the target cell or under a first
reference ion (which can, e.g., be selected to mimic or represent intracellular
conditions) than in the blood or serum of a subject, or under a second reference condition
(which can, e.g., be selected to mimic or represent conditions found in the blood or .
] Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox
potential or the ce of degradative molecules. Generally, cleavage agents are more
prevalent or found at higher levels or activities inside cells than in serum or blood. Examples
of such degradative agents include: redox agents which are ed for particular substrates
or which have no substrate specificity, including, e.g., ive or reductive enzymes or
reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable
linking group by ion; esterases; amidases; endosomes or agents that can create an
acidic environment, e.g., those that result in a pH of five or lower; enzymes that can
hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases
(which can be substrate specific) and proteases, and atases.
A linker can include a cleavable linking group that is cleavable by a particular
enzyme. The type of cleavable linking group orated into a linker can depend on the
cell to be targeted. For example, for liver targeting, cleavable linking groups can include an
ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more
efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in
esterases include cells of the lung, renal cortex, and testis.
Linkers that contain peptide bonds can be used when targeting cell types rich in
peptidases, such as liver cells and synoviocytes.
In some embodiments, cleavable linking group is cleaved at least 1.25, 1.5, 1.75,
2, 3, 4, 5, 10, 25, 50, or 100 times faster in the cell (or under in vitro conditions selected to
mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions
selected to mimic extracellular conditions). In some embodiments, the cleavable linking
group is cleaved by less than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, or 1%
in the blood (or in vitro conditions selected to mimic extracellular conditions) as compared to
in the cell (or under in vitro conditions ed to mimic intracellular conditions).
Exemplary cleavable linking groups include, but are not limited to, redox
cleavable linking groups (e.g., -S-S- and —C(R)2-S-S-, wherein R is H or C1—C6 alkyl and at
least one R is C1-C6 alkyl such as CH3 or CH3CH3); ate~based cleavable linking
groups (e.g., -O-P(O)(OR)-O-, —O—P(S)(OR)-O-. -O-P(S)(SR)—O—, —S-P(O)(OR)-O-. -O-
P(O)(OR)-S-, -S-P(O)(OR)-S-, -O-P(S)(ORk)-S-, -S-P(S)(OR)-O-, -O-P(O)(R)-O-, -O-
P(S)(R)-O-, ~S-P(O)(R)-O-, -S-P(S)(R)—O-, -S—P(O)(R)-S-, -O-P(S)( R)-S—, . -O-P(0)(OH)-
0-, )(OH)-O-, )(SH)-O—, —S~P(O)(OH)-O-, -O-P(O)(OI—I)—S—, -S-P(O)(OH)-S-, -
O-P(S)(0H)—S~, -S-P(S)(OH)-O-, ~O—P(O)(H)-O-, -O-P(S)(H)-O-, —S—P(O)(I-l)-O-, -SP
(S)(H)-O-, )(H)-S-, and )(H)-S-, wherein R is optionally substituted linear or
branched C1-C10 ; acid celavable linking groups (e.g., hydrazones, esters, and esters of
amino acids, ~C:NN— and -OC(O)-); ester—based ble linking groups (e.g., —C(O)O-);
peptide-based ble linking groups, (e.g., g groups that are cleaved by enzymes
such as peptidases and proteases in cells, e.g., — NHCHRAC(O)NHCHRBC(O)—, where RA
and RB are the R groups of the two adjacent amino acids). A peptide based cleavable linking
group comprises two or more amino acids. In some embodiments, the e-based cleavage
linkage comprises the amino acid sequence that is the substrate for a peptidase or a se
found in cells.
In some embodiments, an acid cleavable linking group is cleaveable in an acidic
environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.5, 5.0, or lower), or by agents
such as s that can act as a general acid.
In addition to covalent linkages, two parts of a compound can be linked together
by an affinity binding pair. The term “affinity binding pair” or “binding pair” refers to first
and second molecules that specifically bind to each other. One member of the binding pair is
conjugated with first part to be linked while the second member is conjugated with the
second part to be linked. As used herein, the term “specific binding” refers to binding of the
first member of the binding pair to the second member of the binding pair with greater
affinity and specificity than to other molecules.
Exemplary binding pairs include any haptenic or antigenic compound in
combination with a corresponding antibody or binding portion or fragment thereof (e.g.,
digoxigenin and anti-digoxigenin; mouse immunoglobulin and goat antimouse
immunoglobulin) and nonimmunological binding pairs (e.g., biotin-avidin, biotin-
streptavidin, hormone [e.g., thyroxine and cortisol-hormone g protein, receptor-
or agonist, receptor—receptor antagonist (e. g., acetylcholine receptor-acetylcholine or an
analog thereof), IgG-protein A, lectin-car‘bohydrate, enzyme-enzyme cofactor, enzyme-
enzyme inhibitor, and complementary oligonucleoitde pairs capable of forming nucleic acid
duplexes), and the like. The binding pair can also include a first molecule which is negatively
charged and a second molecule which is positively charged.
One example of using binding pair conjugation is the biotin-avidin or biotin-
streptavidin conjugation. In this approach, one of the molecule or the peptide is biotinylated
and the other is conjugated with avidin or streptavidin. Many commercial kits are also
available for ylating molecules, such as ns.
Another example of using binding pair conjugation is the biotin—sandwich method.
See, e.g., example Davis et al., Proc. Natl. Acad. Sci. USA, 103: 8155-60 (2006). The two
les to be conjugated together are biotinylated and then conjugated together using
tetravalent streptavidin as a linker.
Still another example of using binding pair conjugation is double-stranded nucleic
acid conjugation. In this approach, the first part to be linked is conjugated is with linked a
first strand first strand of the -stranded nucleic acid and the second part to be linked is
conjugated with the second strand of the double-stranded c acid. Nucleic acids can
include, without limitation, defined sequence segments and sequences comprising
nucleotides, cleotides, deoxyn'bonucleotides, tide analogs, modified nucleotides
and nucleotides comprising backbone modifications, branchpoints and nonnucleotide
residues, groups or bridges.
Peptide particles
The inventor has also discovered that the amphiphilic peptides bed herein
undergo ggregation to form olecular aggregates. Thus, in another aspect the
ion es peptide particles comprising an amphiphilic peptide bed herein. In
some embodiments, the peptide particle comprises a plurality of amphiphilic peptides
described herein. For example, a peptide le can comprise at least about 2, at least about
3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least
about 9, at least about 10, at least about 20, at least about 25, at least about 50, at least about
75, at least about 100, at least about 150, at least about 200, at least about 250, at least about
500, at least about 750, at least about 1000, at least about 2500, at least about 5000, at least
about 10,000 or more amphiphilic peptides described herein. The plurality of amphiphilic
peptides present in a peptide particle can comprise one embodiment of an hilic
peptide described herein, or at least two ent embodiments of an amphiphilic peptide
described .
The term “particle” includes spheres; ds; and prisms. The peptide particles
described herein differ from micelles, liposomes, and other particles that comprise a distinct
shell (e.g., a lipid layer), which serves as a wall~forming material, surrounding encapsulated
media located within the shell. The particles described here in are solid particles. The
particles can be, e.g., monodisperse or polydisperse and the variation in diameter of the
particles of a given dispersion may vary. However, because amphiphilic peptides of a
uniform size can be obtained, the particles bed herein generally are monodisperse.
Accordingly, in some embodiments, the er of a particle described herein is within
$2.590, within i570, within i10%, within 115%, within i20%, within t25%, within 130%, or
within i35% of the average diameter.
In some embodiments, a peptide particle bed herein is a nanoparticle. As
used herein, the term “nanoparticle” refers to particles that are on the order of 10'9 or one
nth of a meter and below 10'6 or 1 millionth of a meter in size.
Generally, the peptide particles have an average diameter of from about 5 nm to
about 5000 nm. In some embodiments, the particles have an average diameter of from about
50 nm to about 2500 nm. In some embodiments, the particles have an average diameter of
from about 100 nm to about 2000 nm. In some embodiments, the particles have an e
er of from about 150 nm to about 1700 nm. In some embodiments, the particles have
an average diameter of from about 200 nm to about 1500 nm. In some ment, the
particles have an e diameter of about 260 nm. In one embodiment, the particles have
an average diameter of about 30 nm to about 150nm. Without wishing to be bound by a
theory, particle size can be modulated by changing the concentration of the amphiphilic
peptide in the solution used for fabricating the peptide particles.
In some embodiments, a peptide particle bed herein comprises a mixture of
fully masked amphiphilic peptides and partially or non-masked amphiphilic peptides. As
used herein a “non-masked peptide” refers to an amphiphilic peptide in which none of the N-
PCT/U82012/052027
terminus amino group and the side chain amino groups in the hydrophilic yl segment is
ated with a nitrogen— or amino—protecting group.
By changing the ratio of fully masked to partially masked or non-masked
peptides, net charge of the peptide particle can be varied. Without wishing to be bound by a
theory, higher ratios of fully masked peptides can increase le stability, while higher
ratios of partially and/or sked es can increase loading of molecules carrying
anionic charges (e.g., nucleic acids, such as DNA or RNA including siRNA) and a higher
capacity to penetrate a cell membrane.
In some embodiments, the peptide particle can comprise a fully-masked
amphiphilic peptide (e.g., a fully-acetylated amphiphilic peptide). The term “fully-acetylated
amphiphilic peptide” as used herein refers to an amphiphilic peptide in which all of the N-
terminus amino group and the side chain amino groups in the hydrophilic peptidyl segment is
ated.
In some embodiments, the e particle can comprise a mixture of fully-
masked (e.g., fully-acetylated) and lly masked (e.g., partially-acetylated) peptides. As
used herein, the term “partially—acetylated amphiphilic peptide” refers to an amphiphilic
peptide in which at least one of the N-terminus amino group and the side chain amino groups
in the hydrophilic peptidyl t is acetylated, but not all of them. In some embodiments a
partially-acetylated amphiphilic e can have the N-terminus amino group of the
amphiphilic peptide acetylated, but not any of the side chain amino groups in the hydrophilic
peptidyl segment. In some embodiments, a partially-acetylated amphiphilic peptide can have
at least one (including at least two or more) of the side chain amino groups in the hydrophilic
peptidyl segment acetylated, but not the N—terminus amino group of the amphiphilic peptide.
In some embodiments, a partially-acetylated amphiphilic peptide can have both the N-
terminus amino group of the amphiphilic e and at least one (including at least two or
more), but not all, of the side chain amino groups in the hydrophilic peptidyl segment
acetylated.
In some embodiments, the peptide particle can comprise a mixture of fully-
masked (e.g., fully-acetylated) and nonmasked (e.g., non-acetylated) amphiphilic peptides.
As used herein, the term “non-acetylated hilic peptide” refers to an amphiphilic
peptide in which none of the inus amino group and the side chain amino groups in the
hydrophilic peptidyl segment is acetylated. In some embodiments, the peptide particle can
comprise a mixture of fully—masked (e.g., acetylated), partially-masked (e.g., partially—
acetylated) and sked (e.g., non-acetylated) amphiphilic peptides.
PCT/U520] 2/052027
In some embodiments, the peptide particle does not comprise a fully masked
amphiphilic peptide, e.g., the particle ses partially masked amphiphilic peptides or a
e of partially masked peptides. In some embodiments, the peptide le comprises
a mixture of partially-masked and non-masked peptides.
Without limitations, ratio of fully-masked to partially-masked or non-masked
peptides in the peptide particle can range from about 100:1 to about 1:100. In some
ments, ratio of fully-masked to partially-masked or non-masked es in the
peptide particle ranges from about 95:5 to about 1:1.
] The particles described herein can be used for drug delivery. Thus, a wide variety
of eutic agents can be included in the particles described herein. Accordingly, in some
embodiments, a e particle described herein can comprise an active agent described
herein. An active agent can be covalently linked with a component, e.g., amphiphilic peptide,
of the peptide le. In some embodiments, the active agent in the peptide particle
described herein is not covalently linked to a ent of the particle. Without tions,
the active agent can be absorbed/adsorbed on the surface of the le, encapsulated in the
particle, or distributed (homogenously or non-homogenously) throughout the particle.
] Generally, any ratio of active agent to amphiphilic peptides can be present in the
peptide particle described herein. Accordingly, in some embodiments, ratio of the active
agent to the amphiphilic peptides ranges from about 100:1 to about 1: 100,000. In some
embodiments, ratio of the active agent to the amphiphilic peptides ranges from about 1:1 to
about 1:100,000. In some embodiments, ratio of the active agent to the hilic peptides
ranges from about 1:1 to about 1:10,000. In some embodiments, ratio of the active agent to
the amphiphilic es ranges from about 1:1 to about 1:1000. In some embodiments, ratio
of the active agent to the amphiphilic peptides ranges from about 1:1 to about 1:100. In some
embodiments, ratio of the active agent to the amphiphilic peptides ranges from about 1:1 to
about 1: 10. In some embodiments, ratio of the active agent to the amphiphilic peptides ranges
from about 50:] to about 1:500. In some embodiments, ratio of the active agent to the
amphiphilic peptides ranges from about 10:] to about 1:25.
In some embodiments, the peptide particle can comprise a ligand. Without
limitations, a ligand can be covalently linked with a component, e.g., amphiphilic peptide, of
the particles. In some embodiments, a ligand is not covalently linked to a component of the
particle, e.g., the ligand is absorbed/adsorbed on the surface of the particle, the ligand is
encapsulated in the particle, or the ligand is distributed (homogenously or non-
PCT/U82012/052027
homogenously) throughout the particle. In some ments, the ligand is a targeting
ligand.
{00224} In some embodiments, the ligand forms a layer on the surface of the e
particle, e.g., the ligand forms a corona around the le. When the ligand forms a layer on
the surface of particle, thickness of the layer can range from about 1 nm to about 100 nm. In
some embodiments, thickness of the layer is about 10 nm.
Generally, any ratio of a ligand to amphiphilic peptides can be present in the
particle. Accordingly, in some embodiments, ratio of the ligand to the amphiphilic peptides
ranges from about 100021 to about 1:1,000,000. In some embodiments, ratio of the ligand to
the amphiphilic peptides ranges from about 1:10 to about 1:1,000,000. In some
embodiments, ratio of the ligand to the hilic peptides ranges from about 50021 to
about 1:500. In some embodiments, ratio of the ligand to the amphiphilic peptides ranges
from about 100:1 to about 1:250. In some embodiments, ratio of the ligand to the
amphiphilic peptides ranges from about 1:10 to about 1:1000.
In some embodiments, a peptide particle can comprise both an active agent (e.g., a
eutic agent) and a ligand. In some embodiments, a peptide particle can comprise an
active agent (e.g., a therapeutic agent) distributed within the particle and a ligand on the outer
surface of the particle.
Without limitations, different types of peptide particles can be fabricated, e.g., (1)
particles formed from amphiphilic es only; (2) particles formed from the amphiphilic
peptides to which a molecule of interest, e.g., an active agent or a ligand, s/adsorbs or
forms a coating on a core of amphiphilic es; (3) particles formed from a core formed by
a molecules of interest, e.g., an active agent or a ligand, which is coated with a layer of
amphiphilic peptides; (4) particles formed from amphiphilic es to which a molecule of
interest, e.g., an active agent or a ligand, is covalently linked; (5) les formed from a
mixture of a molecule of interest (e.g., an active agent or a ligand) and amphiphilic peptides;
and (6) particles formed so as to comprise a generally homogeneous e of a molecule of
interest, e.g., an active agent or a ligand with amphiphilic peptides, or any combinations
thereof. For example, a peptide particle can be formed from the amphiphilic peptides to
which a first le of interest, e.g., an active agent or a ligand, absorbs/adsorbs or forms a
coating on a core of amphiphilic peptides, wherein the core of amphiphilic peptides further
comprises a second molecule of interest, e.g., an active agent. In these embodiments, the
second molecule of interest can be the same as or different from the first molecule of interest.
PCT/U82012/052027
In some embodiments, a peptide particle can further compiise a polymer, e. g., a
biocompatible polymer. As used herein, the term “biocompatible" means exhibition of
essentially no cytotoxicity or immunogenicity while in contact with body fluids or tissues.
As used herein, the term “polymer” refers to oligomers, co-oligomers, polymers and co-
rs, e.g., random block, multiblock, star, grafted, gradient copolymers and combination
thereof.
The term “biocompatible polymer” refers to polymers which are non-toxic,
chemically inert, and substantially non-immunogenic when used internally in a subject and
which are substantially ble in blood. The biocompatible polymer can be either non-
biodegradable or preferably biodegradable. Preferably, the biocompatible polymer is also
noninflammatory when employed in situ.
Biodegradable polymers are sed in the art. Examples of suitable
biodegradable polymers include, but are not limited to, linear-chain polymers such as
polylactides, polyglycolides, polycaprolactones, copolymers of polylactic acid and
polyglycolic acid, hydrides, polyepsilon caprolactone, polyamides, polyurethanes,
polyesteramides, polyorthoesters, oxanones, polyacetals, polyketals, polycarbonates,
polyorthocarbonates, polydihydropyrans, polyphosphazenes, polyhydroxybutyrates,
polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid),
mino acids), polyvinylpyirolidone, polyethylene glycol, polyhydroxycellulose,
polymethyl methacrylate, , chitosan, copolymers of polylactic acid and polyglycolic
acid, poly(glycerol sebacate) (PGS), and copolymers, tetpolymers, and copolymers including
one or more of the foregoing. Other biodegradable polymers include, for example, gelatin,
collagen, silk, chitosan, alginate, ose, ucleic acids, etc.
] Suitable non-biodegradable biocompatible polymers include, by way of example,
cellulose acetates (including cellulose diacetate), polyethylene, polypropylene, polybutylene,
hylene terphthalate (PET), nyl chloride, polystyrene, polyamides, nylon,
polycarbonates, polysulfides, polysulfones, els (e.g., acrylics), polyacrylonitn’le,
polyvinylacetate, cellulose acetate butyrate, nitrocellulose, copolymers of urethane/carbonate,
copolymers of styrene/ maleic acid, poly(ethylenimine), poloxomers (e.g. Pluronic such as
mers 407 and 188), Hyaluron, n, agarose, Pullulan and copolymers including
one or more of the ing, such as ethylene/vinyl l mers (EVOl-I).
The peptide paiticles can also comprise additional moieties that can extend the
lifetime of the particles in vivo. For example, the peptide particles can compn'se functional
es that enhance the in viva lifetime of the particles in the blood. One exemplary moiety
PCT/U52012/052027
for increasing the in vivo lifetime is polyethylene . Accordingly, the peptide particles
can comprise polyethylene glycol in addition to the amphiphilic peptide.
Additional ments 01 Qleide Qarticlgs
In one embodiment, a e particle described herein comprises particular
embodiments of an amphiphilic peptide described herein. The amphiphilic peptide present in
this embodiment of the peptide particle comprises a hydrOphobic peptidyl segment and a
hydrophilic peptidyl segment, wherein the hobic peptidyl segment comprises an amino
acid sequence of (Trp-Leu)m-("I‘rp)n or (Leu-Trp)p-(Leu)q, wherein each Tr]: is D-Trp or L-
Trp and each Leu is D-Leu 0r L—Leu, m and p are ndently an integer from 1 to 5, and n
and q are independently 0 or 1, provided that when Tip is D-Trp then Leu is L-Leu, and when
Tip is L-Trp then Leu is D-Leu, or vice versa; and wherein the hydrophilic peptidyl t
comprises an amino acid sequence of (Lys)r, n r is an integer from 1 to 15, and
wherein the peptide particle further comprises on its outer surface a ligand described .
In some embodiments, the peptide particle can comprise one or more
embodiments of an amphiphilic peptide described earlier in the “Exemplary amphiphilic
es” section. In one embodiment, the peptide particle can comprise an amphiphilic
peptide with an amino acid sequence of (L—Lys)—(L-Lys)—(L—Lys)—(L-Trp)-(D-Leu)-(L—Trp)-
(D-Leu)-(L-Trp)—(D—Leu)-(L-Trp)-X, wherein X is absent or NH; As described earlier, in
some embodiments, at least one of the Lys residues of the hydrophilic peptidyl segment or
the N-terminus amino group of the hilic peptide is acetylated. In some ments,
all of the Lys residues of the hydrophilic peptidyl segment are acetylated. In some
embodiments, the N-terminus amino group of the amphiphilic peptide and all of the Lys
es of the hydrophilic peptidyl segment are acetylated.
The ligand present on the outer surface of the peptide particle can be selected
based on types of target molecules (e.g., but not limited to, cells, bacteria, proteins, and/or
nucleic acids) to which the peptide le will bind and/0r interact. For example, to facilitate
delivery of a peptide particle described herein to a cell, a ligand specific for the cell surface
receptor can be selected, thus facilitating the uptake of the peptide le by the cell, e.g.,
via endocytosis. Hence, some embodiments of the peptide particles described herein can be
used for targeted delivery of any active agent described herein using the peptide les as
delivery caniers or vehicles. In one embodiment, the peptide particles can be used to r
to a cell an active agent that is cell-impermeable when delivered by itself.
As described earlier, in some embodiments, the peptide le can comprise a
PCT/U82012/052027
mixture of fully—masked (e.g., fully-acetylated) and partially-masked (e. g., partially-
acetylated) amphiphilic peptides described herein. In those embodiments, the ratio of the
fully-acetylated to the partially-masked amphiphilic peptides can range from about 95:5 to
about 1:1. In certain embodiments, the particle can further comprise sked (e.g., non-
acetylated) amphiphilic peptides.
Accordingly, a mixed peptide particle comprising a fully-acetylated hilic
peptide and a lly—acetylated or non-acetylated amphiphilic peptide is also ed
herein. In specific embodiments, the mixed peptide particle ses a first amphiphilic
e and a second amphiphilic peptide, wherein the first and the second amphiphilic
peptide each independently comprises a hydrophobic yl segment and a hydrophilic
peptidyl segment, wherein the hydrophobic peptidyl segment comprises an amino acid
sequence of (Trp-Leu).11-(Trp)n or (Leu-Trp)p-(Leu)q, wherein each Tip is D-Trp or L-Trp and
each Leu is D-Leu or L-Leu, m and p are ndently an integer from 1 t0 5, and n and q
are independently O or i, provided that when Trp is D-Trp then Leu is L-Leu, and when Trp
is L-Trp then Leu is D-Leu, or vice versa; while the hydrophilic peptidyl segment ses
an amino acid sequence of (Ly/5),, wherein r is an integer from I to 15. Additionally, the N-
terminus amino group and all of the Lys residues of the first hilic e are
acetylated; while at least the N~terminus amino group or one of the Lys residues of the
second amphiphilic peptide is not acetylated. In some embodiments, none of the N-terminus
amino group and the Lys es of the second amphiphilic peptide is acetylated.
In some embodiments, the mixed peptide particle can comprise a plurality (e.g., at
least 2, at least 3, at least 4 at least 5, or more) of the first amphiphilic peptides and a
plurality (e.g., at least 2, at least 3, at least 4 at least 5, or more) of the second hilic
peptides.
In particular embodiments, the first amphiphilic peptide(s) and the second
amphiphilic peptide(s) can be selected from any one or more embodiments of an amphiphilic
peptide described earlier in the “Exemplary amphiphilic peptides” section. In some
embodiments, the first and second amphiphilic peptide can each ndently comprise an
amino acid sequence of (L-Lys)-(L-Lys)-(L-Lys)-(L-Trp)—(D-Leu)-(L-Trp)-(D-Leu)-(L-Trp)-
(D-Leu)-(L-Trp)-X, wherein X is absent or NHg.
The ratio of the first amphiphilic peptide to the second amphiphilic e can be
varied based on a number of factors, e.g., but not limited to, desirable solubility and/0r
stability of the peptide particle, and/or properties of the active agent to be loaded therein. In
some embodiments, the ratio of the first amphiphilic peptide to the second amphiphilic
PCT/U52012/052027
peptide can be in a range of about 1:1000 to about 100021. In some embodiments, the ratio of
the first amphiphilic peptide to the second amphiphilic peptide can be in a range of about 1:1
to about 1000:1. In some embodiments, the ratio of the first amphiphilic peptide to the second
amphiphilic peptide can be in a range of about 2:1 to about 500:1. In some embodiments, the
ratio of the first amphiphilic e to the second amphiphilic e can be in a range of
about 3:1 to about 200:1. In other embodiments, the ratio of the first amphiphilic peptide to
the second amphiphilic peptide can be in a range of about 5:1 to about 100: 1.
] In some embodiments, the mixed peptide particle can further comprise an active
agent described herein. The active agent can be present in the mixed peptide particle in any
amounts, e.g., depending on the loading capacity of the peptide particle and/or binding
capacity of the first or second amphiphilic peptide. In some embodiments, the ratio of the
active agent to the second hilic es can be in a range of about 1:1000 to 1:1. In
some embodiments, the ratio of the active agent to the second amphiphilic peptides can be or
about 1:100 to about 1:10. In some ments, the ratio of the active agent to the second
amphiphilic peptide can be in a range of about 1:50 to about 1:5. In some embodiments, the
ratio of the active agent to the second amphiphilic peptide can be in a range of about 1:10 to
about 1:2.
In some embodiments, the mixed peptide particle can further comprise on its outer
surface a ligand described . As described earlier, selection of a ligand can be
determined based on a target molecule (e.g., but not limited to, cells, ia, proteins,
nucleic acids) to which the mixed peptide particle binds. Non—limiting examples of a ligand
can include a cell surface receptor ligand or a protein such as an antibody. In some
embodiments, the ligand can be covalently linked to at least one of the first and the second
amphiphilic peptide, e.g., the hydrophilic peptidyl segment of at least one of the first and the
second amphiphilic peptide.
The mixed peptide particle described herein can be used to encapsulate any active
agent described . Without wishing to be bound by theory, the presence of the second
amphiphilic peptide in the mixed peptide particle can provide a ic charge for binding
with anionic nucleic acid molecules. Thus, in some embodiments, the active agent can
include a nucleic acid molecule.
A further aspect ed herein is directed to use of one or more ments of
the mixed peptide particle comprising a first hilic peptide and a second amphiphilic
peptide described herein for delivery of a nucleic acid molecule to a cell. Accordingly, in
some ments, the mixed peptide particle for use in ry of a nucleic acid molecule
PCT/U52012/052027
to a cell comprises a first amphiphilic peptide, a second hilic peptide, and a c
acid molecule. In some embodiments, the mixed peptide particle can comprise a plurality
(e.g., at least 2 or more) of nucleic acid molecules or oligonucleotides (e.g., DNA or RNA
including, but not limited to, siRNA, shRNA, miRNA, or any combinations thereof). In some
embodiments, the nucleic acid molecules or ucleotides can be designed for use in
therapeutic intervention, e.g., gene therapy or siRNA therapy.
Peptide ggarrr'cle assemblv
The peptide particles described herein can be assembled by a one-step procedure.
For example, peptide particles can be conveniently assembled from dissolved hilic
peptide by addition of water: an emulsion spontaneously formed as a ternary mixture
(peptide, organic solvent, H30) is brought into the two-phase region (peptide, H20). While
the emulsification process resembles the ouzo effect, amphiphilic peptide droplets harden to
solid particles as the organic t is removed. Neutral as well as charged molecules
efficiently migrate into the dispersed phase and get trapped dun’ng particle formation.
Generally, peptide particles comprising an active agent and a ligand can be
assembled in about 15 minutes using the procedure outlined herein. Additionally, the system
allows for straightforward adjustment of le size and entraps active agents at very high
Without g to be bound by a theory, the simplicity of system and formation
protocol originates in the concerted ction of all ed components of a peptide
particle: amphiphilic es are not only matrix material, but supersedes encapsulation
routines due to their high affinity for other components such as a ligand and/or an active
agent. The process of active agent encapsulation most likely resembles a two-phase liquid
extraction where the active agent escapes the aqueous phase and accumulates in peptide
ts. onally, the peptide’s solubility in mild organic solvents allows for concurrent
dissolution and ssembly of all involved components. The presence of a ligand during
emulsification of the peptides can result in the formation of a ligand corona. Additionally,
the presence of the ligand can allow for straightforward adjustment of particle size due to its
surface activity and thus early stabilization of the peptide emulsion.
Pharmaceutical Coonsilions
For administration to a subject, peptide particles and active agent — amphiphilic
peptide complexes described herein can be provided in pharmaceutically acceptable
WO 28843 PCT/U52012/052027
compositions. These pharmaceutically able compositions comprise a particle or an
active agent ._ amphiphilic e complex formulated together with one or more
pharmaceutically acceptable carriers (additives) and/or diluents. As described in detail
below, the pharmaceutical compositions described herein can be specially formulated for
administration in solid or liquid form, including those adapted for the following: (1) oral
administration, for example, drenches (aqueous or non-aqueous solutions or suspensions),
s, lozenges, dragees, capsules, pills, tablets (e.g., those targeted for buccal, gual,
and systemic absorption), boluses, powders, granules, pastes for ation to the tongue; (2)
parenteral administration, for example, by subcutaneous, intramuscular, intravenous or
epidural injection as, for example, a sterile solution or suspension, or sustained-release
formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release
patch or spray applied to the skin; (4) aginally or intrarectally, for example, as a
pessary, cream or foam; (5) sublingually; (6) ocularly; (7) ermally; (8) transmucosally;
or (9) nasally. Additionally, compounds can be implanted into a patient or injected using a
drug delivery system. See, for example, Urquhart, et al., Ann. Rev. Pharmacol. Toxicol. 24:
199-236 (1984); Lewis, ed. olled Release of Pesticides and Pharmaceuticals” (Plenum
Press, New York, 1981); US. Pat. No. 3,773,919; and US. Pat. No. 35 960, content of
all of which is herein incorporated by reference.
] As used here, the term “pharmaceutically acceptable” refers to those nds,
materials, compositions, and/or dosage forms which are, within the scope of sound medical
judgment, suitable for use in contact with the s of human beings and animals without
excessive toxicity, irritation, allergic response, or other problem or complication,
commensurate with a reasonable benefit/risk ratio.
As used here, the term “pharmaceutically-acceptable carrier” means a
pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler,
t, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc
te, or steric acid), or solvent encapsulating material, involved in ng or transporting
the subject compound from one organ, or portion of the body, to another organ, or portion of
the body. Each carrier must be “acceptable” in the sense of being compatible with the other
ingredients of the ation and not injurious to the patient. Some examples of materials
which can serve as pharmaceutical!y-acceptable carriers include: (i) sugars, such as lactose,
glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its
derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl ose,
microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6)
PCT/U52012/052027
gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8)
excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil,
cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such
as propylene glycol; (1 l) polyols, such as in, sorbitol, mannitol and polyethylene
glycol (PEG); (12) , such as ethyl oleate and ethyl laurate; (13) agar; (l4) buffering
agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16)
pyrogen—free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH
ed solutions; (21) polyesters, polycarbonates and/or polyanhydrides; (22) bulking
agents, such as polypeptides and amino acids (23) serum component, such as serum albumin,
HDL and LDL; (22) C2-C1; alchols, such as ethanol; and (23) other non-toxic compatible
substances employed in pharmaceutical formulations. Wetting agents, coloring agents,
release agents, g agents, sweetening agents, flavoring agents, perfuming agents,
preservative and antioxidants can also be present in the formulation. The terms such as
“excipient”, “carrier”, “pharmaceuticall y acceptable carrier” or the like are used
hangeably herein.
] As used , the term “administer" refers to the placement of a composition
into a subject by a method or route which results in at least partial localization of the
composition at a desired site such that desired effect is produced. Routes of stration
e both local and systemic administration. Generally, local administration results in
more of the therapeutic agent being delivered to a ic location as compared to the entire
body of the subject, whereas, systemic administration results in delivery of the therapeutic
agent to essentially the entire body of the subject.
stration to a subject can be by any appropriate route known in the art
ing, but not limited to, oral or parenteral , including intravenous, intramuscular,
subcutaneous, transdermal, airway (aerosol), pulmonary, nasal, rectal, and topical (including
buccal and gual) administration.
Exemplary modes of stration include, but are not limited to, injection,
infusion, instillation, inhalation, or ingestion. “Injection” includes, without limitation,
intravenous, intramuscular, intraarterial, intrathecal, intraventn'cular, intracapsular,
intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous,
subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, and
intrastemal injection and infusion. In some ments of the aspects bed herein,
stration is by intravenous infusion or injection.
As used herein, a “subject” means a human or . Usually the animal is a
vertebrate such as a primate, rodent, domestic animal or game animal. Primates include
chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., Rhesus.
Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game
animals e cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat,
canine species, e.g., dog, fox, wolf, avian Species, e.g., chicken, emu, ostrich, and fish, e.g.,
trout, catfish and salmon. Patient or subject includes any subset of the foregoing, e.g., all of
the above, but excluding one or more groups or species such as , primates or rodents.
In certain embodiments of the aspects bed herein, the subject is a mammal, e.g., a
e, e.g., a human. The terms, “patient” and “subject” are used interchangeably herein.
The terms, “patient” and “subject” are used interchangeably . A subject can be male
or .
Preferably, the subject is a . The mammal can be a human, non-human
primate, mouse, rat, dog, cat, horse, or cow, but are not limited to these examples. Mammals
other than humans can be advantageously used as subjects that represent animal models of
ers associated with autoimmune disease or mation. In addition, the methods and
compositions described herein can be used to treat domesticated animals and/or pets.
A further aspect provided herein relates to a kit comprising a peptide particle, a
formulation comprising a peptide le, or components for making a peptide particle or a
formulation sing a peptide particle described herein.
] In some embodiments, compositions or kits for making one or more ments
of a peptide particle or a mixed peptide particle are provided herein. In some embodiments,
the composition or kit can comprise an amphiphilic peptide described herein. The
amphiphilic peptide supplied in the composition or kit can be provided in a container.
Depending on a user’s choice of a e le or mixed particle described herein to be
produced, in some embodiments, the composition or kit can comprise a first amphiphilic
peptide and a second amphiphilic peptide described herein. The amphiphilic peptide can be
provided in powder or lyophilized powder. In some embodiments, the ition or kit can
further comprise at least one reagent, e.g., for reconstitution of the powdered amphiphilic
peptide, for emulsification of a particle assembly mixture, or both. In some embodiments, the
composition or kit can further comprise a ligand described herein, e. g., provided in a separate
container. In some embodiments, the composition or kit can further comprise an active agent
W0 28843 PCT/U52012/052027
to be encapsulated into the peptide particle. The active agent can be ed in a separate
container.
In addition to the above ned components, the kit can e ational
material. The informational material can be descriptive, instructional, ing or other
material that relates to the methods described herein and/or the use of the aggregates for the
methods described . For example, the informational material describes methods for
administering the particle to a subject. The kit can also include a delivery device.
In one embodiment, the informational material can include instructions to
administer the formulation in a suitable manner, e.g., in a suitable dose, dosage form, or
mode of administration (e.g., a dose, dosage form, or mode of administration described
herein). In another embodiment, the informational material can include instructions for
identifying a suitable subject, e.g., a human, e.g., an adult human. The informational material
of the kits is not limited in its form. In many cases, the informational material, e.g.,
instructions, is provided in printed matter, e.g., a printed text, drawing, and/or photograph,
e.g., a label or d sheet. However, the informational material can also be provided in
other formats, such as Braille, computer readable material, video recording, or audio
recording. In r ment, the informational material of the kit is a link or contact
information, e.g., a physical address, email address, hyperlink, website, or one ,
where a user of the kit can obtain substantive information about the ation and/or its use
in the methods described herein. Of course, the informational material can also be provided
in any combination of formats.
In some embodiments the individual components of the formulation can be
provided in one container. Alternatively, it can be desirable to provide the components of the
formulation separately in two or more containers, e.g., one container for an amphiphilic
peptide preparation, and at least another for a carrier compound. The different components
can be combined, e.g., ing to instructions provided with the kit. The components can
be combined according to a method described herein, e. g., to prepare and administer a
pharmaceutical composition.
In addition to the formulation, the composition of the kit can include other
ingredients, such as a solvent or buffer, a izer or a preservative, and/or a second agent
for treating a condition or disorder described herein. Alternatively, the other ingredients can
be included in the kit, but in different compositions or containers than the formulation. In
such embodiments, the kit can include instructions for ng the formulation and the other
ingredients, or for using the oligonucleotide together with the other ingredients.
2012/052027
The formulation can be provided in any form, e.g., liquid, dried or 1y0philized
form. It is preferred that the ation be substantially pure and/or sterile. When the
formulation is provided in a liquid solution, the liquid solution preferably is an aqueous
solution, with a sterile aqueous solution being preferred. When the formulation is ed
as a dried form, titution generally is by the addition of a suitable solvent. The solvent,
e.g., sterile water or buffer, can optionally be provided in the kit.
In some ments, the kit contains separate containers, dividers or
compartments for the formulation and informational al. For example, the formulation
can be contained in a bottle, vial, or syringe, and the informational material can be contained
in a plastic sleeve or packet. In other embodiments, the separate elements of the kit are
ned within a single, undivided container. For example, the ation is contained in
a bottle, vial or syringe that has attached thereto the ational material in the form of a
label.
In some embodiments, the kit includes a plurality, e.g., a pack, of individual
containers, each containing one or more unit dosage forms of the formulation. For e,
the kit es a plurality of syringes, s, foil packets, or blister packs, each containing
a single unit dose of the formulation. The containers of the kits can be air tight and/or
waterproof.
Embodiments of the various aspects described herein can be illustrated by the
following numbered paragraphs.
1. A e particle comprising an amphiphilic peptide, the amphiphilic peptide
comprising a hydrophobic peptidyl segment and a hydrophilic peptidyl segment,
n the hydrophobic peptidyl segment comprises an amino acid sequence
of ('I‘rp-Leu)m-(T1p)n or (Leu-Trp)p-(Leu)q, wherein each Trp is D-Trp or L-Trp and
each Leu is D-Leu or L-Leu, m and p are independently an integer from 1 to 5, and n
and q are independently 0 or 1, provided that when Trp is D-Trp then Leu is L-Leu,
and when Trp is L-Trp then Leu is D-Leu, or vice versa; and
wherein the hydrophilic yl segment comprises an amino acid sequence
of (Lys),, wherein r is an integer from 1 to 15, and
wherein the peptide particle further comprises on its outer surface a ligand.
2. The peptide particle of paragraph 1, wherein r is an integer from 2 to 5.
3. The peptide particle of paragraph 1 or 2, wherein r is an integer of 3.
2012/052027
The peptide particle of any of paragraphs 1-3, wherein at least one Lys residue of the
hilic peptidyl segment or the N-terminus amino group of the amphiphilic
peptide is acetylated.
The peptide particle of any of paragraphs 1-4, wherein all of the Lys residues of the
hydrophilic peptidyl segment are ated.
The peptide particle of any of aphs 1-5, wherein the N -terminus amino group of
the amphiphilic e is acetylated.
The peptide particle of any of paragraphs 1-6, wherein the hydrophobic peptidyl
segment is linked to the C-terminus of the hydrOphilic peptidyl segment.
The peptide particle of any of paragraphs 1-7, wherein Leu is D—Leu.
The peptide le of any of paragraphs 1-8, wherein Tip is L—Trp.
. The peptide particle of any of paragraphs 1-9, wherein Lys is L-Lys.
ll. The peptide particle of any of paragraphs 1—10, wherein m or p is between 1 and 3.
12. The peptide le of any of paragraphs l-l 1, wherein m or p is 3.
l3. The peptide particle of any of paragraphs 1- 12, wherein n or q is l.
14. The peptide particle of any of paragraphs 1- 13, wherein the amphiphilic peptide
comprises the amino acid sequence of (L-Lys)-(L-Lys)—(LuLys)-(L-Trp)-(D-Leu)-(L—
Trp)-(D-Leu)-(L—Trp)—(D-Leu)-(L-Tr'p)-X, wherein X is absent or NH;
. The e particle of paragraph 14, wherein at least one of the L-Lys residues is
ated.
16. The e particle of paragraph 14 or 15, wherein the N-terminus amino group of
the amphiphilic peptide is acetylated.
17. The peptide particle of any of paragraphs 1-16, wherein the amphiphilic peptide has a
length of about 5 to about 25 amino acid residues.
18. The peptide particle of any of paragraphs 1-17, wherein at least one backbone amide
linkage of the amphiphilic peptide is an amide replacement linkage.
19. The peptide le of any of paragraphs [-18, n the amphiphilic peptide
comprises a B-amino acid, a y—amino acid, or a ation thereof.
. The peptide particle of any of paragraphs 1-19, wherein at least one of the
hydrophobic peptidyl segment or the hydrophilic peptidyl segment comprises at least
one point mutation.
21. The peptide particle of any of paragraphs 1-20, wherein the ligand es a cell
surface receptor ligand or an antibody.
PCT/U52012l052027
22. The peptide particle of paragraph 21, wherein the cell surface receptor ligand includes
transferrin, EGF, folate, or any combinations f.
23. The peptide particle of any of paragraphs 1-22, wherein the thickness of the ligand
present on the outer surface of the peptide particle ranges from about 1 nm to about
100 nm.
24. The peptide le of any of paragraphs 23, wherein the thickness of the ligand
present on the outer surface of the peptide particle is about 10 nm.
. The peptide particle of any of paragraphs 1-24, wherein the ligand is covalently linked
to the amphiphilic peptide.
26. The peptide particle of any of paragraphs 1—25, n the ligand is covalently linked
to the hydrophilic peptidyl segment of the amphiphilic peptide.
27. The e particle of any of paragraphs 1-26, wherein a ratio of the ligand to the
amphiphilic peptide ranges from about 1:10 to about 1:1,000,000.
28. The e particle of any of paragraphs 1-27, wherein the particle has a size of
about 5 nm to about 5,000 nm.
29. The peptide particle of paragraph 28, wherein the particle has a size of about 30 nm to
about 150 nm.
. The e le of any of paragraphs 1-29, wherein the peptide particle comprises
a mixture of a fully-acetylated amphiphilic peptide of any of paragraphs 1-29, and a
partially-acetylated amphiphilic peptide of any of paragraphs 1-29.
31. The e particle of paragraph 30, wherein the ratio of the fully-acetylated to the
partially-acetylated amphiphilic peptide ranges from about 95:5 to about 1:1.
32. The peptide particle of any of paragraphs 30—31, wherein the peptide particle further
comprises a non-acetylated amphiphilic peptide.
33. The peptide particle of any of paragraphs 1-32, further comprising an active agent.
34. The peptide particle of paragraph 33, wherein the active agent is dispersed within the
particle.
. The peptide particle of any of paragraphs 33-34, wherein the active agent has no net
charge.
36. The peptide particle of any of paragraphs 33-34, wherein the active agent has a net
charge.
37. The e le of any of paragraphs 33-36, wherein the active agent is ed
from the group consisting of proteins, peptides, antigens, antibodies or portions
thereof, antibody-like molecules, enzymes, nucleic acids, aptamers, small molecules,
PCT/U52012/052027
antibiotics, ceutically active agents, therapeutic agents, contrast agents, and
any combinations f.
38. The peptide particle of any of paragraphs 33-37, wherein the active agent is a
pharmaceutically active agent or a therapeutic agent.
39. The peptide particle of any of paragraphs 33—38, wherein the active agent is a nucleic
acid molecule.
40. The peptide particle of paragraph 39, wherein the nucleic acid molecule includes
siRNA, miRNA, shRNA, or any combinations thereof.
41. The peptide particle of paragraph 39, n the c acid molecule is DNA.
42. The peptide particle of any of paragraphs 33—41, n a ratio of the active agent to
the hilic e ranges from about 1:1 to about 00.
The peptide particle of paragraph 42, wherein the ratio of the active agent to the
amphiphilic peptide ranges from about 1:1 to about 1:100, or from about 1:1 to about
1:10.
44. Use of the peptide particle of any of paragraphs 33-43 for targeted delivery of an
active agent.
45. The use of paragraph 44, wherein the active agent is cell-impermeable when it is
delivered to a cell by itself.
46. Use of a composition comprising a positively-charged amphiphilic peptide as a cell-
penetrating agent or transfection agent, wherein the positive-charged amphiphilic
peptide comprises a hydrophobic peptidyl segment and a hydrophilic peptidyl
segment,
wherein the hydrophobic peptidyl segment comprises an amino acid sequence
of eu)m-(Trp)n or (Leu—Trp)p-(Leu)q, wherein each Trp is D-Trp or L-Tip and
each Leu is D-Leu or L-Leu, m and p are independently an integer from 1 to 5, and n
and q are independently 0 or 1, provided that when Tip is D—Trp then Leu is L-Leu,
and when Tip is L—Trp then Leu is D-Leu, or vice versa;
wherein the hydrophilic peptidyl segment comprises an amino acid sequence
of (Lys),, wherein r is an integer from 1 to 15; and
wherein at least one of the Lys residues or the N-terminus amino group of the
hilic peptide is not acetylated.
PCT/U82012/052027
47. The use of paragraph 46, wherein all of the Lys residues and the N—terminus amino
group of the amphiphilic peptide are not acetylated.
48. The use of paragraph 46 or 47, wherein r is an integer from 2 to 5.
49. The use of any of paragraphs 46-48, wherein r is an integer of 3.
50. The use of any of paragraphs 46-49, wherein the hobic peptidyl segment is
linked to the C-terminus of the hydrophilic yl segment.
51. The use of any of paragraphs 46-50, wherein Leu is D-Leu.
52. The use of any of paragraphs 46-51, wherein Tip is L—Trp.
53. The use of any of paragraphs 46-52, wherein Lys is L-Lys.
54. The use of any of paragraphs 46-53, wherein m or p is between 1 and 3.
55. The use of any of paragraphs 46-54, n m or p is 3.
56. The use of any of paragraphs 46-55, wherein n or q is l.
57. The use of any of paragraphs 4656, wherein the amphiphilic peptide has a length of
about 5 to about 25 amino acid residues.
58. The use of any of paragraphs 46-57, wherein at least one backbone amide linkage of
the amphiphilic peptide is an amide replacement linkage.
59. The use of any of paragraphs 46-58, wherein the amphiphilic peptide comprises a [5-
amino acid, a y—amino acid, or a combination thereof.
60. The use of any of paragraphs 46-59, wherein at least one of the hydrophobic peptidyl
segment or the hydrophilic peptidyl segment comprises at least one point on.
61. The use of any of paragraphs 4660, wherein the particle has a size of about 5 nm to
about 5,000nm.
62. The use of paragraph 61, wherein the particle has a size of about 30 nm to about
150 nm.
63. The use of any of paragraphs 46-62, wherein the hilic e comprises the
amino acid sequence of (L-Lys)-(L-Lys)-(L-Lys)-(L—Tip)—(D-Leu)-(L-Tip)-(D-Leu)—
(L—Tip)—(D-Leu)-(L-T1p)—X, n X is absent or NH;
64. The use of any of paragraphs 46-63, wherein the composition further comprises a
nucleic acid le to be delivered into a cell.
65. A peptide particle comprising a first amphiphilic peptide and a second amphiphilic
peptide, the first and the second hilic e each independently comprising a
hydrophobic peptidyl segment and a hydrophilic peptidyl segment,
PCT/U52012/052027
n the hydrophobic peptidyl segment comprises an amino acid sequence
of (Trp-I..eu).11-(Tip)n or (Leu-Tip)p-(Leu)q, wherein each Tip is D-Trp or L—Trp and
each Len is D-Leu or L—Leu, m and p are independently an integer from 1 to 5, and n
and q are independently O or 1, provided that when Tip is D-Trp then Leu is L-Leu,
and when Trp is L-Trp then Leu is D—Leu, or vice versa; and
wherein the hydrophilic peptidyl segment ses an amino acid sequence
of(Lys),, wherein r is an r from 1 to 15, and
wherein the N—terminus amino group and all of the Lys residues of the first
amphiphilic peptide are acetylated; and
wherein at least the N-terminus amino group or one of the Lys es of the
second amphiphilic peptide is not acetylated.
66. The peptide particle of aph 65, wherein none of the N-terminus amino group
and the Lys residues of the second amphiphilic peptide is acetylated.
67. The peptide le of paragraph 65 or 66, further comprising an active agent.
68. The peptide particle of paragraph 67, wherein the active agent includes a nucleic acid
molecule.
69. The peptide particle of any of paragraphs 65-68, wherein the ratio of the active agent
to the second amphiphilic peptide is in a range of about 1:1000 to 1:1, or about 1:100
to about 1:10.
70. The e paiticle of paragraph 69, wherein the ratio of the active agent to the
second amphiphilic peptide is in a range of about 1:10 to about 1:2.
71. The peptide paiticle of any of paragraphs 65-70, wherein the ratio of the first
amphiphilic peptide to the second amphiphilic e is in a range of about 1:1 to
about 1000:1, or about 5:1 to about 100:1.
72. The peptide particle of any of paragraphs 65—71, further comprising on its outer
surface a ligand.
73. The peptide particle of paragraph 72, n the ligand includes a cell surface
receptor ligand or an dy.
74. The peptide particle of paragraph 73, wherein the cell surface receptor ligand includes
transferrin, EGF, folate, or any combinations f.
75. The peptide particle of any of paragraphs 65-74, wherein the thickness of the ligand
present on the outer surface of the peptide paiticle ranges from about 1 nm to about
100nm.
76. The peptide particle of any of paragraphs 75, wherein the thickness of the ligand
present on the outer surface of the peptide le is about 10 nm.
77. The peptide particle of any of paragraphs 65-76, wherein the ligand is covalently
linked to at least one of the first and the second amphiphilic peptide.
78. The peptide particle of any of paragraphs 65-77, wherein the ligand is covalently
linked to the hydrophilic peptidyl segment of at least one of the first and the second
amphiphilic peptide.
79. The peptide particle of any of paragraphs 65-78, wherein a ratio of the ligand to the
amphiphilic peptide ranges from about 1:10 to about l:1,000,000.
80. The peptide particle of any of aphs 65-79, wherein r is an integer from 2 to 5.
81. The peptide particle of any of paragraphs 65-80, wherein r is an integer of 3.
82. The e particle of any of paragraphs 65-81, wherein the hydrophobic yl
segment is linked to the C-terminus of the hydrophilic peptidyl segment.
83. The peptide particle of any of paragraphs 65-82, wherein Leu is D-Leu.
84. The peptide particle of any of paragraphs 65-83, wherein Tip is L-Trp.
85. The peptide particle of any of paragraphs 65-84, wherein Lys is L—Lys.
86. The peptide particle of any of paragraphs 65-85, wherein m or p is between 1 and 3.
87. The peptide particle of any of paragraphs 65-86, wherein m or p is 3.
88. The peptide le of any of paragraphs 65-87, wherein n or q is l.
89. The peptide le of any of paragraphs 65-88, wherein the first and the second
amphiphilic e each independently has a length of about 5 to about 25 amino
acid residues.
90. The peptide particle of any of paragraphs 65~89, wherein at least one backbone amide
linkage of the first or the second amphiphilic peptide is an amide replacement linkage.
91. The peptide particle of any of paragraphs 65-90, wherein at least one of the first and
the second amphiphilic peptide comprises a B-amino acid, a o acid, or a
combination thereof.
92. The peptide particle of any of paragraphs 65-9] at least one of the
, wherein
hydrophobic yl segment or the hydrophilic yl segment ses at least
one point mutation.
93. The peptide particle of any of paragraphs 65-92, wherein the peptide particle has a
size of about 5 nm to about 5,000nm.
W0 20131028843
94. The peptide particle of paragraph 93, wherein the peptide particle has a size of about
nm to about 150 nm.
95. The peptide particle of any of paragraphs 65-94, n the first and second
amphiphilic peptide each independently comprises the amino acid sequence of (L-
Lys)-(L-Lys)-(L-Lys)-(L-Trp)-(D-Leu)-(L-Trp)-(D-Leu)-(L—Trp)—(D—Leu)-(L-Trp)—X,
wherein X is absent or NH:
96. Use of the e particle of any of paragraphs 65-95 for delivery of a nucleic acid
molecule to a cell.
97. The use of paragraph 96, wherein the nucleic acid molecule es siRNA, miRNA,
shRNA, or any combinations f.
98. The use of paragraph 96, wherein the nucleic acid molecule includes DNA.
99. An hilic peptide comprising a hydrophobic peptidyl segment and a hydrophilic
peptidyl segment,
wherein the hydrophobic peptidyl t comprises an sequence of 2 to 10
alternating D— and L-amino acids selected from alanine, valine, isoleucine, leucine
(Len), phenylalanine, ne or tryptophan (Trp), and
wherein the hydrophilic peptidyl segment comprises charged, or uncharged
but polar amino acids, or derivatives thereof.
100. The amphiphilic peptide of paragraph 99, wherein the hydrophobic yl segment
comprises an amino acid sequence of (Trp-Leu)m-(Trp)n or (Leu-Tr'p)p—(Leu)q,
wherein each Trp is D-Trp or L-Trp and each Leu is D~Leu or L—Leu, m and p are
independently an integer from 1 to 20, and n and q are independently 0 or 1, provided
that when Trp is D-Trp then Leu is L—Leu, and when Trp is L—Trp then Leu is D-Leu,
or vice versa.
101. The amphiphilic peptide of paragraph 99 or 100, wherein the hydrophilic peptidyl
segment comprises at least one charge present either on the N-terminus or an amino
acid residue.
102. The amphiphilic peptide of paragraph 101, wherein the at least one charge is either a
cationic or an c charge.
103. The amphiphilic peptide of paragraph 99 or 100, wherein the hydrophilic peptidyl
segment comprises uncharged but polar amino acids.
104. The amphiphilic e of any of paragraphs 99 to 103, wherein the hydrophilic
yl segment comprises at least one charge and at least one uncharged but polar
amino acid.
W0 20131028843 PCT/USZOIZ/052027
105. The amphiphilic peptide of any of paragraphs 99 to 104, wherein to the hydrOphobic
peptidyl segment a polymer is linked ntly.
106. The amphiphilic peptide of any of paragraphs 99-105, wherein at least one amino
group in the amphiphilic peptide is acetylated.
107. The hilic peptide of paragraph 102, n the at least one cationic charge is
in an amino acid residue ed from the group consisting of Lys, Arg, His, and any
combinations thereof.
108. The amphiphilic peptide of paragraph 102, wherein the at least one anioic charge is in
an amino acid residue selected from the group consisting of Asp or Glu, and any
combinations thereof.
109. The hilic e of paragraph 103, wherein the at least one uncharged but
polar amino acid residue is selected from the group consisting of Set, Thr, Asn or Gln,
and any ations thereof.
110. The amphiphilic peptide of paragraph 105, wherein the polymer is ed from the
group consisting of PEG, PGG, PEO, polycaprolactone, polylactic acid, polyglycolic
acid, polyhydroxyalkaboates, dextrans, polyanhydrides, A, polyorthoester,
polyfumarate, hydrogels, any art—recognized biocompatible and/or biodegradable
polymers, and any combinations thereof.
111. The amphiphilic peptide of any of paragraphs 99 to l 10, wherein the hydrophilic
peptidyl segment comprises an amino acid sequence of (Lys)r, wherein r is an integer
from 1 to 15.
112. The amphiphilic peptide of paragraph 111, where r is 3.
113. The hilic peptide of any of paragraphs 99-112, wherein the at least one amino
group is a N—teiminus amino group of the amphiphilic peptide.
114. The amphiphilic peptide of any of paragraphs 99-113, wherein the at least one amino
group is on a Lys residue of the hydrophilic peptidyl segment.
115. The amphiphilic e of any of paragraphs 99-114, wherein all of the amino groups
in the hydrophilic peptidyl segment are acetylated.
116. The hilic peptide of any of paragraphs 99-115, wherein the N-terminus amino
group of the amphiphilic peptide and at least one of the amino groups in the
hydrophilic peptidyl segment are acetylated.
117. The amphiphilic peptide of any of paragraphs 99-116, wherein the N—terminus amino
group of the amphiphilic peptide and all of the amino groups in the hydrophilic
peptidyl segment are acetylated.
PCT/U82012/052027
118. The amphiphilic peptide of any of paragraphs 99-117 wherein the hydrophobic
peptidyl segment is linked to the C-terminus of the hydrophilic peptidyl segment.
119. The amphiphilic peptide of any of paragraphs 99-1 18, wherein Leu is D-Leu.
120. The amphiphilic e of any of paragraphs 99419, wherein Tip is L-Trp.
121. The hilic peptide of any of paragraphs 99-120, n Lys is L—Lys.
122. The amphiphilic peptide of any of paragraphs 99-121, wherein m or p is between 1
and 3.
123. The amphiphilic peptide of paragraph 122, wherein m or p is 3.
124. The amphiphilic e of any of paragraphs 99-123, wherein n or q is 1.
125. The amphiphilic peptide of any of paragraphs 99- l 24, wherein the amphiphilic
peptide ses the amino acid sequence of (L-Lys)-(L-Lys)—(L—Lys)-(L-Trp)-(D-
Leu)-(L-Tip)-(D-Leu)- (L-Trp)—(D-Leu)-(L-T1p), wherein at least one of the L-Lys
residues is acetylated.
126. The amphiphilic peptide of any of paragraphs 99-125, wherein the amphiphilic
peptide ses the amino acid sequence of Ac-(L-Lys)-(L-Lys)—(L—Lys)—(L~Trp)-
)- (L-Tip)-(D-Leu)- (L—Trp)-(D-Leu)- (L-Trp).
127. The amphiphilic peptide of paragraph 126, wherein at least one of the L-Lys residues
is acetylated.
128. The amphiphilic e of any of paragraphs 99—127, wherein the hilic
peptide comprises the amino acid sequence of Ac-(L-Lys(Ac))-(L-Lys(Ac))—(L-
Lys(Ac))—(L-Trp)-(D-Leu)- (L-Trp)-(D-Leu)- (L-Tip)-(D-Leu)- (L—Trp)~X, wherein X
is absent or NH:.
129. The amphiphilic peptide of any of paragraphs 99-128, wherein the amphiphilic
peptide has a length of about 5 to about 25 amino acid residues.
130. The amphiphilic peptide of any of paragraphs 99-129, wherein at least one backbone
amide linkage is an amide replacement linkage.
131. The amphiphilic peptide of any of paragraphs 99-130, wherein the amphiphilic
peptide ses at least one B-amino acid, y—amino acid, or any combinations
thereof.
132. The amphiphilic peptide of any of paragraphs , wherein at least one of the
hobic peptidyl segment or the hydrophilic peptidyl segment ses at least
one point mutation.
133. A paiticle comprising one or more amphiphilic peptides of any of paragraphs 99-132.
PCT/U52012/052027
134. The particle of aph 133, further comprising a ligand.
135. The particle of paragraph 133 or 134, wherein the ligand is a cell surface receptor
ligand or an antibody.
136. The particle of aph 135, wherein the cell surface receptor ligand is transferrin,
or EGF or .
137. The particles of any of paragraphs 133-136, wherein the ligand is present on an outer
surface of the particle.
138. The particle of any of paragraphs 133—137, wherein the ligand is adsorbed on the
outer surface of the particle.
139. The particle of paragraph 137 or 138, wherein a thickness of the ligand t on the
outer e of the le ranges from about 1 nm to about 100 nm.
140. The particle of paragraph 139, wherein the thickness of the ligand present on the outer
surface of the particle is about 10 nm.
141. The particle of any of paragraphs 133-140, wherein the ligand is covalently linked to
the amphiphilic e.
142. The particle of any of paragraphs 133441, wherein the ligand is covalently linked to
the hydrophilic peptidyl segment of the amphiphilic peptide.
143. The particle of any of paragraphs 133- 142, further comprising an active agent.
144. The le of paragraph 143, wherein the active agent is dispersed within the
particle.
145. The particle of any of paragraphs 143-144, wherein the active agent has no net charge.
146. The particle of any of paragraphs 143—144, wherein the active agent has a net charge.
147. The particle of any of paragraphs 143-146, wherein the active agent comprises at least
one aromatic group.
148. The particle of any of paragraphs 143-147, wherein the active agent is selected from
the group consisting of proteins, peptides, antigens, antibodies or portions thereof,
dy—like molecules, enzymes, nucleic acids, aptamers, small molecules,
antibiotics, pharmaceutically active agents, therapeutic agents, contrast agents, and
any combinations f.
149. The particle of any of paragraphs 143-148, wherein the active agent is a
pharmaceutically active agent.
150. The particle of any of paragraphs 9, n the active agent is a nucleic acid
molecule.
PCT/U82012/052027
151. The particle of paragraph 150, wherein the c acid le is siRNA miRNA or
shRNA.
152. The particle of aph 150, wherein the nucleic acid molecule is DNA.
153. The particle of any of paragraphs 143- 152, wherein a ratio of the active agent to the
amphiphilic peptides ranges from 1:1 to l:100,000.
154. The particle of paragraph 153, wherein the ratio of the active agent to the amphiphilic
peptides ranges from 1:1 to about 1:1,000.
155. The particle of any of paragraphs 134-154, wherein a ratio of the ligand to the
amphiphilic peptides ranges from about 1: 10 to about l:1,000,000.
156. The particle of any of paragraphs 133-155, wherein the particle has a size of about
nm to about 5,000nm.
157. The particle of paragraph 156, wherein the particle has a size of about 30 nm to about
150 nm.
158. The particle of any of paragraphs 133- 157, wherein the particle comprises a mixture
of acetylated and partially-acetylated amphiphilic peptides of any of paragraphs
99-132.
159. The particle of paragraph 158, wherein the ratio of the fully-acetylated to the
partially—acetylated amphiphilic peptides ranges from about 95:5 to about 1: 1.
160. The particle of any of aphs 133-159, wherein the particle further comprises
non-acetylated hilic peptides.
161. A method of using an hilic peptide compound as a delivery .
162. The method of paragraph 161, wherein the delivery system is a targeted delivery
system.
163. The method of paragraph 161 or 162, wherein the delivery system is for therapeutic or
diagnostic purposes.
164. Use of peptide compositions as cell penetration peptide or transfection agent,
respectively.
Some seler’recl definitions
Unless stated otherwise, or implicit from t, the following terms and phrases
e the meanings provided below. Unless explicitly stated otherwise, or apparent from
t, the terms and phrases below do not exclude the meaning that the term or phrase has
acquired in the art to which it pertains. The definitions are provided to aid in describing
particular embodiments of the aspects descn'bed herein, and are not intended to limit the
PCT/U520] 2/052027
claimed invention, because the scope of the invention is limited only by the . Further,
unless otherwise required by t, singular terms shall e pluralities and plural terms
shall include the singular.
As used herein the term “comprising” or “comprises” is used in reference to
compositions, methods, and tive component(s) thereof, that are essential to the
invention, yet open to the inclusion of unspecified ts, whether essential or not.
Additionally, the term “comprising” or “comprises” includes “consisting essentially of" and
“consisting of.”
As used herein the term “consisting essentially of" refers to those elements
required for a given embodiment. The term permits the presence of additional elements that
do not materially affect the basic and novel or functional characteristic(s) of that embodiment
of the invention.
The term “consisting of” refers to compositions, methods, and respective
components thereof as described herein, which are exclusive of any element not recited in
that description of the embodiment.
Other than in the ing examples, or where otherwise indicated, all numbers
expressing quantities of ingredients or reaction conditions used herein should be understood
as modified in all instances by the term “about.” The term “about” when used in connection
with percentages can mean 11%.
The singular terms “a,” “an,” and “the” include plural nts unless context
clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the
context clearly tes otherwise.
Although methods and materials similar or lent to those described herein
can be used in the practice or testing of this disclosure, le methods and als are
described below. The term “comprises” means “includes.” The iation, “cg.” is
derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example.
Thus, the abbreviation “e.g.” is synonymous with the term “for example.”
The term “statistically significant” or “significantly” refers to statistical
significance and generally means a two standard deviation (28D) above or below a reference
level. The term refers to statistical evidence that there is a ence. It is defined as the
probability of making a decision to reject the null hypothesis when the null hypothesis is
actually true. The decision is often made using the p-value.
WO 28843 PCT/U52012/052027
The term “nanosphere” means a particle having an aspect ratio of at most 3:1.
The term “aspect ratio” means the ratio of the longest axis of an object to the shortest axis of
the object, where the axes are not necessarily perpendicular.
The term “longest dimension” of a particle means the longest direct path of the
le. The term “direct path” means the shortest path ned within the particle between
two points on the surface of the le. For example, a helical particle would have a longest
dimension corresponding to the length of the helix if it were stretched out into a straight line.
The term “nanorod” means a particle having a longest dimension of at most 200
nm, and having an aspect ratio of from 3:1 to 20:1.
The term “nanoprism” means a particle having at least two rallel faces
connected by a common edge.
The h” of a particle means the longest dimension of the particle.
The “width” of a particle means the average of the widths of the particle; and the
“diameter” of a le means the average of the diameters of the particle.
The “average” dimension of a plurality of particles means the average of that
dimension for the plurality. For example, the “average diameter” of a plurality of
nanospheres means the average of the diameters of the nanospheres, where a diameter of a
single nanosphere is the average of the diameters of that nanosphere.
As used herein, the term “pharmaceutically-acceptable salts” refers to the
conventional nontoxic salts or quatemary ammonium salts of a compound, e.g., from non-
toxic organic or inorganic acids. These salts can be prepared in situ in the administration
vehicle or the dosage form manufacturing process, or by separately reacting a purified
compound in its free base or acid form with a le organic or inorganic acid or base, and
isolating the salt thus formed during subsequent purification. Conventional nontoxic salts
include those derived from inorganic acids such as sulfuric, ic, phosphoric, nitric, and
the like; and the salts prepared from organic acids such as acetic, propionic, ic,
glycolic, c, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic,
phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric,
toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like. See, for
e, Berge et al., “Pharmaceutical Salts”, J. Pharm. Sri. 66:1-19 (1977), content of
which is herein incorporated by reference in its entirety.
] In some embodiments of the aspects described herein, representative salts include
the romide, hydrochloride, sulfate, bisulfate, phosphate, e, acetate, ate,
valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate,
PCT/U82012/052027
maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and
laurylsulphonate salts and the like.
] As used herein, a ratio can be a mole ratio or weight ratio or molar ratio.
As used herein, a “cell penetration peptide” or “cell penetrating peptide” is
defined as e that has ne permeability and is capable of crossing biological
membrane or a physiological barrier. Cell penetrating peptides (CPPs) are also called cell-
permeable peptides, n transduction domains (PTD) or membrane-translocation
sequences (MTS). CPPs have the ability to translocate in vitro and/or in vivo the mammalian
cell membranes and enter into cells, and directs a conjugated compound of st, such as a
drug or marker, to a desired cellular destination, e.g. into the cytoplasm ol, endoplasmic
reticulum, Golgi apparatus, etc.) or the nucleus. ingly, the CPP can direct or facilitate
penetration of a compound of interest across a phospholipid, mitochondrial, ma] or
nuclear membrane. The CPP can also direct a compound of interest from outside the cell
through the plasma membrane, and into the cytoplasm or to a desired location within the cell,
e.g., the nucleus, the ribosome, the mitochondria, the endoplasmic reticulum, a lysosome, or a
some. Alternatively or in addition, the CPP can direct a compound of interest across
the brain, trans-mucosal, hematoretinal, skin, gastrointestinal and/or pulmonary
barriers.
Penetration across a biological membrane or a physiological barrier can be
determined by various ses, for example by a cell penetration test having a first
incubation step for the CPP conjugated to a marker in the presence of culture cells, followed
by a fixating step, and then revelation of the presence of the marked peptide inside the cell. In
another embodiment, the revelation step can be done with an incubation of the CPP in the
presence of d antibodies and directed against the CPP, followed by detection in the
cytoplasm or in immediate proximity of the cell nucleus, or even within it, of the
immunologic reaction between the CPP's amino acid ce and the labeled antibodies.
Revelation can also be done by marking an amino acid ce in the CPP and detecting the
presence of the marking in the cell compartments. Cell penetration tests are well known to
those skilled in the art. However, for example a cell ation test was described in the
above-mentioned patent application No WO 97/02840.
As used herein, the term "transfection agent" or "transfection reagent" refers to a
compound that bind(s) to or complex(es) with a compound and enhances their entry into
cells. Generally, the term transfection agent is used for compounds that enhance the delivery
of nucleic acids into a cell.
W0 20131028843 PCT/U52012/052027
To the extent not already indicated, it will be understood by those of ordinary skill
in the art that any one of the various embodiments herein bed and illustrated may be
further modified to incorporate features shown in any of the other embodiments disclosed
herein.
The following examples illustrate some embodiments and aspects of the
invention. It will be apparent to those skilled in the relevant art that various modifications,
additions, substitutions, and the like can be performed without altering the spirit or scope of
the invention, and such modifications and variations are encompassed within the scope of the
invention as d in the claims which follow. The following examples do not in any way
limit the invention.
EXAMPLES
ary Materials and Methods (for Examples 1-2)
Exemplary Materials: All chemicals and reagents including rose bengal (RB)
(Aldrich 330000, 95%) and S-carboxy-fluorescein (CF) (Sigma Aldrich C0537, 99%) were
obtained from Sigma—Aldrich and used without further purification unless ise noted
below. Fmoc-protected amino acids and coupling reagents were purchased from IRIS Biotech
and Novabiochem. 24—well crystallization plates were purchased from Hampton Research
(Cryschem Plate).
Peptide Synthesis: All es were synthesized on solid phase using Fmoc
protection group chemistry dual steps of the synthesis are listed in Table l. Rink
Amide AM resin (200 mg, loading: 0.4 mmol/g no.8 mmol/g) was used as solid phase in a
mL syringe. All reactions were carried out in dimethylformamide (DMF) usly
treated with um oxide to reduce the abundance of free amines. Fmoc—amino acids were
dissolved in DMF (0.5M) prior to synthesis. Fmoc protection groups were cleft twice for each
ng step using piperidine in DMF (40%). lH-benzotriazolium 1-
{bis(dimethyiamino)methylene]—5chloro-,hexafluorophosphate (1-),3-oxide (HCTU) was
used as a coupling agent and N,N-diisopropylethylamine (DIPEA) dissolved in l-methy1-2—
pyr‘rolidinone (NMP) as a base. All couplings were executed with 4 equivalents (eq) amino
acid, HCTU (4 eq) and DIPEA(12 eq) relative to the resin loading capacity. After each
ng step, the unreacted terminal amino group was capped by acetylation with a solution
of acetic anhydride (5 eq) and DIPEA in DMF (5 eq).
2012/052027
Table 1: Automated steps of the Batch Fmoc solid phase peptide synthesis
[Step] Solvent/Reagent Repetition Time Description
(min)
i 40 % Piperidine/DMF l 5 Fmoc
deprotection
2 40 % Pipeiidine/DMF 1 10 Fmoc
deprotection
3 DMF 5 1 Wash
4 4 eq Fmoc protected amino acid, 1 60 Coupling (a)
4 eq HCTU, 12 eq DIPEA
DMF 2 1 Wash
6 5 eq acetic anhydride, 5 eq 1 20 End g (h)
DIPEA
7 DMF 3 1 Wash
m) In DMF Alex/NMP; ' ’ In DMF Alox; wherein DMF Alox is DMF previously treated with
aluminum oxide
The same protocol was applied in a scaled up synthesis using Rink Amide AM
resin (5 g) where the reaction was carried out in a 500 m1 solid phase glass reactor using 3 eq
of amino acids and coupling reagents. The pH was kept constant at 9 throughout the reaction
and the resin was probed for free amino groups using a Kaiser- and trinitrobenzene sulfonate—
test (TNBS) after each coupling and cleavage step. There was no need for NMP as a
cosolvent.
Overall yields lly range between 10% and 15% at ~95% purity which is
typical for solid phase peptide synthesis.
After synthesis, the peptide resin was washed with DMF, isopropyl alcohol, DMF,
dichloromethane and diethyl ether before it was dried overnight on a vacuum line. Peptide
cleavage from the resin and l of protection groups was peiformed with cold TFA
(95%), triethylsilane (2.5%) and H30 (2.5%). The ice cooled-cleavage mixture was added to
the resin and incubated for 2h —3 h at room temperature. The filtered cleavage cocktail was
precipitated in and washed with cold diisopropyl ether (40 mL). The white solid was dried
ght on a vacuum line.
e Purification: All peptides were purified on a Shimadzu Prominence
HPLC with ters listed in Table 2. The cmde es were ground and dissolved in a
mixture of DMF and acetonitrile (4 mL, 1:1) and diluted with H30 (0.1% TFA) to a final
PCT/U82012/052027
volume of 20 mL. Gelation of crude product is eliminated under these solvent conditions. The
sample was subsequently filtered through a 0.45 pm PTFE syringe filter and pumped onto a
Merck LiChrospher 100, RP-lSe column (5 pm, 250—10) at a flow rate of 4 mL/min and
eluted with a linear gradient of water (0.1% TFA) to acetonitrile . Sample elution
was followed by absorption at 280 nm and collected according to fixed fraction volumes of 5
mL. The presence of product peptide was qualified by mass ometry (Fig. 1A) and
quantified in analytical HPLC runs (Figure 13). Fractions ning more than 80% product
(A230) were applied to a second ation step on the same chromatography material
carried out with acetic acid (2%) in the aqueous phase. Fractions containing more than 95%
product were combined, neutralized with ammonia and lized.
Table 2: Parameters ofHPLC purification
Feature Preparative Analytical
Solvent A H20 bidist, 0.1% TFA or 2% ACOH H20 bidist, 0.1% TFA
Solvent B MeCN MeCN
Column LiChrospher 100, RP-18e (5pm), LiChrospher 100, RP-18e(51.tm),
250-10 250-4.6
Gradient 5%B -) 95%B, 120 min 20%B ‘3 70%B, 30 min
Injected ing to requirements 25 “L
volume
Flow rate 5 mL/min l.5 mUmin
Detection A330 A330
Fractionation K > 500 mAU '
Fraction size 5 mL -
Post Purification Modification: Acetylation of primary amines on N-terminus and
lysines was med on d peptide dissolved in DMF by ng a 40-fold excess of
acetic ide and DIPEA. Completeness of the reaction was controlled by mass
spectrometry before the reaction mixture was repun'fied according to the procedure described
earlier.
Bead Formation and Co-Assemb/y: CD3ac and rose bengal (RB) were dissolved
in H302EtOH at a ratio of 1:1 and mixed to yield final RB concentrations of 61.5 x 106 M,
184.5 x 10'6 M, 307.5 x 10" M, 615 x 10'6 M and 922.5 x 10‘6 M. The concentration of
CD3ac was kept constant at 615 x 10—6 M. Solvent exchange to H30 was carried out by
PCT/U52012/052027
counter-evaporation in 24—well sitting drop crystallization ; 50 uL xed solution of
CD3ac and RB was d to a sitting d1‘0p well and counter-evaporated four times against 1
mL H20 during 16 h. All experiments were carried out in triplicates. CD3ac spheres
precipitate after ca. 30 min and sediment during the next 5 h.
] In order to quantify the amount of encapsulated RB, the bead pellet was
ended after solvent equilibration and normalized with H20 to a final volume of 100 LIL.
Subsequently, all samples were centrifuged for 30 min at 20 000 g, before 80 mL of
supernatant was separated. The remaining pellet fraction was diluted 1:1 with 20 uL DMSO
to dissolve the peptide assemblies. The concentration of RB in pellet and supernatant
fractions was determined by absorption measurements and corrected for RB in the remaining
uL of the pellet fraction.
Estimating Bead Volume and Parlition Coefficient: In order to estimate the
y of CD3ac precipitates, beads (307.5 x 10'6 M CD3ac starting concentration) were
prepared large enough to exceed the diffraction limit of visible light. A low concentration of
RB (10 x 10'6 M) was co-precipitated to allow an estimate of the bead diameter by confocal
fluorescence microscopy (1.35 pm) and facilitate counting on a hemacytometer (Hausser
Scientific). An average of 72 beads were counted in an observed cell volume of 250,000 um3
that equals a bead volume fraction of 3.71 x 104. A on of 50 LLL 307.5 x 10'6 M CD3ac
thus contains a total bead volume of 18.6 nL and the y of CD3ac can be determined
c 2: 1.35 g/cm3). The logarithmic partition coefficient of RB in an s solution of
CD3ac beads was calculated according to
[RB]CDJac
log PCD3flC/1120 = log( ) (1)
lRBlu,o
Ultraviolet Visible Spectroscopy: Absorption measurements were carried out on a
Nanodrop 1000 (Thermo Scientific). tion coefficients of CD3ac in
H30:EthanolzDMSO 1:12 (21,780 M"- cm", 280 nm) and rose bengal in HgozDMSO 1:1
(11,639 MW cm“, 562 nm) were obtained. DMSO was used to dissolve precipitated CD3ac
after assembly and to reduce solvent evaporation during preparation time as the measured
sample volume amounts for only 4 “L. If necessary, the sample was further diluted with
H202EtOHzDMSO 1:1:2 to yield absorption intensities in the linear range of the instrument.
RB concentrations were determined by weigh-in prior to co—assembly. After cipitation
of CD3ac and RB, pellet and supernatant fractions were diluted 1:1 with DMSO (assembled
CD3ac dissolves in a solution of HzozDMSO 1:1).
PCT/U82012/052027
Circular Dichroism (CD): CD experiments were carried out on an Applied
Photophysics Chirascan in Q8 cuvettes (1 mm path length). Sample concentrations were
adjusted to yield dynode values between 300 V and 500 V in the measured wavelength range.
Blank measurements were d out with water immediately prior to sample measurements.
Each spectrum was ed from three scans in wavelength intervals of 1 nm, each of two
independent sample preparations. All a were smoothed applying the 2nd-order Savitzky
Golay algorithm. CD data are reported in molar units (deg cm2 dmol"), shown as degrees
molar ellipticity.
Scanning Electron copy: Scanning electron microscopy (SEM) was carried
out on a Hitachi 8-4800. SEM sample holders were cooled to - [96°C before a drop of the
bead suspension was directly applied to the cold metal surface. The frozen sample on the
plate was subsequently lyophilized, sputtered with um and analyzed.
] Dynamic Light Scattering: Dynamic light scattering was measured on an
ALV/CGS-SF platform based goniometer system equipped with an ALVI—SOOO/E ator
and an Argon-Ion laser with a wavelength of 633 nm (35 mW) at scattering angles between
° and 150°. An ALV-SOOO/E correlator calculates the photon intensity autocorrelation
on g2(t). All experiments were med at T = 293 K and evaluated by second order
cumulant fit (considering previously determined spherical particle shape by SEM).
spersities were determined by the contin-algorithm at all angles and never exceeded
0.11. Angular dependent measurements were carried out in steps of 10° from 30° to 150°. In
order to avoid influence of multiple scattering, concentration dependent experiments were
performed. For both angular and concentration ence, a hydrodynamic radius was
calculated from the Stokes-formula
k 52‘
VII: (2)
67070
where rh is the hydrodynamic radius of spherical particles, D is the diffusion constant, k3 is
the Boltzmann constant, T is the te temperature and 1] is the viscosity of water. A graph
of 1/1}] versus angle (concentration) was plotted and the hydrodynamic radius (I‘ho) was
calculated by extrapolating both concentration and angle measurements to zero.
Mass Spec/rometry: Mass spectrometry was performed on an LTQ—Orbitrap
(Thermo Scientific). 5 tiL of a CD3ac solution (10 x 10—6 M, H30:MeCN 2:1) was loaded
onto a 100 pm capillary column packed with Magic C18 AQ (3 um particle diameter). The
peptide was eluted in a 30 min nt from H20 (4% formic acid) to MeCN. The orbitrap
was set to positive mode and a resolution of 10,000.
Conjbcal Microscopy: Confocal microscopy images were obtained on a Nikon Ti
motorized inverted microscope equipped with DIC, phase and epi-fluorescence optics, a
Yokagawa CSUAIO spinning disc confocal with 488 nm, 568 nm and 647 nm laser lines. A
Hamamatsu ORCA-AG cooled CCD camera was used for confocal, and a Hamamatsu
ORCA—R2 was used for widefield imaging. CD3ac (615 x 10'6 M) was co-dissolved with (a)
RB (10 x 10‘6 M), (b) CF (10 x 10'6 M) and (C) RB and CF (both 10 x 10‘6 M) in a volume of
50 pL 50% EtOH each and counter-evaporated against water. The resulting suspension was
normalized with H30 to a total volume of 50 “L per sample and subsequently applied to the
confocal microscope.
Example 1: Solid Peptide CD3ac Nanoparticles - Structural terization
Conventional hydrophobic peptides are generally difficult to get synthesized and
purified, and they are also generally difficult to dissolve and tend to precipitate to amorphous
structures in aqueous solution. In accordance with various aspects and embodiments
described herein, a de novo designed peptide CD3ac consisting of ten amino acids:
Ac-(LK(AC))3 —LW-DL-LW-DL-LW-DL-LW-NH2,
where LK(Ac) = ated L-lysine; LW : L-tiyptophan; DL = D-leucine, demonstrates
different propeities from other peptidic materials: CD3ac readily dissolves in most organic
ts (EtOH, iPiOI-l, DMSO, DMF, MeCN) and precipitates to evenly structured bead—
like spheres upon t exchange to water (Fig. 2A).
] The CD3ac peptide (mass 1652.910 g/mol; purity >95%, A280) can be considered
amphiphilic as its sequence is divided into two sections: a hydrophobic block consisting of
altemating L-tryptophane and ine, and a hydrophilic one consisting of three ated
L-lysines. The terms “hydrophilic” and “hydrophobic” as used herein are not absolute but
describe the relative ty within the amino acid sequence, e.g., of CD3ac. Although the
CD3ac peptide is hydrophobic, it can be sized at high yield and purified with rd
procedures on reverse phase C18 chromatography al (see the Materials and Methods
Section bed earlier), as compared to conventional hydrophobic peptides.
CD3ac is able to precipitate to spherical aggregates in the colloidal size range, and
it can do so in a robust and reproducible manner. Solvent exchange was carried out by
dialysis or, in order to reduce material consumption, by counter-evaporation against water in
WO 28843 PCT/U82012/052027
24-well crystallization plates. The size distribution of the resulting peptide bead suspension
was measured by scanning electron microscopy (SEM, Figs. 2A—2C), and concentration- and
angle~dependent dynamic light scattering (DLS, Figs. 3A-3B). Both methods reveal a particle
radius of about 260 nm. The sphere’s radius can be influenced by the concentration of
initially dissolved CD3ac (before t ge) and lies in the size range between about
200 nm and about 1500 nm corresponding to initial CD3ac concentrations between 61.5 x
'6 M to 923 x 10’6 M. The DLS data shown in Figs. 3A-3B refer to CD3ac particles formed
from initially dissolved CD3ac at 123 x 10'6 M. The obtained peptide particles (beads) have
low polydispersity without a need for sizing procedures such as sonication or ion,
which are commonly applied to achieve a narrow size distribution in e.g., lipid suspensions.
Secondary structure can play, in part, a crucial role in the assembly of CD3ac
beads. Without wishing to be bound by , due to light scattering, it can be difficult to
obtain quantifiable circular dichroism data of colloidal suspensions containing particles larger
than 50 nm in diameter. Thus, four structural derivatives of CD3ac (CD1, CDZ, CD3 and
CD4), which are not acetylated, and therefore are charged and water soluble (see Table 3)
were synthesized.
Table 3: Amino acid sequences and molecular weight of exemplary synthesized es and
derivatives thereof
[Name]
H—LK-LK-LK-LW-DL-LW—DL~LW-DL-LW-NH2
H-LK-LK-LK—LK-LW-DL-LW-DL-LW-DL-LW-NHg 1612.965
Ac—LK(Ac)-LK(AC)-LK(Ac)—LW-DL—LW-DL-LW—DL-LW-NHg 10
LCD3 H-LK-LK-LK-LW-LL—LW-LL-LW-LL~LW-NH3 1484.870
LCD3ac Ac-LK(AC)—LK(Ac)-LK(Ac)—LW-LL-LW-LL-LW-LL—LW-NH; 10
] Fig. 4 shows circular dichroism spectra of CD1 to CD4 in water. lly,
charged poly-L—lysine peptides adopt a random coil secondary ure and exhibit negative
ellipticities between 180 nm and 210 nm; presented herein shows that peptides with shorter
oligo-lysine sequences show increasing ellipticities in this wavelength range. Also, a typical
random coil spectrum has little to no influence on ellipticities above 210 nm; thus, the
wavelength range between 210 nm and 260 nm can be assigned almost entirely to the
ce of the alternating sequence of L-Trp and D-Leu. For example, the intensity and
PCT/U52012/052027
position of the peak at 223 nm remains nearly unchanged as the number of attached lysine
residues is varied, indicating that the secondary structure of repeating units of LW—DL is little
or not affected by the length of N—terminally attached oligo-lysine — possibly not even
influenced by the presence of multiple cationic charges on the attached lysine residues.
The circular dichr‘oism a of the CD4‘CD1 series can be theoretically
extrapolated to an imaginary CDO, which would not contain any lysine, to obtain a spectrum
with maxima at about 196 nm and 223 nm. Similar spectra have not been observed in prior
tic hydrophobic peptides, but were reported previously in structural s of
gramicidin A, a 15 amino acid antibiotic peptide derived from the soil living bacterium
Bacillus brevis [16, 17].
The secondary structure motif of gramicidin is a wide helix rarely ed in
nature and versatile in terms of helical pitch, handedness and dimeric configuration
(quaternary structure) [l7c,18], depending on the dielectric constant of its environment [19].
While gramicidin A contains an alternating motif of L-Trp and D-Leu, CD3ac presented
herein is distinct from gramicidin in various s, e.g., e sequence and ,
significant modifications of terminally attached formyl and ethanolamine t in
gramicidin. For example, the gramicidin sequence is hydrophobic throughout its length, but
CD3ac presented herein is amphiphilic due to N—terminal on of at least one L-lysine
(e.g., 1 L—lysine, 2 L-lysines, or 3 L-lysines) and acetylation of at least one amino group of
the amphiphilic peptide.
Without wishing to be bound by theory, a repeated sequence of LW-DL can lead
to a set of phi- and psi-angles distinctly different from the ones observed in isolated alpha-
helices, beta-sheets and random coils, and be most likely governed by steric nce; stable
intramolecular hydrogen bonds can be occasionally observed in atively short peptides
. While such secondary structures and intramolecular hydrogen bonds can exist in
CD3ac, CD3ac is most likely too short to fold back on itself.
The importance of secondary structure in regard of the bead-like assembly was
demonstrated by LCD3ac, a peptide of cal tution (amino acid ce) but
entirely composed of L—amino acids. LCD3ac precipitates to amorphous structure in the size
range of micrometers (Fig. 5A) and the ar dichroism um of charged LCD3 has
dominant or-helical characteristics (Fig. 5B). Combined data of SEM and circular dichroism
indicate that the feature of spherical precipitation depends, at least in part, on the presence of
D-Leu and the specific secondary structure induced by it.
PCT/U82012/052027
Example 2: Solid Peptide CD3ac Nanoparticles - Cargo Encapsulation
CD3ac is the first peptide synthesized by Fmoc chemistry which forms solid
particles in the nano- and micrometer size range and holds promise for dmg ry
applications. gh precipitated CD3ac s, in some embodiments, do not generally
adhere to each other and have no observable affinity to glass or plastic surfaces, they can
encapsulate cargo molecules during their formation. CD3ac were co-dissolved with 10 x
'6 M 5-carboxyfluorescein (CF), 10 x 10'6M 4,5,6,7—tetrachloro-2’,4’,5’,7’—
tetraiodofluorescein (RB) and an equimolar e of both dyes, respectively. The
ment was carried out at pH 5 where RB is charged but CF is largely protonated
ting low solubility in aqueous solution. The solvent volume was re-adjusted to 50 uL
after r-evaporation, so that the fluorescence contrast between background and peptide
beads can at least qualitatively determine cargo accumulation within the spheres.
CF as well as RB is taken up by CD3ac-beads, rather independent of the dye’s
charge state (Figs. 6A-6C). However, CF-loaded beads ate to like assemblies
(Fig. 6B) s RB-loaded spheres do not adhere to each other (Fig. 6A), most likely due
to the display of charged RB on or close to the bead su1face.
Hydrophobic dye such as CF and relatively hydrophilic dye such as RB can be
both encapsulated by CD3ac-beads. Without wishing to be bound by theory, guest molecules
can pie-associate with CD3ac early (in solution) and assemble upon removal of ethanol. The
extent of pie-association, and thus coassembly efficiency, would depend on the affinity of
host and guest compounds; in the case of xanthene-derivatives such as CF and RB, the
interaction of delocalized ring-structures could contribute to their sociation with
CD3ac.
To analyze the molar composition of loaded CD3ac beads, the dye content of RB
loaded CD3ac beads was quantified. RB is readily available and soluble in ethanol as well as
water. While not wishing to be bound by theory, solubility in water is mandatory to avoid
cargo precipitation outside the peptide beads upon solvent exchange. In addition, light
absorption of RB is not strongly quenched in mixtures of water and DMSO, which allows for
convenient and e quantification by optical density.
Briefly, CD3ac and RB were co-dissolved at various tration ratios in 50%
EtOH. 50 uL each were applied to 24-well crystallization plates and counter-evaporated
against four times 1 mL H30 during 16 h. All experiments were carried out in triplicates.
2012/052027
CD3ac spheres usually precipitate after about 30 min, depending on the concentration of RB.
After solvent equilibration, the formed bead pellet was re-suspended and normalized with
H30 to a final volume of 100 1.1L. Samples were centrifuged for 30 min at 20,000 g, before
80 uL of supernatant was separated. uently, the remaining pellet fraction was diluted
1:] with 20 tLL DMSO to dissolve the peptide assemblies. ry to ethanol, the use of
DMSO helps to reduce sample evaporation and yields stable absmption values over at least
min (the sample volume for a UV—Vis experiment is 4 uL, see the Exemplary Materials and
Method section described earlier).
The co-assembly quantification data are summarized in Fig. 7A. The
concentration of CD3ac was kept constant at 615 x 10'6 M in the experiments described
herein. Initially dissolved molar ratio of dye to e is given as [CD3ac]i. For
example, at [RBli/[CD3acL = l as the experimental starting ion, after bead formation,
about one~third of the sphere’s molar composition (nRBp/nCDBacp) is RB (open circles as
shown in Fig. 7A) and y 25% of initially dissolved dye was loaded into CD3ac beads
(nRBp/nRBi, open triangles as shown in Fig. 7A). As shown in Fig. 7B, absorption of pellet
and supernatant fractions at 280 nm ption maximum of tryptophans) indicates that
CD3ac precipitates almost tatively in the presence of a wide tration range of RB
(the molar ratio of RB to CD3ac [RB]i/[CD3ac]i in the experiments described herein spans
1.5 orders of ude). Addition of higher RB concentrations can lead to more dye
molecules co-assembled within CD3ac beads; however, the relation of initially dissolved and
co-assembled RB is not linearly proportional, and the efficiency of co-assembly (nRBp/nRBi)
will reach a saturation limit.
The encapsulation efficiency of RB in CD3ac beads can amount for at least about
% w/w or at least about 40 mol-% or higher in analyzed concentration ratios, which
con‘esponds to an about 900-fold increase of RB concentration or a logarithmic partition
coefficient of RB in H30 of 2.95. Similar or even higher efficiencies are contemplated
for hydrophobic cargo molecules; however, te quantification of water-insoluble
compounds can be prone to artifacts due to cargo precipitation outside the peptide beads upon
solvent exchange.
The ability of CD3ac to efficiently tare—associate and co-precipitate RB is
remarkable, at least partly because RB is doubly charged and water soluble. In fact, its
solubility in water is about five times higher than in ethanol. As presented herein, bead
assembly of CD3ac is not inhibited by the presence of equimolar concentrations of RB, and it
PCT/U52012/052027
is contemplated that, not to be bound by theory, peptide and dye interact mainly on aromatic
interactions leading to rather unspecific binding (as compared to e.g., avidin/biotin). This
functionality can complement the encapsulation properties of solid lipid nanoparticles as well
as vesicular systems.
Presented herein is a highly hydrophobic sequence of 10 amino acids sized
and purified at high yields and preparative quantities. The peptide ) can assemble into
evenly-shaped beads of low size polydispersity in the absence of any templating strategies.
Circular dichroism ements of charged derivatives of CD3ac indicate a structural
relation to D,L—helical gramicidin and the essential role of D-Leu in regard of its specific
secondary structure. LCD3, which exclusively contains L-amino acids, exhibits Cit-helical
characteristics and precipitates amorphously in its acetylated state. CD3ac can encapsulate
both hilic and hydrophobic nds with efficiencies exceeding existing
encapsulation strategies [15], for example, resulting in thmic partition coefficients of at
least 2.95, and the encapsulation efficiency is not limited by the concentration of the
hydrophilic species in on, unless it reaches a saturation limit.
In accordance with various aspects and embodiments bed herein, the solid
peptide particle state in conjunction with a highly efficient cargo encapsulation can be
utilized to decrease ation of sensitive and cost intensive pharmaceuticals and applied to
deliver high ds into cells. Such peptide drug ry system can entrap and
accumulate guest molecules (e.g., active agents) in a convenient one-step procedure.
Therefore, ted herein is non-polymeric drug delivery system based on natural amino
acid building blocks and synthesis by Fmoc chemistry, which can augment the current
toolbox of colloidal species and holds promise for medical ations.
Example 3. CD3ac nanoparticles with a protein corona for drug delivery into cells
As described in Examples l and 2, CD3ac peptide nanoparticles can be assembled
from dissolved CD3ac by addition of water: an emulsion spontaneously forms as the ternary
mixture (CD3ac, organic solvent, H20) is brought into the two—phase region , H20).
The emulsification process resembles the ouzo effect (8), however, CD3ac droplets harden to
solid particles as the organic solvent is removed. Examples 1 and 2 demonstrate that neutral
as well as charged aromatic molecules can migrate into the dispersed phase and get trapped
during particle ion (5).
In e 3, presented herein is a new drug delivery system consists of the
CD3ac peptide matrix, entrapped cargo (Flutax—2) and a corona of errin, optionally
WO 28843 PCT/U52012/052027
labeled with Alexa Fluor' 568 (Tfn-AF568) for visualization purposes. To evaluate the spatial
arrangement of the reagents in self—assembled CD3ac particles, CD3ac peptides were
dissolved along with Flutax-2 and Tfn-AF568 in 50% EtOH and the EtOH content was
reduced in steps as shown in the Exemplary Materials and Methods later. Figs. 8A—81 shows
fluorescence images of the resulting CD3ac peptide drug carrier nanoparticles. In this
embodiment, the CD3ac nanoparticles were about 3 pm in diameter, the size designed to be
large enough to distinguish the distribution of fluorescence in the core and at the surface by
conventional light microscopy. Without wishing to be bound, smaller or larger CD3ac
peptide nanoparticles can be produced. Tfn—AFS68 shows a bright ring of fluorescence at the
particle periphery whereas Flutax-2 fluorescence is equally distributed throughout the le
(Figs. 8A-8C). The entrapment efficiency was measured by determining the partition
coefficient of Fiutax-2 between peptide particles and water (Figs. 9A-9D). The partition
coefficient of Flutax-Z between peptide les and water was determined to be 5.25, i.e.,
under applied experimental conditions, more than 80% of co-dissolved Flutax-Z escapes the
aqueous phase and gets entrapped in particles. Such ion coefficient value is ably
high for a water soluble compound.
Proteins are generally surface-active and can adsorb onto solid-liquid interfaces.
Accordingly, it was sought to determine whether particles in contact with protein solutions
can get covered with a layer of proteins referred to as “protein corona”(10). As such, it was
assessed whether the nced rim of red fluorescence represents a corona ting of
Tfn-AF568. To assess this, the particles described herein were incubated for 6 hours in
50 ug/mL trypsin. The rim eared while the spatial distribution of the Flutax-Z cargo
remained unaltered (Figs. 8D- 8F). Quantification of gray—level profiles indicated that the
intensity of the Tfn-AF568 rim was reduced by 3-fold after trypsin incubation (Fig. 86). At
the same time, removal of the 568 corona resulted in an increase of green
fluorescence of F1utax~2 up to a factor of 13 (Fig. 8H), ating in the spectral overlap of
Tfn-AF568-absorption and Flutax-2—emission. Together, these ments indicate that self-
assembly of CD3ac, -2 and Tfn-AFS68 leads to the formation of particles with
entrapped Flutax—2 and a corona of surface-adsorbed Tfn-AF568. Trypsination of the self-
assembled particles can result in proteolytic degradation of Tfn-Af568 ed by surface
desorption of the fragments (Fig. 8]).
] les for drug delivery are lly between 8 nm and 200 nm in diameter as
this size range is less likely to be cleared by kidney and liver (4). Also, or mediated
PCT/U52012/052027
endocytosis, a possible mechanism for the uptake of targeted drug-containing particles, is
size—dependent and more efficient for particles smaller than about 150 nm (11). In order to
reduce CD3ac particle size, lower e concentrations were dissolved prior to
emulsification: Figs. lOA-lOC show fluorescence microscopy images of peptide particles
prepared from 492 uM, 246 uM and 123 th CD3ac, assembled in the presence of 10 rig/ml.
Tfn-AF568. The resulting size differences are summarized in Fig. 10D by ity profiles
of particle-associated fluorescence. The characteristic ring, still visible at 492 uM, cannot be
observed on smaller particles due to the diffraction limit of visible light, although light
copy confirms the presence of Tfn-AF568 on particles smaller than 300 nm (Fig. 10E).
To confirm corona formation of Tfn-AF568 on nanoparticles (d < 100 nm), transmission
electron microscopy (TEM) was applied.
For the sake of y, PNPC‘W’” is used herein as an acronym for CD3ac
Cargo
peptide nanoparticles self-assembled in the presence of cargo (e.g., —Z used herein) and
corona (e.g., Tfn-AF568 used herein). Figs. 10F-101 show TEM images of PNP les in
various configurations: _2 (Figs.10 F-lOG) and PNPTI’H‘F56a
Flumt -’.’. (Figs.10H ~101). Both
samples were stained with uranyl acetate, setting apart bright particles and dark background.
PNPFMW”: were ed in large numbers, and evenly distributed on the carbon film (Fig.
10F). By contrast, only few particles could be detected in the PNPun-arsesFlwar—2 ; instead,
they clustered together (Fig.10H), ting the process of de-wetting and residual water
evaporation during sample preparation and thus differential affinity to the hydrophobic
carbon support. Higher magnification (Fig. 101) shows a rim of intermediate contrast on the
nanoparticle interface. Its average thickness of 9.85 nm (st. dev. = 2.1, n = 99) is in
agreement with the expected protein diameter (12). Although both samples were prepared by
the same protocol, the average diameter of PNPWW2 (100 nm, Fig. 10J) was twice that of
[’I‘t’l’rfi'_’“r568
FIulm'-2 (51 nm, excluding corona, Fig. 10K). Without wishing to be bound by theory,
the average size of peptide particles depends not only partly on the peptide tration but
also partly on the presence of surface active molecules which ize the emulsion early in
the process of phase tion (8). Thus, these electron microscopic analyses indicate that
peptide particle diameters can be controlled down to a few ten nanometers, e.g., by
modulating different sing parameters, for example, but not d to, e
concentration and/0r concentration and/0r types of surface active molecules. Together with
PCT/U52012/052027
the fluorescence microscopy images of Figs. SA-SF, the TEM images indicate the ce of
a Tfn—AF568 corona on PNPs.
Example 4. Delivery of Flutax-Z into CHO cells by CD3ac nanoparticles with a protein
corona
Selective binding to transferrin receptors (TfR) depends on the functionality of the
n : its function can be compromised by protein denaturation, steric hindrance
(crowding) or unfavorable orientation relative to the PNPs’ surface. Accumulation of PNPs
on cell surfaces can be uted to specific corona-receptor interactions and/or unspecific
associations. For example, electrostatic (Coulomb) and electrodynamic (Van der Waals)
forces can contribute to unspecific association (13-15). In order to test functionality of the
detected corona in mediating specific binding, the number of cell surface-associated PNPs
was correlated to the density of available TfR using two independent mental protocols:
a) PNP binding by Tfn in on; and b) comparison of PNP g between TfR-
expressing Chinese hamster ovary (CHO) cells and TRVb cells, which are derived from
Chinese hamster ovary tissue that lacks nous TfR but expresses TfR2 (16). Figs. 11A-
llH show microscopy images of CHO cells ted for one hour with PNPm'AFS“
FIuIru-l . A
significant lation of PNPs was detected within the projected cell perimeter
(Figs. llA-C) which could be blocked by incubating CHO cells with 17 tLM unlabeled Tfn
(Fig. 1 1D —1 IF). This indicates that PNP interactions with the cell surface depend on freely
valent TfR. Fig. llG shows that the lower TfR density in TRVb leads to a significantly
reduced association rate of PNPm""F568
Harm—2 . Incubation of TRVb with [7 uM unlabeled Tfn
blocks binding of PNPU'MF568
Fluuu—Z , indicating that in these cells PNPU’MF568 interact mostly via
FIuIar—Z
the low—abundant receptor TfR2. Application of excess Tfn might not only compete with the
PNPs for TfR but may also exchange fluorescent Tfn-AF568 in the le corona with non—
fluorescent Tfn. To assess this possibility, the fluorescence intensity distribution of
PNPTfW‘”68 incubated at 37°C in the presence and absence of 17 uM Tfn after 24 hours
were compared and there were insignificant differences (Figs. 9C-9D). This indicates that the
rate of TfR-mediated binding of PNPS to the cell surface is much faster than the protein
exchange on the PNP surface. Together with the results ted in Figs. llA-l 1H, PNPs
are shown to bind to TfR specifically via the 568 corona.
While PNPU'MFS“ can bind to cells via interactions with TfR, Tfn could
Murat—2
dissociate from the PNP corona before internalization takes place, and/or the size difference
WO 28843 PCT/U52012/052027
between single Tfn proteins and a NP may affect cellular uptake. Thus, it was next sought to
determine if the particles can be internalized by cells. Distinction between associated and
internalized PNPs can be not straightforward due to the flat shape of surface-adherent cells
and a limited z-resolution of light microscopy. As shown earlier, removal of Tfn-AF568 from
the particle e can be detected by a pronounced shift of green to red fluorescence ratio
(G/R). As such, G/R distribution was measured to distinguish n PNPs associated and
internalized into cells, as shown in Figs. 12A—12M, respectively. CHO cells were fixed and
imaged after 1 hour (Figs. 12A-~12E) and after 6 hours (Figs.12G —12K) of incubation with
I>NPTf"‘*“‘"568 . After 1 hour the G/R distribution showed a tight peak around 1.5 for both PNPs
Flumr-Z
within (Fig. 12E, black bars) and outside (Fig. 12E, gray bars) the cell perimeter. As shown
in Fig. 12K, after 6 hours, the population of PNPs within the cell perimeter (black bars)
displayed a significant shift towards higher G/R values, while the GR distribution of PNPs
outside the cell perimeter (gray bars) remained confined around 1.5. Without wishing to be
bound by theory, it is contemplated that after incubation for 1 hour, most PNPs have not yet
reached a lysosomal compartment and those which have been internalized still have an intact
corona containing Tfn-AF568; after six hours, the majority of PNPs have been orted
into lysosomes and their protein coronas have been proteolytically digested. The r
degradation products can dissociate from the particle e due to weaker Van der Waals
forces (17). In y to an increase in G/R after removal of the corona by trypsin (Fig. 8H),
the proteolytic digestion of the PNP corona in lysosomes can yield an increase in the G/R
values of internalized PNPs. This is corroborated by the unchanged G/R values of PNPs
detected on the glass surface. Changes in G/R can be used herein as a qualitative indicator of
internalized PNPs (because of the relatively slow digestion kinetics) to demonstrate that
PNPs with a Tfn-AF568 corona can enter or be en by the cells, for example, by
in-mediated endocytosis via TfR(l8).
To assess whether binding and internalization of PNPs can result in the selective
import of small molecule cargo, the release of encapsulated —Z into cells was analyzed
24 hours post addition of PNPmMF568 into the cells (Figs. l3A-13I). Flutax-2 is an Oregon
rim-2
Green (OG) modified derivative of paclitaxel(19), a mitotic inhibitor applied in cancer
therapy (20). Unlike its unlabeled form, Flutax-Z is charged and water-soluble at the applied
concentration and does uently not te cell membranes. Thus, it was used a
model compound to investigate efficiency and specificity of small molecule delivery by PNPs
to the cytosol. CHO cells were ted for 24 hours with 0.67 rtM Flutax—Z, either
PCT/U32012/052027
dissolved in media (Figs. 13A-13C) or entrapped in PNPTI’H‘H“
Flumx-Z (Figs. 13D-13G). Flutax—Z
emission in the cytosol was ed to quantify the amount of delivered compound into the
cells. Direct permeation of dissolved Flutax-Z through cell membranes could not be ed
as the resulting fluorescence did not exceed the level of autofluorescence (Fig. 133 and 131).
On the other hand, incubation with PNPTIW’W“ resulted in a strong diffuse green
FIumr—l
fluorescence signal (Figs. 13E and 136), indicating the delivery of Flutax—Z to the l.
The delivery was significantly reduced by competition of PNP-cell interactions with 17 uM
ved and unlabeled Tfn in cell culture medium (Fig. 13H). Also, the l rate of
delivery was significantly lower for TRVb cells, which express only TfR2 (Fig. 13H).
Presented herein is a targeted drug delivery system consisting of CD3ac peptide
matrix, cell membrane-impermeable Flutax-2 as cargo and Tfn-AF568 as a specific cell
surface receptor ligand, according to one or more embodiments bed herein. All three
components can ssemble to form drug-loaded and functionalized particles by
application of a one-step-procedure (e.g., a single step of about 15 minutes). Without wishing
to be bound, the simplicity of system and formation protocol originates in the conceited
interaction of all involved components: CD3ac is not only matrix material, but edes
encapsulation routines due to its high affinity to small ic molecules. The process of
cargo uptake most likely resembles a two-phase liquid tion where Flutax-2 s the
aqueous phase and accumulates in peptide droplets, probably due to high affinity between
delocalized ring systems of tryptophanes and Flutax-2. Additionally, the peptide’s solubility
in mild c solvents allows for concurrent dissolution and self-assembly of all involved
ents. The presence of 568 during emulsification of CD3ac results in the
formation of a protein corona, targeting PNPs against TfR. Additionally, the presence of the
protein on particle surface can allow for modulation of particle size due to its surface activity
and thus early stabilization of the peptide emulsion. Upon internalization of PNPs into
lysosomal compartments, proteolytic digestion on a time scale of a few hours can remove the
corona, and in turn release the entrapped cargo into the cytosol on a time scale of days. The
fluorescence ratio of encapsulated green (e.g., Flutax-Z used herein) and surface adherent red
dyes (e.g., Tfn-AF568) can shift to a higher value (e.g., by a factor of 13) as the corona is
removed and this shift can allow fora ative description of cellular particle uptake. PNP
binding to TfR and size range of the particles te particle uptake, e.g., via clathrin
mediated endocytosis. Without wishing to be bound by theory, cargo release can go back to
the proteolytic degradation of PNPs in the 1ysosome. The structure of charged CD3ac
PCT/U52012/052027
degradation products is likely to penetrate lipid membranes and might lead to the disruption
of lysosomes (21).
Exemplary Materials and Methods (for Examples 3-4)
Stock solutions: sis and pun'fication of CD3ac was described in ary
Materials and Methods for Examples 1-2 (See, e.g., Dittrich and Meier (2010)
Macromolecular Bioscience 10: 1406). Briefly, the e was synthesized on a solid phase
using Fmoc protection group chemistry and d on C18 reverse phase (RP)
chromatography material applying a gradient of acetonitrile and water. Purity was ined
by peak integration of RP-HPLC elution profiles at A280 and exceeds 95%. CD3ac stock
solutions were prepared by dissolving the peptide in EtOH:HgO (1:1 v/v). The concentration
was determined by tion (Thermo Scientific Nanodrop 2000) at 280 nm in a mixture of
EtOHzH20:DMSO 1:1:2 considering 8280 = 21780. The peptide concentration was adjusted to
742 itM with EtOHzHZO (1:1 v/v), and aliquots of 200 [AL were stored at —80 °C until further
use. Tfn—AF568 (Invitrogen, T-23365) was dissolved at a concentration of 500 ug/mL and
stored at +4°C. Flutax—2 (Invitrogen, P22310) was dissolved at a concentration of 40 “M in
H302EtOI-l (1:1) and stored at -80°C.
Particle assembly, loading and coronaformation: PNPs were led by
mixing stock solutions of CD3ac, Tfn—AF568 and Flutax-Z to yield final concentrations of
123 uM CD3ac, 6 uM Flutax-Z and 10 pg/mL Tfn-AF568 in H;O:EtOH (1:1, v/v).
Emulsification was d by a first dilution step (1:1, H30) followed by an equilibration
period of 15 minutes before the l content was further reduced to 25 % by the second
on step (1:1, H30). 50 uL aliquots of the resulting suspension were applied to 24-well
sitting drop crystallization plates (Hampton Research, Cryschem) and counter-evaporated 3
times against 1 mL H30 during six hours.
ed Cell Experiments: CHO cell lines were grown in F122DMEM 1:1
(Cellgro, 10—090) plus 10% fetal bovine serum (Gibco). 2 x 104 cells in 0.5 mL media were
seeded on cover glasses (VWR, 724) in 24 well plates (Falcon, 353047) and incubated
for 16 hours. Cells were washed 1x with PBS and incubated for an additional 30 min in
Ham’s F12 medium (Cellgro, 10—080) before 50 uL nanoparticle (NP)-solution (as prepared
above) in 250 uL F 12 was applied. The concentration of CD3ac used in cell incubation thus
ponds to 8.3 ug/mL, ignon'ng the weight of associated Flutax-2 and Tfn-AF568. In
competition assays, cells were pie-incubated for 30 min in F12 medium containing 17 uM
Tfn (Sigma, T1283) before a solution of 50 uL PNP in 250 uL F12 containing 17 uM Tfn
was added. Samples were fixed with 3 % paraforrnaldehyde , P6148) in PBS, mounted
on glass slides using fluorescent mounting medium (Dako, S3023) and analyzed within 24
hours.
Fluorimelry: Fluorescence experiments were cam‘ed out on a BMG FLUOstar
Omega plate reader on black 384 wellfiplates (MPIOO-l, Matrical). Dilution series of Tfn-
AF568 and Flutax-2 were measured in SO:FBS 6:3:1 (V:V:V) and the data points
were fitted linearly.
Table 4: Exemplary parameters determinedfrom linear data regression
——StdEn-or Std Error
234.76 85.56
5750.49 2.515x10
I_— 099986
{00337} To determine the encapsulation efficiencies of Flutax-Z, PNPs were assembled
with the procedure described above in the presence a fixed tration of 568
(10 pg/mL) and various amounts of Flutax-2 (1.6 pM, 4 pM, 8 pM, 12.5 pM and 16 uM).
After assembly in crystallization plates (see above) PNP s were normalized with H30
to 100 pL and centrifuged for 1 hour at 16,000 g before 80 “L were separated from the pellet
fraction. Both fractions were normalized to 133.3 rd. in H302DMS02FBS 6:3:1 (v:v:v) before
120 uL were applied to the well-plate and the fluorescence intensity was measured.
Transmission electron microscopy: PNP samples were prepared as described
above. 5 pL of PNPs suspended in H20 were applied to a carbon film coated copper grid
(400 square mesh, Electron Microscopy Sciences) and dried. The sample was stained with
pL l % uranyl e during one minute. Excess stain was removed with a filter paper
and subsequently d to a Tecnai G2 Spirit BioTWlN.
Microscopy: Fixed cells were analyzed on a Nikon Ti ed microscope
equipped with 60x Plan Apo NA 1.4 objective lens. DAPI fluorescence was excited with a
360/40 filter and collected with a 460/50 emission filter. Oregon Green fluorescence was
excited with a 360/40 and collected with a 480/40 emission filter. AF568 fluorescence was
excited with a 545/30 and ted with a 620/60 emission filter. Images were acquired with
a l-lamamatsu ORCA R2 cooled CCD camera controlled with MetaMorph 7 software.
Gamma, blightness, and contrast were adjusted on displayed images (identically for
compared image sets) using Image] software. 2-Series optical ns were collected with a
WO 28843 PCT/U82012/052027
step size of 0.25 microns ranging from the glass slide to the highest detectable PNP using a
Prior Proscan I] focus motor. Samples observed after 1 hours and 6 hours of PNP-incubation
are (merged) maximum stack-projections of AF568 and Oregon Green (0G) channels. The
samples observed after 24 hours were obtained by average—projection of Oregon Green
fluorescence and maximum-projection of AF-568 stacks. The average projection of 0G was
used to quantify differences in Flutax-Z cence in the cytosol. Cell perimeters were
segmented manually in DIC . Fluorescence point maxima were extracted by Image]
(v. 1.43u) using a noise tolerance of 50 in the public class mFinder.
Example 5. Delivery ofnocodazole into Held cells with one or more embodiments of
CD3ac nanoparticles
Fig. 16A show one embodiment of the CD3ac nanoparticles, wherein EGF
(optionally labeled with Texas red for visualization purposes) is a cell-targeting . Such
CD3ac nanoparticles with EGF as a ligand can be taken up by the cells, as shown in Fig. 16B.
To produce CD3ac beads encapsulated with nocodazole, in some ments, 21 uM
CD3ac, 2 ug/mL EGF (labeled with Texas Red for visualization purpose) and 20-40 ttM
nocodazole were dissolved in an organic solvent (Fig. 17A or 170). Solvent exchange with
water can result in formation of an emulsion and thus CD3ac solid nanoparticles containing
nocodazole and EGF. In some embodiments, at least a portion of EGF was ulated into
CD3ac beads. Additionally, EGF can adsorb on the outer surface of the CD3ac beads,
resulting in EGF-functionalized CD3ac beads.
After incubation of HeLa cells in media ning such CD3ac particles
encapsulated with two different concentrations of nocodazole (20 uM or 40 MM), fluorescent
microscopic images (Figs. l7B-17F, and l7H-17K) show the EGF~functionalized CD3ac
les were uptaken by the HeLa cells, and the microtubule in those HeLa cells treated
with EGF-functionalized CD3ac particles were largely depolymerized. However, HeLa cells
treated with the supernatant of pie—incubated and centrifuged CD3ac suspensions still contain
intact ubules. This indicates that nocodazole can be delivered into the cells by the
nctionalized CD3ac particles.
Without wishing to be bound by theory, the bead binding and uptake by the cells
can occur through the interaction of EGF adsorbed on the surface of the CD3ac particles with
EGFR present on the HeLa cells.
Example 6. CD3ac nanoparticle targeting with IgG
PCT/U82012/052027
The CD3ac nanoparticles targeting with IgG can be prepared in ep
procedure as described herein. Fig. 18A shows that IgG antibodies (e.g., but not limited to,
ransferrin IgG or anti-rabbit IgG) can be taken up by the CD3ac nanoparticles. In
addition, as shown in Fig. 18B, incubation of the anti-transferrin lgG~functionalized CD3ac
nanoparticles with transfern'n A—546 ted fluorescence signals (indicated by white dots),
ting that the IgG is present on the CD3ac nanopaiticle surface and enables binding of
the IgG with transferrin A-546. Similarly, incubation of the anti-transferrin IgG —
functionalized CD3ac nanOpaiticles with a secondary antibody (e.g., abbit IgG can be
used if the anti-transfem'n IgG is raised in rabbits) also resulted in binding of the IgG present
on the CD3ac nanoparticle surface with the secondary dies (indicated by white dots in
Fig. 18C). The IgG orientation at the interface of the nanoparticles is likely isotropic
(“random”), e.g., the antigen binding site and/or the epitope for the ary antibodies are
exposed and accessible.
Example 7. Delivery of nucleic acid molecules (e.g., DNA or RNA) by peptide les
(e.g., CD3 peptide particles or mixed e particles comprising CDJac and CD3
peptides)
DNA/siRNA transfection can be established by a peptide particle that is i) charged
and ii) . While CD3ac particles (peptide sequence shown in Table 3) are ble in
water, they are generally not charged and therefore unlikely bind to nucleic acid molecules
(e.g., DNA or RNA including, but not limited to, siRNA). CD3 peptide (peptide sequence
shown in Table 3) contains 4 primary amines (3 lysines + 1 N-terminus) that can be either
charged or acetylated.
To evaluate cell transfection efficiency using CD3 peptides, HeLa cells were
incubated with a mixture of CD3 peptides (with a peptide sequence shown in Table 3) and
anionic nucleic acid molecules (e.g., single-stranded DNA), both dissolved in the cell culture
medium at a molar ratio of about 3.7: 1 (CD3: ssDNA). In order to easily ize the
presence of ssDNA inside a cell, a portion of the ssDNA added into the cell culture medium
was labeled with a detectable label (e.g., Alexa Fluor 488; AF488). As shown in Figs. 19A-
19B, the ce of CD3 peptides in the cell culture media leads to increased fluorescence in
the cytosol (Fig. 19A), as compared to the control (Fig. 19B). Thus, a mixture of positivelycharged
hilic peptides described herein (e.g., CD3 peptides) and anionic nucleic acid
molecules (e.g., DNA or RNA ing, but not limited to, siRNA) can increase efficiency
of transfecting cells with nucleic acid molecules, as compared to cell transfection in the
2012/052027
absence of the positively-charged amphiphilic peptides described herein (e.g., CD3 peptides).
Without wishing to be bound by theory, due to the amphiphilic ure and cationic head
groups of the peptides bed herein (e.g., CD3 peptides), some embodiments of the
amphiphilic peptides described herein (e.g., CD3 peptides) can be used as enetrating
peptides or cell transfection agents.
It was next sought to determine if etylated amphiphilic peptides (e.g., CD3
peptides) can self-assemble in the presence of nucleic acid molecules to form nucleic-acid
containing peptide articles. To this end, a mixture of CD3 peptides, ssDNA, and transferrin
was ted to electrophoresis in agarose (as any formed e particles would be too
large to migrate through the agarose gel). Some ssDNA in the mixture was labeled for
visualization of its nt in agarose gel, while d transferrin (e.g., AF568-Tfn) was
added into the e-nucleic acid mixture to r the presence of peptide particles. (As
described earlier in Examples 3-6, a ligand (e.g., transferrin) added to a peptide mixture
generally forms on the outer surface of the peptide particles.) As shown in Fig. 20A, co-
localization of Tfn—AF568 signal and ssDNA-AF488 signal at the loading zone of the agarose
after electrophoresis for about 40 mins indicates that peptide particles were formed from the
mixture comprising CD3 es and nucleic acid molecules (e.g., AF488-ssDNA), and thus
were unable to migrate into the agarose gel over time, while other excess protein molecules
(e.g., ssDNA and Tfn) migrated toward the anode.
The efficiency of co-precipitation of non-acetylated amphiphilic peptides (e.g.,
CD3 peptides) and nucleic acid molecules (e.g., ssDNA) was also assessed and quantified,
e.g., by a l-IP-WAX (weak anion exchange) chromatography method. For example, CD3
peptides and ssDNA were co-precipitated to form ssDNA-containing peptide particles prior
to centrifugation and separation of supernatant and pellet, both of which were then subjected
to a l-lP-WAX chromatography machine. As shown in Fig. 20B, a majority of the CD3
peptides and ssDNA were detected in the pellet of the peptide les, as compared to the
amounts in the supernatant, indicating that formation of containing peptide particles
by the co-precipitation method is highly efficient.
It should be noted that a mixture of CD3 peptides and c acid molecules can
self-assemble to form stable particles in pure water; however, they are generally not stable
and dissolve, responding to increasing salt strengths and higher atures.
t limitations, there are two exemplary methods to decrease the solubility of
nucleic acid (e.g., DNA or RNA including siRNA)—containing peptide nanoparticles. For
example, the first approach can entail a mixture of fully-acetylated peptides (e.g., CD3ac with
W0 2013/028843 PCT/U52012/052027
a peptide ce as shown in Table 3) and partially and/or non-acetylated es (e.g.,
CD3 with a peptide sequence as shown in Table 3) during particle assembly. Even though
CD3 is soluble in water, it can co-pr‘ecipitate with CD3ac. Thus, a peptide nanoparticle’s net
charge can be easily modulated, e.g., by controlling the concentration or molar ratio of
partially and/or non—acetylated peptides (e.g., CD3) and acetylated peptides (e.g.,
CD3ac). By way of example only, more CD3ac can increase the particle stability while more
CD3 can yield higher loading capacities for siRNA/DNA as well as a higher potential to
penetrate cell membranes due to its net charges. One of skill in the art can ine the
optimum ratio of CD3 to CD3ac in mixed peptide nanopar‘ticles for ular ations,
e.g., siRNA or DNA delivery. In some embodiments, the partially and/or non—acetylated
peptides (e.g., CD3) can be present between 5 mole % and 50 mole% in mixed peptide
nanoparticles. In some embodiments, the fully-acetylated peptides (e.g., CD3ac) can be
present between 50 mole% and 95 mole % in mixed peptide nan0particles. In various
embodiments, the concentration or molar ratios of the partially and/or non-acetylated peptides
(e.g., CD3) to acetylated peptides (e.g., CD3ac) can range from about 1: 100 to about
50: l; or from about 1:50 to about 10:1, or from about 1:20 to about 121.
Accordingly, in some embodiments, a e of fully-acetylated hilic
peptides (e.g., CD3ac peptides), lly-acetylated or non-acetylated amphiphilic peptides
(e.g., CD3 peptides) and nucleic acid molecules can be prepared to form stable peptide
particles containing nucleic acid molecules (e.g., DNA or RNA including siRNA). For
example, to trate formation of stable nucleic acid—containing peptide particles at
physiological conditions, CD3ac peptides were added to a mixture of CD3 peptides and
single-stranded DNA (ssDNA) at a molar ratio of about 11: 1.8: 1 (CD3ac: CD3: ssDNA). It
was determined that the presence of CD3ac peptides stabilizes ssDNA—containing peptide
particles at physiological conditions. All the three components co—precipitated to form
containing peptide particles that were stable at the corresponding salt strength.
] In some embodiments, a ligand (e.g., transferrin) can also be added into the
mixture comprising acetylated hilic peptides (e.g., CD3ac peptides), partially-
acetylated or non-acetylated amphiphilic peptides (e.g., CD3 peptides), and nucleic acid
les (e.g., DNA or RNA including siRNA) to form nucleic acid—containing stable
peptide particles against the protein to which the ligand binds (See, e.g., Examples 3-6 for
some embodiments of the peptide particles described herein for use in targeted delivery of an
active agent). For example, transferrin (Tfn labeled with AF568 for ease of visualization by
imaging) was added to the mixture to form nucleic acid-containing stable peptide particles
PCT/U52012/052027
against transferrin receptors present on the cell surface. As discussed in Example 3, the ligand
(e.g., Tfn) is generally present on the outer surface of the peptide particles.
To determine efficiency of delivering nucleic ontaining peptide particles
into cells, HeLa cells were ted with nucleic acid-containing peptide particles (e.g.,
formed from a mixture of CD3ac peptides, CD3 peptides and ssDNA as described above). As
discussed earlier, some ssDNA in the mixture were labeled with a detectable label (e.g.,
AF488) for ease of visualization by imaging. In addition, Tfn-AF568 was added to form
nucleic-acid containing peptide particles as a means to visualize the formed peptide particles.
As shown in Fig. 21, the Tfn-AF568 fluorescence signal from the formed peptide particles
co-localized with the AF488—ssDNA fluorescence signal in the cytosol, indicating that
containing peptide particles are stable at physiological conditions and delivered into
the cells (e.g., HeLa .
It was next sought to determine the effect of net charges of nucleic acid-
containing peptide es on their stability at a physiological condition, e.g., in serum. As
shown in Table 5 below, stable peptide particles are generally formed when the ratio of
cationic charges to anionic charges of the nucleic acid-containing peptide les is close to
zero (e.g., between about 5 and about 0, or between about 3 and about 0). The charge ratio
can be adjusted by molar ratios of anionic nucleic acid molecules (e.g., ssDNA), and cationic
amphiphilic peptides described herein (e.g., partially-acetylated or etylated
amphiphilic peptides such as CD3) in a e assembly e. Without wishing to be
bound by theory, a negative net charge of peptide particles (e. g., a ratio of cationic charges to
anionic charges less than 1) can help to prevent particle aggregation.
Without wishing to be bound by , while the net charges of nucleic acid-
containing peptide articles can influence the particle stability at physiological conditions, the
amount of fully-acetylated amphiphilic peptides (e.g., CD3ac peptides) relative to non-
acetylated amphiphilic peptides (e.g., CD3 peptides) can also contribute to the particle
ity. For example, as discussed earlier, a e of non-acetylated amphiphilic es
(e.g., CD3 peptides) and nucleic acid les can ssemble to form particles; however,
they are generally not stable and dissolve, responding to increasing salt ths and higher
temperatures. In contrast, peptide particles formed from fully-acetylated amphiphilic peptides
(e.g., CD3ac peptides) are more stable. Accordingly, increasing the molar ratio of fully—
acetylated amphiphilic peptides (e.g., CD3ac) to non—acetylated amphiphilic peptides (e.g.,
CD3) can increase stability of the resultant peptide particles at a physiological condition, e.g.,
in serum, which is in agreement with the data shown in Table 5.
W0 20131028843 PCT/U82012l052027
Table 5. Eflects of charge ratios (or molar ratios) in a peptide e on stability of
resultant peptide particles in serum
Peptide assembly mixture Molar ratio Charge ratio Stability in
composition (ssDNA: CD3ac: CD3) (cation: anion) serum
('3 U u; 1.238—04 M
CD3ac 04 M 1:200:200
ssDNA 6.20e-07 M
| _—r§3—______
1.23e-05 M
CDSac 1.23e-O4 M 1:200:20 3.306
ssDNA 6.20e-07 M
DB 06 M
CD3ac 1.23e-04 M 0- 331
ssDNA 6.20e—07 M
The second approach to decrease the solubility of DNA/siRNA-containing peptide
nanoparticles can involve custom synthesis of a single peptide with an acetylation degree,
e.g., varying from acetylation of at least one amino group in the hydrophilic peptidyl segment
of the amphiphilic peptide described herein to complete ation of all amino groups in the
hydrophilic peptidyl segment of the amphiphilic peptide described herein. By way of
example only, an amphiphilic e can be custom synthesized with an acetylation degree
between CD3 and CD3ac. For example, an amphiphilic peptide can be custom synthesized
with at least one charged or non-acetylated group, e.g., at the inus, ing at least
one two charged or non-acetylated groups or at least three d or non—acetylated groups.
In one embodiment, the amphiphilic peptide can be designed to be cationic (e.g., for siRNA
or DNA delivery) by modulating charges toward or on its N-terminus (e.g., with acetylation)
to yield the amphiphilic character of the le. For example, at least one amino group
(e.g., l, 2, 3, 4, 5 or more amino groups, depending on the number of amino groups present in
the hydrophilic peptidyl segment) of the hydrophilic peptidyl segment of the amphiphilic
peptide bed can remain non-acetylated, and at least one amino group (e.g., 1, 2, 3, 4, 5
or more amino groups, depending on the number of amino groups present in the hydrophilic
peptidyl segment) of the hydrophilic peptidyl segment of the amphiphilic peptide described
can be acetylated. In n embodiments, such amphiphilic peptide can comprise an amino
acid sequence of H-LK(AC)-LK(AC)-LK(Ac)-LW-DL—LW-DL-LW-DL-LW-NHg. In some
embodiments, the amphiphilic peptide can comprise an amino acid sequence of l-l-LK-
LK(AC)—LK(Ac)-LW-DL-LW-DLwLW-DL-LW-NHg. In alternative ments, the
amphiphilic peptide can comprise an amino acid sequence of H—LK-LK-LK(Ac)-LW—DL-
WO 28843 PCT/U52012/052027
-4
LW-DL-LW-DL-LW-NI-h The ratio of acetylated amino groups to non-acetylated amino
groups in an amphiphilic peptide can control the cationic and c properties of the
amphiphilic peptides described herein. In some ments, the ratio of acetylated amino
groups to non—acetylated amino groups in an amphiphilic peptide can be smaller than 1, about
1, or larger than 1.
e 8. ity of nucleic acid-containing peptide particles (e.g., CD3 peptide
particles or mixed peptide particles comprising CD3ac and CD3 peptides)
] The ity of nucleic acid-containing CD3 e panicles was characterized in
pure water. Below is an exemplary CD3 peptide particle formulation r comprising
nucleic acid molecules (e.g., ssDNA) and a ligand (e.g., transferrin, Tfn):
Peptide particle formulation 1 jCD3 + ssDNA + Tfn)
21 uM CD3 (H-LK-LK-LK-LW-DL-LW-DL-LW-DL—LW—NHZ)“
.4 uM (5‘-TFGTGCCGCCTTTGCAGGTGTATC-3‘)2“‘
0.24 “M (AF488-5‘-TTGTGCCGCCTTFGCAGGTGTATC-3‘)24'
4.14 ug/mL Tfn-AF568
To evaluate the stability of peptide particles formed from formulation 1 (PNPI) in
water, a sample of the peptide particles PNPl was shaken in an eppendorf tube containing
water for about l5 mins either at about room temperature or at about 37 °C. The PNPl
sample was then centrifuged to spin down the peptide particles and the supernatant was
collected for further analysis. The Tfn-AF568 concentration in the atant was measured
and quantified by fluorescence intensity. As shown in Fig. 22A, a higher concentration of
Tfn-AF568 was detected in the supernatant from the PNPl sample shaken at a temperature of
about 37 °C than at about room temperature, indicating that the stability of PNPl particles in
water is ature—dependent and more PNPl particles tend to dissociate at a higher
temperature, thus releasing a greater amount of Tfn-AF568 into the supernatant.
A time—course study of the PNPl stability in water was also performed. Samples
of the PNPl particles were shaken in eppendorf tubes containing water at a temperature of
either about 4 °C or about 37 °C. At each pie—determined time point (as indicated in
Fig. 22B), a PNPl sample was then centrifuged to spin down the e particles and the
supernatant was collected for further analysis. The Tfn-AF568 concentration in the
supernatant was measured and quantified by fluorescence intensity. Similar to Fig. 22A,
WO 28843 PCT/U82012/052027
Fig. 22B shows that the stability of PNPl particles in water is temperature—dependent and the
PNP] paiticles tend to dissociate faster at a higher ature, e.g., at a temperature higher
than 4 °C.
It was next sought to compare the stability of PNPl particles and peptide particles
formed from formulation 2 (PNPZ), as shown below, in cell culture media, e.g., containing
about 10% serum.
Peptide particle formulation 2 (CD3ac + CD3 + ssDNA + Tfn)
123uM CD3ac (AC-LK(AC)-LK(AC)-LK(AC)-LW-DL~LW-DL~LW—DL—LW—NHZ)
21 uM CD3 (H-LK~LK-LK—LW—DL-LW-DL-LW-DL-LW-NH2)“
.4 “M (5‘-TTGTGCCGCCTTTGCAGGTGTATC-3‘)24'
0.24 uM -5‘JTGTGCCGCC'IVI'I‘GCAGGTGTATC-3‘)24
4.14 ug/mL Tfn-AF568
HeLa cells were incubated with either PNPl or PNP2 particles for about 30
minutes at temperatures of about 4 °C and 37 °C. As HeLa cells generally perform clathrin-
mediated endocytosis at about 37 °C, but not at about 4°C, any Tfn-AF 568 dissolved in the
media will be internalized by the cells. Thus, after the tion, the cells were fixed with
paraformaldehyde for imaging and detecting the fluorescence intensity. As shown in the
upper panels of Fig. 22C, a diffuse and stronger Tfn—AF568 fluorescence signal was detected
in the cytosol when the cells were incubated with the PNPl particles at about 37 °C, as
compared to more ted Tfn-AF568 fluorescence detected in the cells incubated at about
4 °C. However, this contrast was not observed in the cells incubated with the PNP2 particles,
as shown in the lower panels of Fig. 22C. Instead, ted and comparable Tfn~AF568
scence signals were observed in both the cells incubated at about 4 °C and about 37 °C,
in the presence of the PNP2 particles. These findings indicate that the PNPl particles tend to
dissociate at about 37 °C, thus releasing into the culture media Tfn—AF568, which is then
internalized by the cells; while the PNP2 particles appear to be more stable in serum (e.g.,
about 10% serum) at about 37 °C for at least about 30 mins, thus retaining most of the Tfn-
AF568 in the PNPZ les and/or on the surface of the PNP2 paiticles.
] Comparing the cells in Fig. 22C with the negative control (i.e., cells ted in
the presence of ssDNA without CD3 or CD3ac es) shown in Fig. 22D, the fluorescence
intensity of AF488—ssDNA in the negative control is significantly lower than that in the cells
incubated with ssDNA-containing PNP] or PNP2 particles. This indicates that the PNPl or
PCT/U82012/052027
PNP2 particles can be used to faciliate cell transfection, and deliver a nucleic acid le
(e.g., DNA or RNA) to a cell. It is noted that AF488-ssDNA fluorescence was also ed
in the cells incubated in the presence of PNPl 0r PNP2 particles at about 4 °C. Without
wishing to be bound by theory, while cell transfection in the presence of PNPl or PNP2
particles at about 4 °C is unlikely to be TfR (transferrin receptor)—dependent, it is probably
caused by passive transport through the cell membrane in the presence of CD3 peptides as
discussed in Example 7.
References (for Examples 1 -2)
[l] H. Goesmann, C. Feldmann, Angew. Chem., Int. Ed., 2010, 49, 1362.
[2a] Y. Kakizawa, R. Nishio, T. Hirano, Y. Koshi, M. Nukiwa, M. Koiwa, J. Michizoe, N.
Ida, J. Control e 142,8; [2b] K. Kita-Tokarczyk. J. Giumelard, T. Haefele, W.
Meier, Polymer 2005, 46, 3540; {20] L. Zhang, J. M. Chan, F. X. Gu, J.-W. Rhee, A. Z.
Wang, A. F. Radovic-Moreno, F. Alexis, R. Langer, O. C. Farokhzad, ACS Nano 2008,
2, 1696; [2d] A. Blanazs, S. P. Armes, A. J. Ryan, ol. Rapid Commun. 2009, 30,
267; [2e] T. Smait, H. Lomas, M. Massignani, M. V. -Merino, L. R. Perez, G.
Battaglia, Nano Today 2008, 3, 38.
J. N. Israelachvili, Intermolecular and Surface Forces: With Applications to Colloidal and
Biological Systems, American Chemical Society, 1985, p. 296.
[4a] S. Rai, R. Paliwal, P. N. Gupta, K. Khatri, A. K. Goya], B. Vaidya, S. P. Vyas, Cun‘.
Nanosci. 2008, 4, 30', [4b] Y. Liu, K. Li, J. Pan, B. Liu, S.-S. Feng, erials 2009,
31, 330.
D. Nishit, M. Samir, Adv. Funct. Mater. 2009, 9999, NA-NA.
C. Lo , H. Lomas, M. Massignani, T. Smart, G. Battaglia, J. Mater. Chem. 2009, 19,
3576.
U. K. Slotta, S. Rammensee, S. Gorb, T. Scheibel, Angew. Chem., int. Ed. 2008, 47,
4592.
S. Raman, G. Machaidze, A. Lustig, U. Aebi, P. Burkhard, Nanomedicine 2006, 2, 95.
[9a] M. Nigen, C. rd, T. Croguennec, M.-N. Madec, S. Bouhallab, Biophys. Chem.
2009, 146, 30; [9b] M. Nigen, T. Croguennec, D. Renard, S. Bouhallab, mistry
2007, 46, 1248.
T. E. Rajapaksa, M. Stover—Hamer, X. Fernandez, H. A. Eckelhoefer, D. D. Lo, T. E.
Rajapaksa, J. Control Release 2009.
[1 la]Q. Sun, S. Cai, B. R. Peterson, Q. Sun, J. Am. Chem. Soc. 2008, 130, 10064.
[1 lb]S. Yang, D. J. Coles, A. Esposito, D. J. Mitchell,1. Toth, R. F. Minchin, S. Yang, J.
Controlled Release 2009, 135, 159.
M. G. Ryadnov, A. Bella, S. Timson, D. N. Woolfson, J. Am. Chem. Soc. 2009, 131,
13240.
[1321] L. Aulisa, H. Dong, J. D. Hartgerink, Biomacromolecules 2009, 10, 2694; [13b] K.
J. Channon, G. L. Devlin, C. E. MacPhee, J. Am. Chem. Soc. 2009, 131, 12520; [13c] J.
Ryu, C. B. Park, Angew. Chem, Int. Ed. 2009, 48, 4820, S4820/4821—S4820/ 4826; [13d]
H. Dong, S. E. Paramonov, J. D. Hangerink, J. Am.Chem. Soc. 2008, 130, 13691; [l3e]
Y. Zimenkov, S. N. Dublin, R. Ni, R. S. Tu, V. Breedveld, R. P. Apkarian, V. P.
Conticello, J. Am. Chem. Soc. 2006, 128, 6770.
Vydac, http://www.nestgip.com/pdf/Vapp/AN9802.pdf 2010.
['15] [1521] H. M. Redhead, S. S. Davis, L. Illum, J. Controlled Release 2001, 70, 353; [151)]
W. Lin, M. C. Garnett, S. S. Davis, E. Schacht, P. Femiti, L. Illum, J. Controlled Release
2001,71,117.
W. R. Veatch, E. T. Fossel, E. R. Blout, mistry 1974, 13, 5249.
[17a] D. A. Kelkar, A. Chattopadhyay, Biochim. Biophys. Acta, Biomembr. 2007, 1768,
2011; [17b] R. D. iss, R. Dubos, J. Biol. Chem. 1940, 132, 791; [17c] R. D.
Hotchkiss, R. Dubos, J. Biol. Chem. 1940, 132, 793.
[l8a] D. W. Urry, D. F. Mayers, J. , Biochemistry 1972, 11,487; [18b] Y. Chen,
A. Tucker, B. A. Wallace, J. Mol. Biol. 1996, 264, 757; [18c] D. A. Doyle, B. A.
Wallace, J. Mol. Biol. 1997, 266, 963.
[19a] F. Heitz, A. Heitz, Y. deelle, s. Chem. 1986, 24, 149; [19b] S. V.
Sychev, N. A. Nevskaya, S. Iordanov, E. N. Shepel, A. 1. nikov, V. T. Ivanov,
Bioorg. Chem. 1980, 9, 121.
L. Eidenschink, B. L. Kier, K. N. L. Huggins, N. H. Andersen, Proteins: , Funct.,
. 2009, 75, 308.
References (for Examples 3-4)
(1) Multifunctional nanocarriers. Adv Drug Deliv 58, 1532-1555 (2006).
(2) Stark. Nanoparticles in ical s. Angew Chem Int Ed, n~a,
doi:10.1002/anie.200906684(2011).
(3) Soussan, E., Cassel, S., Blanzat, M. & Rico-Lattes, I. Dmg delivery by soft matter:
matrix and vesicular carriers. ACIE 48, 274-288, doi:10.1002/anie.200802453 (2009).
PCT/U52012/052027
(4) Ne], A. E. et a1. Understanding biophysicochemical interactions at the nano-bio
interface. Nat Mater 8, 543—557, doi:10.1038/nmat2442 .
(5) Dittrich, C. & Meier, W. Solid Peptide Nanoparticles: Structural Characterization and
Quantification of Cargo Encapsulation. olecular Bioscience 10, 1406-1415,
doi:10.1002/mabi.201000221 (2010).
(6) Meriifield, R. B. Solid Phase Peptide Synthesis. 1. The Synthesis of a eptide. J
Am 85, 2149-2154, doi:10.1021/ja00897a025 (1963).
(7) Nilsson, B. L., Soellner, M. B. & Raines. R. T. Chemical synthesis of proteins. Annu
Rev Bioph Biom 34, 91-118, doi: 10.1 nurev.biophys.34.040204. 144700 (2005).
(8) Sitnikova, N. L., Sprik, R., Wegdam, G. & Eiser, E. Spontaneously formed trans-
anethol/water/alcohol emulsions: ism of formation and stability. LAGMUIR
21, 7083-7089, doi:10.1021/1a0468161 (2005).
(9) Ashley, C. E. et al. The targeted delivery of multicomponent cargos to cancer cells by
nanoporous particle-supponed lipid bilayers. Nature, .1038/nmat2992(2011).
(10) Monopoli, M. P. et a1. Physical-Chemical Aspects of Protein Corona: Relevance to in
Vitro and in Vivo Biological s of rticles. J. Am. Chem. Soc. 133, 2525-
2534, doi:10.102l/ja107583h (2011).
(11) Ehrlich, M. et a1. Endocytosis by random initiation and stabilization of clathrin-coated
pits. CEL 118, 591-605, doi:10.1016/j.cell.2004.08.017 (2004).
(12) MacGillivray, R. T. A. et a1. Two High—Resolution Crystal Structures of the
Recombinant N-Lobe of Human Transferrin Reveal a Structural Change Implicated in
Iron Release. Biochemistry 37, 7919-7928, doi:10.1021/bi980355j (1998).
(13) Min, Y., Akbulut, M., Kn'stiansen, K., Golan, Y. & Israelachvili, J. The role of
interparticle and external forces in nanoparticle assembly. Nat. Mater. 7, 527-538,
.1038/nmat2206 (2008).
(14) Fleck, C. C. & Netz, R. R. Electrostatic colloid-membrane g. Eur0phys. Lett.
67, 314-320, doi:10.1209/ep1/i2004x (2004).
(15) Dagastine, R. R. et al. Dynamic Forces Between Two Deformable Oil ts in
Water. Science (Washington, DC, United States) 313, 210-2 13,
doi:10.l126/science.1125527 (2006).
(16) McGraw, T. E., Greenfield, L. & Maxfield, F. R. Functional sion of the human
transfen‘in receptor cDNA in Chinese hamster ovary cells deficient in endogenous
transferrin receptor. JCB 105, 4, doi:10.2307/1612534 (1987).
PCT/U82012/052027
(17) Parhi, P., Golas, A., Bamthip, N., Noh, H. & Vogler, E. A. Volumetric interpretation
of protein adsorption: Capacity g with adsorbate molecular weight and
adsorbent surface energy. Biomaterials 30, 824,
doi:10.l016/j.biomaterials.2009.09.005 (2009).
(18) Harding, C., Heuser, J. & Stahl, P. Receptor—mediated endocytosis of transferrin and
recycling of the transferrin receptor in rat reticulocytes. JCB 97, 329-339,
doi:10.2307/1610388 (1983).
(19) Lillo, M. P., Cafiadas, 0., Dale, R. E. & Acufia, A. U. Location and properties of the
taxol g center in microtubules: a picosecond laser study with fluorescent
taxoids. Biochemist 41, 12436-12449 .
(20) Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nat Rev
Can 4, 5, doi:10.1038/nrc1317 (2004).
(2]) Stewart, K. M., Horton, K. L. & Kelley, S. O. Cell-penetrating peptides as delivery
vehicles for biology and medicine. Org Biomol Chem 6, 2242-2255,
doi:10.1039/b7l9950c (2008).
(22) Hyuk, I. S., Jeong, U. & Xia, Y. Polymer hollow particles with llable holes in
their surfaces. Nat. Mater. 4, 671-675, doi:10.1038/nmat1448 (2005).
t of all patents and other publications identified herein is expressly
incorporated herein by nce for all purposes. These publications are provided solely for
their disclosure prior to the filing date of the present ation. Nothing in this regard
should be construed as an admission that the inventors are not entitled to antedate such
disclosure by virtue of prior invention or for any other reason. All statements as to the date
or representation as to the contents of these documents is based on the information available
to the applicants and does not constitute any admission as to the correctness of the dates or
contents of these documents.
Claims (25)
- Claims A peptide particle comprising an amphiphilic peptide, the amphiphilic peptide comprising a hydrophobic peptidyl segment and a hydrophilic yl segment, wherein the hydrophobic peptidyl segment consists essentially of an amino acid sequence of (Trp-Leu)m-(Trp)n 0r (Leu-Trp)p-(Leu)q, wherein each Trp is D-Trp or L-Trp and each Leu is D-Leu or L-Leu, m and p are independently an integer from 1 to 5, and n and q are independently 0 or 1, provided that when Trp is D-Trp then Leu is L-Leu, and when Trp is L-Trp then Leu is D-Leu, or vice versa; and wherein the hydrophilic peptidyl segment consists essentially of an amino acid sequence of (Lys)r, wherein r is an integer from I to 15, and wherein the peptide particle r comprises a ligand for binding to a target cell adsorbed on its outer surface.
- The peptide particle of claim 1, n at least one Lys residue of the hydrophilic peptidyl segment or the inus amino group ofthe hilic peptide is acetylated.
- The peptide particle of claim 1 or claim 2, n the amphiphilic peptide comprises the amino acid sequence of (L-Lys)-(L—Lys)-(L-Lys)-(L-Trp)-(D-Leu)-(L-Trp)-(D- Leu)-(L-Trp)-(D-Leu)-(L-Trp)-X, wherein X is absent or NH; The peptide particle of claim 3, n at least one ofthe L-Lys residues is acetylated, and/or the N-terminns amino group of the amphiphilic peptide is ated.
- The peptide particle of any one of claims 1-4, wherein the ligand includes a cell surface receptor ligand or an antibody.
- The peptide particle of any one of claims 1-5, wherein the e particle comprises a mixture of a fully-acetylated amphiphilic peptide of any one of claims 1-5, and a panially-acetylated hilic peptide of any one of claims 1-5, and optionally a non-acetylated amphiphilic peptide of any one of claims 1-5.
- The peptide particle of any one of claims 1-6, further comprising an active agent.
- Use of the e le of claim 7 in the manufacture of a composition for targeted delivery of an active agent.
- An in vitro method for targeted delivery of an active agent, the method comprising contacting a cell with the peptide particle of claim 7. 7325831_l (6HManors) PN244.
- NZ 21-Jan-18
- 10. Use of: (a) a positively-charged amphiphilic peptide comprising a hydrophobic peptidyl segment and a hydrophilic peptidyl segment, wherein the hydrophobic peptidyl segment consists ially of an amino acid sequence of (Trp-Leu)m-('I‘rp)n or (Leu-Trp)p-(Leu)q, wherein each Trp is D-Trp 0r L-Trp and each Leu is D—Leu or L-Leu, m and p are independently an integer from 1 to 5, and n and q are independently O or 1, provided that when Trp is D-Trp then Leu is L-Leu, and when Trp is L-Trp then Leu is D-Leu, or vice versa, wherein the hydrophilic peptidyl segment consists essentially of an amino acid sequence ),, wherein r is an integer from I to 15, and wherein at least one of the Lys residues or the N-terminus amino group of the amphiphilic peptide is not acetylated; and (b) a nucleic acid molecule, in the manufacture of a cell-penetrating agent or transfecting agent.
- 11. An in vitro method for penetrating or transfecting a cell, the method comprising contacting a cell with a composition comprising: (a) a vely-charged amphiphilic peptide comprising a hydrophobic peptidyl segment and a hydrophilic peptidyl segment, wherein the hydrophobic peptidyl segment consists ially of an amino acid ce of (Trp-Leu)m-(Trp)n or (Leu-Trp)p-(Leu)q, wherein each Trp is D—Trp or L- Trp and each Leu is D-Leu or L—Leu, m and p are independently an integer from 1 t0 5, and n and q are independently 0 or 1, provided that when Tip is D-Trp then Leu is L-Leu, and when Trp is L-Trp then Leu is D-Leu, or vice versa, wherein the hydrophilic peptidyl t ts essentially of an amino acid sequence of (Lys),, wherein r is an r from 1 to 15, and wherein at least one of the Lys residues or the N-terminus amino group of the amphiphilic peptide is not acetylated; and (b) a nucleic acid molecule.
- 12. The use of claim 10 or the method of claim 1 1, wherein all ofthe Lys es and the N-terminus amino group of the amphiphilic peptide are not acetylated.
- 13. The use or method of any one of claims 10-12, wherein the amphiphilic peptide consists essentially of the amino acid sequence of (L-Lys)-(L-Lys)-(L-Lys)-(L-Trp)- (D-Leu)-(L-Trp)-(D-Leu)-(L-Trp)-(D-Leu)-(L-Trp)—X, n X is absent or NH; 7325831_i IQB) P962“,NZ 2143046 l 12
- 14. A peptide particle comprising a first amphiphilic peptide and a second amphiphilic peptide, the first and the second hilic peptide each ndently comprising a hydrophobic peptidyl segment and a hilic peptidyl segment, wherein the hobic peptidyl segment consists essentially of an amino acid sequence of ("l"rp-Leu)m-(Trp)n or (Leu-Trp)p-(Leu)q, wherein each Trp is D-Trp or L-Trp and each Leu is D-Leu or LvLeu, m and p are independently an integer from 1 to 5, and n and q are independently 0 or 1, provided that when Trp is D-Trp then Leu is L-Leu, and when Trp is L-Trp then Leu is D-Leu, or vice versa; and wherein the hydrophilic peptidyl segment consists essentially of an amino acid sequence of (Lys)r, wherein r is an integer from 1 to 15, and wherein the N-terminus amino group and all of the Lys residues of the first amphiphilic peptide are ated; and wherein at least the N—terminus amino group or one of the Lys es of the second amphiphilic peptide is not acetylated.
- 15. The peptide particle of claim 14, wherein none of the N-terminus amino group and the Lys residues of the second amphiphilic peptide is acetylated.
- 16. The peptide particle of claim 14 or claim 15, further comprising an active agent.
- 17. The peptide particle of claim 16, wherein the active agent includes a nucleic acid molecule.
- 18. The peptide particle of any one of claims 14-17, further comprising on its outer surface a ligand.
- 19. The peptide particle of any one ofclaims 14-18, wherein the first and second amphiphilic peptide each independently ses the amino acid sequence of (L- Lys)-(L-Lys)-(L-Lys)~(L-Trp)-(D-Leu)-(L-Trp)-(D-Leu)-(L-Trp)-(D-Leu)-(L~Trp)-X, wherein X is absent or NH;
- 20. Use ofthe peptide particle of any one of claims 14-19 in the manufacture ofa composition for delivery of a nucleic acid molecule to a cell.
- 21. An in vitro method for delivery of a nucleic acid molecule to a cell, the method comprising contacting a cell with the peptide particle of any one of claims 14-19.
- 22. The use m 20 or the method m 21, wherein the nucleic acid molecule includes siRNA, miRNA, shRNA, DNA, or any combination thereof.
- 23. The peptide particle of claim 1 or claim 14, substantially as hereinbefore described with reference to the es and figures. I_1 (GHMallels) P96244,NZ 2IvJan~18
- 24. The use of any one of claims 8, 10 or 20, substantially as hereinbefore described with reference to the es and figures.
- 25. The in vitro method of any one of claims 9, l 1 or 21, substantially as hereinbefore described with reference to the examples and figures. 732553i_l (GHMalw'S) P9624A.NZ 21-Jan-18
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161526526P | 2011-08-23 | 2011-08-23 | |
US61/526,526 | 2011-08-23 | ||
PCT/US2012/052027 WO2013028843A1 (en) | 2011-08-23 | 2012-08-23 | Peptide nanoparticles and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ622045A NZ622045A (en) | 2016-02-26 |
NZ622045B2 true NZ622045B2 (en) | 2016-05-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2748182T3 (en) | Peptide nanoparticles and their applications | |
US20150218252A1 (en) | Self-assembling peptides, peptide nanostructures and uses thereof | |
KR101475447B1 (en) | Vesicles of self-assembling block copolymers and methods for making and using the same | |
Kim et al. | One-dimensional supramolecular nanoplatforms for theranostics based on co-assembly of peptide amphiphiles | |
JP2002543110A (en) | Amplification of folate-mediated targeting to tumor cells using nanoparticles | |
WO2006099779A1 (en) | A rgd-containing cyclic peptid and the active-targeting liposome thereof | |
Kazi et al. | Design of 5-fluorouracil (5-FU) loaded, folate conjugated peptide linked nanoparticles, a potential new drug carrier for selective targeting of tumor cells | |
US20230270882A1 (en) | Peptide-nanoparticle conjugates | |
Novelli et al. | Curcumin loaded nanocarriers obtained by self-assembly of a linear d, l-octapeptide-poly (ethylene glycol) conjugate | |
US20210093729A1 (en) | Preparation and application of surface double modified human serum albumin as targeting nano drug carrier | |
JP2002532388A (en) | Novel oligomer conjugates that facilitate the transfer of biological molecules into cells | |
US20090238886A1 (en) | Retro-Inversion Peptides That Target GIT Transport Receptors and Related Methods | |
KR102156649B1 (en) | Drug delivery system comprising enzyme-responsive amphiphilic peptide | |
Herlan et al. | Cyclic peptoid-peptide hybrids as versatile molecular transporters | |
NZ622045B2 (en) | Peptide nanoparticles and uses thereof | |
TWI362270B (en) | ||
JP7068711B2 (en) | Cytoplasmic delivery peptide | |
TW201807025A (en) | Active-targeting-type polymer derivative, composition containing said polymer derivative, and uses of said polymer derivative and said composition | |
US7166296B2 (en) | Pharmaceutical formulations and ligands for use therein; mimetics for UEA-1 | |
Navarro Barreda | Macro-and nanoscale self-assembled amino acid derivatives as reduction-sensitive and photoactive materials | |
US20230210994A1 (en) | Cell-penetrating conjugate systems | |
US20240059739A1 (en) | Peptides for increasing drug delivery to cancer | |
Tong et al. | A Small Peptide Increases Drug Delivery in Human Melanoma Cells. Pharmaceutics 2022, 14, 1036 | |
CN115232195A (en) | Oligopeptide two-dimensional nanomaterial and application thereof | |
CN115996745A (en) | BRK peptides and methods of use |